[{"title01":"Comment on “Acute Promyelocytic Leukemia with other RARA rearrangements”.","title02":"Comment on “Acute Promyelocytic Leukemia with other RARA rearrangements”.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300363. Online ahead of print","author":"Su Z, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816827"},{"title01":"Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”.","title02":"Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”.","journal":"Haematologica","issue":"2026 March 1; 111(3):1136-1137. doi: 10.3324\/haematol.2025.289363","author":"Lastovytska I, Heidenreich S, Klyuchnikov E, Niederwieser C, Gagelmann N, Richter J, Massoud R, Rathje K, Perekhrestenko T, Zeck G, Luck C, Janson D, Wolschke C, Ayuk F, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773030"},{"title01":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","title02":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 March; 40(3):609-621. doi: 10.1038\/s41375-025-02843-9","author":"Kealy D, Ellerington R, Bansal S, Medeiros JJF, Hawley CA, Zeng AGX, Lukaszonek J, West KA, Sinha AD, Caalim G, Gawne RT, Pope J, Ferreira BL, Blacknell NM, Drylie B, Chatzigerou J, Khoo HM, Wilkinson AC, Fielding AK, Wang G, Psaila B, Kent DG, Hitchcock IS, Holding AN, Mason AS, Gupta V, Dick JE, Bridge KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41629621"},{"title01":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","title02":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","journal":"Haematologica","issue":"2026 March 1; 111(3):990-996. doi: 10.3324\/haematol.2024.286697","author":"Leontyeva Y, Landtblom AR, Hultcrantz M, Lambe M, Bower H, Lambert PC, Andersson TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994348"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 March 1; 111(3):1070-1074. doi: 10.3324\/haematol.2025.288166","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","title02":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","journal":"Br J Haematol","issue":"2026 March 3. doi: 10.1111\/bjh.70404. Online ahead of print","author":"Speight B, Hamblin A, Talley P, Tsoulaki O, Robinson R, Dean P, Khorashad J, Kulasekararaj A, Godfrey AL, Mead AJ, McVeigh TP, Snape K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773566"},{"title01":"Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.","title02":"Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.","journal":"Blood advances","issue":"2026 March 10; 10(5):1473-1480. doi: 10.1182\/bloodadvances.2025018011","author":"Barbui T, Scandura JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370203"},{"title01":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.","title02":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 March 10; 10(5):1603-1613. doi: 10.1182\/bloodadvances.2025018724","author":"Leiva O, Soo S, Liu OC, You V, Palmer A, Kahla J, Murtaza Y, Odenike O, Patel AA, DeCara JM, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","title02":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019152. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.","title02":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031366. Online ahead of print","author":"Mora B, Palandri F, Guglielmelli P, Kuykendall AT, Maffioli M, Iurlo A, De Stefano V, Salmoiraghi S, Devos T, Itri F, Cervantes F, Kiladjian JJ, Della Porta MG, Albano F, Gotlib J, Benevolo G, Caramella M, Ruggeri M, Rumi E, Ross DM, Pessina C, Colugnat I, Orsini F, Micucci G, Rotunno G, Komrokji RS, Cattaneo D, Chiusolo P, Bortolotti M, Barbui T, Cilloni D, Breccia M, Palumbo GA, Branzanti F, Margotto L, Franchi M, Vannucchi AM, Passamonti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785373"},{"title01":"A niche for every stem cell in myeloproliferative neoplasms.","title02":"A niche for every stem cell in myeloproliferative neoplasms.","journal":"Blood","issue":"2026 March 12; 147(11):1143-1144. doi: 10.1182\/blood.2025032458","author":"Mendez-Ferrer S, Fleischman AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817558"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","title02":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","journal":"J Clin Oncol","issue":"2026 March 4; JCO2501929. doi: 10.1200\/JCO-25-01929. Online ahead of print","author":"Zhou H, Zhao H, Hou X, Wang Y, He Z, Li Y, Ma Y, Zhao Y, Huang Y, Chen L, Xiao S, Zhu H, Zhu Y, Fang W, Zhang L, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779981"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative.","title02":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative.","journal":"Haematologica","issue":"2026 March 1; 111(3):794-796. doi: 10.3324\/haematol.2025.288632","author":"Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905092"},{"title01":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy.","title02":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy.","journal":"Haematologica","issue":"2026 March 1; 111(3):1061-1064. doi: 10.3324\/haematol.2025.288078","author":"Bordbar M, Faghihi A, Zekavat OR, Shahriari M, Bordbar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702901"},{"title01":"Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding.","title02":"Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding.","journal":"Blood advances","issue":"2026 March 10; 10(5):1508-1517. doi: 10.1182\/bloodadvances.2025018315","author":"Wang D, Sra M, Ito S, Ng DQ, Glaeser-Khan S, Wang DY, Hirniak S, Lee AI, Cuker A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504430"},{"title01":"Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).","title02":"Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).","journal":"Blood advances","issue":"2026 March 10; 10(5):1799-1808. doi: 10.1182\/bloodadvances.2025018382","author":"Zhang E, Kasthuri RS, Parambil J, Prasad V, Iyer VN, Whitehead KJ, Hodges PG, Pishko AM, Conrad MB, Phelan D, Rodriguez-Lopez J, McCrae KR, Al-Samkari H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512167"},{"title01":"Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming.","title02":"Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming.","journal":"Blood advances","issue":"2026 March 10; 10(5):1444-1456. doi: 10.1182\/bloodadvances.2025017625","author":"Carminita E, Camacho V, Branfield S, Walsey E, Barrachina MN, Tabang DN, Lee DH, Becker IC, Brodsky SV, Issa SM, Gendron N, Machado S, Wolberg AS, Steen H, Kerlin B, Machlus KR, Zarjou A, Italiano JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411491"},{"title01":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","title02":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018706. Online ahead of print","author":"Ali H, Mohan SR, Kishtagari A, Prchal JT, Maher KR, Chai Y, Gudi G, Taverna P, Mark TM, Tantravahi SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785311"},{"title01":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","title02":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031135. Online ahead of print","author":"Liu Y, Zhang W, Cai J, Zhou D, Zhao H, Dong W, Zhao B, Lu Y, Hao S, Ding Y, Jiang N, Qiao T, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824385"},{"title01":"Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.","title02":"Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.","journal":"N Engl J Med","issue":"2026 March 5; 394(10):1030-1033. doi: 10.1056\/NEJMc2516228","author":"Gottschlich A, Bucklein V, El-Marouk K, Kaiser R, Schmid M, Janert TA, Winkelmann M, Ziemann F, Hanel G, Handtke S, Thiele T, Wichmann C, Kobold S, Zugmaier G, Rausch C, Schulze-Koops H, Lindner LH, Spiekermann K, von Bergwelt-Baildon M, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41780009"},{"title01":"Sustained response off-treatment and thrombotic events in patients with immune thrombocytopenia treated with fostamatinib: a systematic review and meta-analysis.","title02":"Sustained response off-treatment and thrombotic events in patients with immune thrombocytopenia treated with fostamatinib: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2026.288458. Online ahead of print","author":"Clerici B, Mondini C, Pontisso E, Sala S, Tarasconi E, Pisetta C, Birocchi S, Podda GM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784025"},{"title01":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","title02":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300199. Online ahead of print","author":"Zadro Y, Lafaurie M, Sommet A, Lapeyre-Mestre M, Moulis G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816826"},{"title01":"Lack of association between vaccine-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.","title02":"Lack of association between vaccine-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70419. Online ahead of print","author":"Schonborn L, Tzvetkova A, Thiele T, Volker U, Ameling S, Franzenburg S, Kaderali L, Greinacher A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797449"},{"title01":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","title02":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70414. Online ahead of print","author":"Shah SD, Vibhakar A, Shah RP, Rathod N, Modi G, Patel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802829"},{"title01":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","title02":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70403. Online ahead of print","author":"Sorin B, Azzouguen B, Loustau V, Boutin E, Henique H, Graveleau J, Souchaud-Debouverie O, Pascal L, Gilardin L, Costedoat-Chalumeau N, Reynaud Q, Pan-Petesch B, Cheze S, Terriou L, Comont T, Sauvetre G, Royer B, Mahevas M, Michel M, Canoui-Poitrine F, Godeau B, Guillet S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814575"},{"title01":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","title02":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031332. Online ahead of print","author":"Wang YM, Zhou H, Leng S, Ma JJ, Li H, Li G, Sun T, Xu Y, Han S, Gu Y, Dong L, Yan Z, Zhang L, Peng J, Liu XG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770851"},{"title01":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","title02":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","journal":"Leukemia","issue":"2026 March; 40(3):661-665. doi: 10.1038\/s41375-025-02858-2","author":"Zhao LP, Kosmider O, Heiblig M, Moulinet T, Lacombe V, Comont T, Lobbes H, Karam JD, Terriou L, Ardois S, Le Guenno G, Jachiet V, Wolff L, Vertenoeil G, Hadjadj J, Bouaziz JD, Lemaire P, Fain O, Terrier B, Georgin-Lavialle S, Larcher L, Clappier E, Sebert M, Ades L, Mekinian A, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545701"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):622-629. doi: 10.1038\/s41375-026-02874-w","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 March; 40(3):649-660. doi: 10.1038\/s41375-026-02886-6","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","title02":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","journal":"Leukemia","issue":"2026 March; 40(3):468-480. doi: 10.1038\/s41375-026-02865-x","author":"Lee NC, Miao R, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703030"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 March 1; 111(3):1070-1074. doi: 10.3324\/haematol.2025.288166","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","title02":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.288146. Online ahead of print","author":"Feng J, Wang K, Gou J, Wang Y, Hu B, Wei W, Ge J, Feng Y, Feng S, Solary E, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784036"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018188. Online ahead of print","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 March; 40(3):698-701. doi: 10.1038\/s41375-026-02860-2","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","title02":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","journal":"Blood","issue":"2026 March 12; 147(11):1215-1228. doi: 10.1182\/blood.2025031454","author":"Lu M, Mia MB, Xia L, Mosoyan G, Hayat M, Schaniel C, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397284"},{"title01":"Focal MPN-associated JAK2-mutated skeletal lesion with normal blood counts and bone marrow.","title02":"Focal MPN-associated JAK2-mutated skeletal lesion with normal blood counts and bone marrow.","journal":"Blood","issue":"2026 March 5; 147(10):1135. doi: 10.1182\/blood.2025032152","author":"Eren OC, Konoplev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785000"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"Proteostasis meets signaling: UBE2G1 in hematopoietic stem cell aging.","title02":"Proteostasis meets signaling: UBE2G1 in hematopoietic stem cell aging.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2026.300724. Online ahead of print","author":"Miller V, Nachmias B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784031"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","title02":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025015971. Online ahead of print","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz AS, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings MB, Bader P, Diaz-de-Heredia C, Winiarski JH, Masmas TNN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen SJ, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre TCC, Slatter MA, Albert MH, Neven B, Gennery AR, Kulagin AD, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"A CHARMed life after HCT: health span beyond life span.","title02":"A CHARMed life after HCT: health span beyond life span.","journal":"Blood advances","issue":"2026 March 10; 10(5):1743-1745. doi: 10.1182\/bloodadvances.2025018938","author":"Hamilton BK, Ragon BK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759034"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","title02":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","journal":"Blood advances","issue":"2026 March 10; 10(5):1657-1669. doi: 10.1182\/bloodadvances.2025018340","author":"Artz AS, Logan B, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris L, Imus P, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall S, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.","title02":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.","journal":"Blood advances","issue":"2026 March 10; 10(5):1783-1798. doi: 10.1182\/bloodadvances.2025017662","author":"Alexander JL, Davila Saldana BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing JJ, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JA, Rayes A, Madden L, Shereck E, Miller HK, Satter LF, Martinez C, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen A, Chong H, Chopek A, Gillio AP, Joshi A, Rangarajan H, Moore TB, Andolina JR, DeSantes KB, Vander Lugt M, Prockop SE, Shyr DC, Sullivan KE, Parikh S, Weinacht KG, Torgerson TR, Marsh R, Dvorak CC, Chan AY, Haddad E, Heimall JR, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346295"},{"title01":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","title02":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","journal":"Blood advances","issue":"2026 March 10; 10(5):1746-1755. doi: 10.1182\/bloodadvances.2025018031","author":"Badar T, Marando L, Latorre E, Lasho T, Olivia FD, Lin C, McCormick BJ, El Kettani M, Shah KJ, Kusne Y, Jamy O, Diebold K, Coltoff A, Finke C, Foran J, Kharfan-Dabaja M, Fan YS, Jiang L, He R, Thomas M, Patel A, Viswanatha D, Shah MV, Saliba A, Mangaonkar A, Kirschner K, Al-Kali A, Gangat N, Litzow M, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499760"},{"title01":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","title02":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019152. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","title02":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2026 March 12; 147(11):1147-1167. doi: 10.1182\/blood.2025031480","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","title02":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","journal":"Blood","issue":"2026 March 5; 147(10):1019-1036. doi: 10.1182\/blood.2025028762","author":"Verkamp B, Jordan MB, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481377"},{"title01":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","title02":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031135. Online ahead of print","author":"Liu Y, Zhang W, Cai J, Zhou D, Zhao H, Dong W, Zhao B, Lu Y, Hao S, Ding Y, Jiang N, Qiao T, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824385"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025030059. Online ahead of print","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 March; 40(3):698-701. doi: 10.1038\/s41375-026-02860-2","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","title02":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","journal":"Lancet Oncol","issue":"2026 March; 27(3):349-360. doi: 10.1016\/S1470-2045(25)00707-7","author":"Louis FM, van der Voort A, van Ramshorst MS, Daletzakis A, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJM, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Egeler MD, van de Poll-Franse LV, Mann RM, Sonke GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713473"},{"title01":"Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.","title02":"Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.","journal":"Lancet Oncol","issue":"2026 March; 27(3):372-382. doi: 10.1016\/S1470-2045(25)00720-X","author":"van den Hoek L, Burgmans M, Tong T, Goeman J, Speetjens F, Zunder S, van Erkel A, van der Meer R, van Rijswijk C, Lutjeboer J, Koolhaas D, Jonker-Bos M, Roozen I, Kropff S, van Meerten EVP, Zoethout R, Sitsen E, Helmerhorst H, Tijl F, Blank C, Kapiteijn E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785896"},{"title01":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","title02":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","journal":"Lancet","issue":"2026 March 12. doi: 10.1016\/S0140-6736(26)00150-9. Online ahead of print","author":"Doeven T, Glenthoj A, Grace RF, van Beers EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41833294"},{"title01":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","title02":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","journal":"J Clin Oncol","issue":"2026 March 3; JCO2501657. doi: 10.1200\/JCO-25-01657. Online ahead of print","author":"Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Geriniere L, Egenod T, El Hajbi F, Ferru A, Clement-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774886"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025030059. Online ahead of print","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","title02":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031466. Online ahead of print","author":"Mimura K, Kaino A, Ochi Y, Chang YH, Seki M, Takeda J, Katayama S, Niizuma H, Sasahara Y, Mizoguchi Y, Shimomura M, Koyamada R, Ono R, Hasegawa D, Mitani K, Kubota H, Yoshihara S, Hiramoto N, Otsuki A, Okamura Y, Katsuoka F, Kinoshita K, Hasegawa M, Togo-Ohno M, Maeda H, Kakiuchi N, Takeuchi M, Sato-Otsubo A, Kato S, Watanabe K, Katayama K, Imoto S, Shiraishi Y, Koh K, Suenobu S, Hiyama E, Goyama S, Kikuchi A, Ogawa S, Kato M, Nannya Y, Takita J, Yoshida K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790573"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030207. Online ahead of print","author":"Minnie S, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SR, Schmidt CR, Comstock ML, Lyons J, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 March; 40(3):594-608. doi: 10.1038\/s41375-025-02828-8","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","title02":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","journal":"Leukemia","issue":"2026 March; 40(3):502-510. doi: 10.1038\/s41375-025-02857-3","author":"Mehta RS, Aljawai YM, Kebriaei P, Rondon G, Fingrut W, Smallbone P, Oran B, Olson A, Champlin RE, Shpall EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526616"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","title02":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","journal":"Leukemia","issue":"2026 March; 40(3):511-521. doi: 10.1038\/s41375-025-02850-w","author":"Zhou J, Hu T, Li D, Li S, Li M, Shi X, Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526615"},{"title01":"Tele-prehabilitation for allogeneic HCT.","title02":"Tele-prehabilitation for allogeneic HCT.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e131-e132. doi: 10.1016\/S2352-3026(26)00033-5","author":"Salas MQ, Salinas Gonzalez RS, Fernandez-Aviles F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791830"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e133-e143. doi: 10.1016\/S2352-3026(25)00328-X","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","title02":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e157-e168. doi: 10.1016\/S2352-3026(25)00358-8","author":"Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Hollein A, Kraus S, Schafer-Eckart K, Hanel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Rohnert MA, Oelschlagel U, Wagenfuhr L, Thiede C, Herold S, Poitz D, Stolzel F, Baldus CD, Serve H, Wermke M, Bornhauser M, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791831"},{"title01":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","title02":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e169-e180. doi: 10.1016\/S2352-3026(25)00361-8","author":"Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791832"},{"title01":"Maintenance intensification after allogeneic HSCT: refining selection.","title02":"Maintenance intensification after allogeneic HSCT: refining selection.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00064-5. Online ahead of print","author":"Perrot A, Frenzel L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831470"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Sickle cell disease.","title02":"Sickle cell disease.","journal":"Lancet","issue":"2026 March 14; 407(10533):1095-1111. doi: 10.1016\/S0140-6736(25)02278-0","author":"Colombatti R, Jastaniah W, Makani J, Andemariam B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831848"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","title02":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","journal":"Haematologica","issue":"2026 March 1; 111(3):1081-1088. doi: 10.3324\/haematol.2025.288306","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","title02":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","journal":"Haematologica","issue":"2026 March 1; 111(3):892-905. doi: 10.3324\/haematol.2025.288464","author":"Wu N, Ding W, Wu J, Ling M, Yue K, Cheng C, Jia M, Liu J, Huang XJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994352"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Sickle cell disease.","title02":"Sickle cell disease.","journal":"Lancet","issue":"2026 March 14; 407(10533):1095-1111. doi: 10.1016\/S0140-6736(25)02278-0","author":"Colombatti R, Jastaniah W, Makani J, Andemariam B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831848"},{"title01":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","title02":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","journal":"J Clin Oncol","issue":"2026 March 10; 44(8):698-708. doi: 10.1200\/JCO-25-02087","author":"Faramand RG, Xie Z, Jain MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671523"},{"title01":"Thyroid hormones induce an acute platelet release mechanism via integrin alphaVbeta3.","title02":"Thyroid hormones induce an acute platelet release mechanism via integrin alphaVbeta3.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289252. Online ahead of print","author":"Foster HR, Herbert N, Di Buduo CA, Schmidt AP, Fang J, Biswas R, Taimoor M, Waller AK, Howard D, Vallance TM, Lawrence M, Mueller A, Moreau T, Evans AL, Turro E, Fischer R, Wilcox DA, Hoffmeister KM, Balduini A, Ghevaert C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816842"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","title02":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):843-851. doi: 10.3324\/haematol.2025.287777","author":"Murphy T, Zhang B, Zhang T, King I, Capo-Chichi JM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KWL, Arruda A, Lu Z, Khalaf D, Rockwell C, Leber B, Sabloff M, Tierens A, Stockley TL, Chan SM, Ng SWK, Wang JCY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637740"},{"title01":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","title02":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","journal":"Haematologica","issue":"2026 March 1; 111(3):997-1006. doi: 10.3324\/haematol.2025.288006","author":"Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098096"},{"title01":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","title02":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","journal":"Haematologica","issue":"2026 March 1; 111(3):1081-1088. doi: 10.3324\/haematol.2025.288306","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","title02":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","journal":"Haematologica","issue":"2026 March 1; 111(3):1017-1028. doi: 10.3324\/haematol.2025.288381","author":"Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch JSZ, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994343"},{"title01":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","title02":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","journal":"Haematologica","issue":"2026 March 1; 111(3):892-905. doi: 10.3324\/haematol.2025.288464","author":"Wu N, Ding W, Wu J, Ling M, Yue K, Cheng C, Jia M, Liu J, Huang XJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994352"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","title02":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025015971. Online ahead of print","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz AS, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings MB, Bader P, Diaz-de-Heredia C, Winiarski JH, Masmas TNN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen SJ, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre TCC, Slatter MA, Albert MH, Neven B, Gennery AR, Kulagin AD, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","title02":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","journal":"Blood advances","issue":"2026 March 10; 10(5):1576-1586. doi: 10.1182\/bloodadvances.2025017837","author":"Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124669"},{"title01":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","title02":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","journal":"Blood advances","issue":"2026 March 10; 10(5):1657-1669. doi: 10.1182\/bloodadvances.2025018340","author":"Artz AS, Logan B, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris L, Imus P, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall S, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1773-1782. doi: 10.1182\/bloodadvances.2025018057","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","title02":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1469-1472. doi: 10.1182\/bloodadvances.2025017795","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Graft manipulation and GVHD: what goes around comes around.","title02":"Graft manipulation and GVHD: what goes around comes around.","journal":"Blood","issue":"2026 March 12; 147(11):1137-1138. doi: 10.1182\/blood.2025032408","author":"Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817555"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1125-1134. doi: 10.1182\/blood.2025030151","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","title02":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031983. Online ahead of print","author":"Kumar R, Neidemire-Colley L, Garfinkle EA, Steere C, Surana S, Murray A, Giordano G, Martin O, Woodbury ED, Rivaldi A, Singh S, Corps K, Lederer K, Karunasiri M, Gorr MW, Wold LE, Sehgal L, Oestreich KJ, Grieselhuber NR, de Lima MJ, Blazar BR, Maillard I, Miller KE, Choe HK, Ranganathan P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770848"},{"title01":"Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma.","title02":"Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025018482. Online ahead of print","author":"Song Z, Cheng Y, Yang H, Zhang L, Zou L, Guo Y, Cao J, Huang H, Wang Z, Huang S, Fang Y, Lyu J, Zhang Y, Liu Y, Zhou K, Zhang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824782"},{"title01":"From phase 1 to approval: lymphoma’s long road.","title02":"From phase 1 to approval: lymphoma’s long road.","journal":"Blood advances","issue":"2026 March 10; 10(5):1809-1810. doi: 10.1182\/bloodadvances.2025018860","author":"Hertzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41771007"},{"title01":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","title02":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025018855. Online ahead of print","author":"Chen Z, Huang H, Fang X, Tian Y, Weng H, Gale RP, Zou L, Zhang W, Li Z, Guo H, Ge J, Huang Z, Chen N, Liang Y, Hong H, Lin T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824796"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine.","title02":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine.","journal":"Blood","issue":"2026 March 12; 147(11):1191-1198. doi: 10.1182\/blood.2025031423","author":"Hosoya H, Bastidas Torres AN, Fernandez-Pol S, Gubatan J, Najidh S, Duran GE, Dong F, Ehlinger ZJ, Lohman C, Wright C 3rd, Sahaf B, Mackall C, Miklos DB, Sidana S, Kurtz DM, Khodadoust MS, Mikkilineni L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288531"},{"title01":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","title02":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","journal":"Blood","issue":"2026 March 12; 147(11):1199-1214. doi: 10.1182\/blood.2024027700","author":"Feldman AL, Dasari S, Rimsza LM, Scott DW, Oishi N, Hu G, Farinha P, Amador C, Campo E, Chan WC, Cook JR, Delabie J, Fu K, Greiner TC, Hilton LK, Inghirami G, Iqbal J, Jaffe ES, Morin RD, Ondrejka SL, Ott G, Pittaluga S, Raess PW, Rosenwald A, Savage KJ, Slack GW, Slager SL, Song JY, Wright GW, Wang HW, Zeng Y, Yoshino T, Wu X, Wilcox RA, Wang X, Shi M, Satou A, Perry AM, Miranda RN, Medeiros LJ, Maurer MJ, Mou E, Ko YH, Karube K, Kahl BS, Jiang L, Jaye DL, Gru AA, de Leval L, Chen W, Chapman JR, Cerhan JR, Barrionuevo C, Ansell SM, Aljudi AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329859"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1125-1134. doi: 10.1182\/blood.2025030151","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","title02":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","journal":"Blood","issue":"2026 March 6. doi: 10.1182\/blood.2025031402. Online ahead of print","author":"Di Giacomo D, Polonen P, Bardelli V, Kimura S, Pierini V, Pagliaro L, Arniani S, Chang Y, Gao Q, Montefiori LE, Wu Y, Park CS, Wright WC, Vento F, Wei H, Matteucci C, Lei S, Rosikiewicz W, Nardelli C, Lema Fernandez AG, Ostergaard A, Backhaus EA, Baviskar P, Cerrano M, Leoncin M, Manabe A, Hirabayashi S, Takita J, Hasegawa D, Miyamoto S, Macchiarulo A, Xu J, Teachey DT, Roti G, Iacobucci I, La Starza R, Mecucci C, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791840"},{"title01":"Pretransplant promise for PD-1 in Hodgkin lymphoma.","title02":"Pretransplant promise for PD-1 in Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1015-1017. doi: 10.1182\/blood.2025032407","author":"Zammar G, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785003"},{"title01":"Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.","title02":"Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025031733. Online ahead of print","author":"Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774517"},{"title01":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","title02":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","journal":"Leukemia","issue":"2026 March; 40(3):481-490. doi: 10.1038\/s41375-025-02841-x","author":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, Shelat SG, Burgess MR, Godwin C, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501501"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","title02":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","journal":"Haematologica","issue":"2026 March 1; 111(3):1017-1028. doi: 10.3324\/haematol.2025.288381","author":"Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch JSZ, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994343"},{"title01":"Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.","title02":"Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300401. Online ahead of print","author":"Parrondo RD, De Menezes R, Sledge H, Nayyar M, Yadav K, Bergsagel L, Fonseca R, Kapoor P, Buadi F, Gertz MA, Dispenzieri A, Roy V, Sher T, Binder M, Abdallah N, Chhabra S, Rajkumar VS, Gonsalves WI, Cook J, Dingli D, Lin Y, Fernandez A, Flott C, Yadav U, Warsame RM, Wiedmeier-Nutor EE, Kourelis T, Leung N, Siddiqui MA, Kumar S, Chanan-Khan AA, Ailawadhi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784017"},{"title01":"REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed\/refractory multiple myeloma outside of clinical trials.","title02":"REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed\/refractory multiple myeloma outside of clinical trials.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.289281. Online ahead of print","author":"Uttervall K, Kortum MK, Perrot A, Farmer SL, Cavo M, Kishore B, Jacquet C, Casanova M, Hansson M, Weisel K, Magen H, Liberatore C, Hansen CT, Gatt ME, Shragai T, Da Via MC, Alvarez TS, Streetly M, Raab MS, Manier S, Aegesen J, Albrecht C, Hu P, Smirnov P, Santra D, Rubio-Azpeitia E, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784028"},{"title01":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","title02":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70415. Online ahead of print","author":"Qu F, Hui M, Yang F, He Y, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796105"},{"title01":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","title02":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70376. Online ahead of print","author":"Amiot Q, Assadi-Gazvini C, Bugier S, Arnautou P, Maillot J, Malfuson JV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797264"},{"title01":"Enostosis 100 days post-transplant in multiple myeloma.","title02":"Enostosis 100 days post-transplant in multiple myeloma.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70412. Online ahead of print","author":"Browner C, Erber W, Cirillo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797418"},{"title01":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","title02":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70428. Online ahead of print","author":"Aughey E, Estrada-Merly N, Akhtar OS, Dhakal B, Mohan M, Narra R, Pasquini MC, D'Souza A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797476"},{"title01":"Giant myeloma cells or crystal-storing histiocytes?","title02":"Giant myeloma cells or crystal-storing histiocytes?","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70422. Online ahead of print","author":"Chen H, Li L, Ma C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41808566"},{"title01":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","title02":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1559-1563. doi: 10.1182\/bloodadvances.2025018454","author":"Cedena MT, Puig N, Paiva B, de la Puerta JE, Perez-Montana A, Casanova M, Brena J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso R, Alvarez MA, Capote FJ, Garcia-Sanchez R, Perez JJ, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380099"},{"title01":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.","title02":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.","journal":"Blood","issue":"2026 March 5; 147(10):1070-1082. doi: 10.1182\/blood.2025029572","author":"Jelinek T, Zihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O, Moreno C, Fotiou D, Radova E, Tamariz-Amador LE, Theodorakakou F, Muronova L, Manubens A, Tsitsilonis O, Popkova T, Gonzalez C, Anilkumar Sithara A, Corrado F, Bidikian N, Guerrero C, Kapustova V, Bilek D, Hagner PR, Larrayoz M, Martinez Climent JA, Broskevicova L, Mihalyova J, Merz M, Sevcikova T, Ghobrial IM, San Miguel J, Dimopoulos MA, Rodriguez-Otero P, Radocha J, Kastritis E, Paiva B, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405507"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030207. Online ahead of print","author":"Minnie S, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SR, Schmidt CR, Comstock ML, Lyons J, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"TCR T cells targeting IgA- and IgG-expressing multiple myeloma.","title02":"TCR T cells targeting IgA- and IgG-expressing multiple myeloma.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031897. Online ahead of print","author":"Douvlataniotis K, Titov A, Zeun J, Bilici M, Palashati H, Loh W, Rustad EH, Yang W, Tran TT, Lund-Johansen F, Bollineni RC, Kepple JD, Huth LP, Munthe LA, Boxaspen T, Schjesvold F, Waage A, Wagner DL, Bull KR, Hester J, Issa F, Giannakopoulou E, Olweus J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770814"},{"title01":"IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.","title02":"IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031047. Online ahead of print","author":"Horns JM, Beder T, Kunstner A, Barz MJ, Bendig S, Bozzetti C, Chitadze G, Darzentas N, Iben K, Kotrova M, Martin-Subero JI, Mondal M, Neumann M, Fernandez Perez R, Stroh AS, Wessels W, Lenk L, Velten L, Boll B, Braitsch K, Bucklein VL, Duell J, Faul C, Fiedler W, Hanoun M, Janjetovic S, Klingler F, Knop S, Rollig C, Schwartz S, Spriewald BM, Steffen B, Wethmar K, Busch H, Gokbuget N, Baldus CD, Bastian L, Bruggemann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824395"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","title02":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300086. Online ahead of print","author":"Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784015"},{"title01":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","title02":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70397. Online ahead of print","author":"Cholack GA, Mwangi R, Vodicka P, Habermann TM, Hinder V, Robinson DP, Feldman AL, Witzig TE, Villasboas JC, Ansell SM, Link BK, Wang Y, Thompson CA, Slager SL, Maurer M, Novak AJ, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806244"},{"title01":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","title02":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70423. Online ahead of print","author":"De Re V, Lopci E, Brisotto G, Elia C, Vitullo A, Paduano V, De Zorzi M, Mussolin L, Quarello P, Bianchi S, Buffardi S, Garaventa A, Muggeo P, Pillon M, Sala A, Vinti L, d'Amore E, Mauz-Korholz C, Mascarin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41819087"},{"title01":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","title02":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","journal":"Br J Haematol","issue":"2026 March 5. doi: 10.1111\/bjh.70408. Online ahead of print","author":"Hwang YY, Au-Yeung R, Kwong YL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787739"},{"title01":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","title02":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70326. Online ahead of print","author":"Fu YC, Liu LP, Zhou YP, Yang MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787912"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70401. Online ahead of print","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Field-testing the MALT-IPI in a single center real-world cohort of patients with extranodal marginal zone lymphoma.","title02":"Field-testing the MALT-IPI in a single center real-world cohort of patients with extranodal marginal zone lymphoma.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025019076. Online ahead of print","author":"Sunder-Plassmann V, Kiesewetter B, Simonitsch-Klupp I, Brand R, Dolak W, Mayerhoefer M, Raderer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774849"},{"title01":"Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma.","title02":"Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1457-1468. doi: 10.1182\/bloodadvances.2025017160","author":"Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269777"},{"title01":"Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.","title02":"Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.","journal":"Blood advances","issue":"2026 March 10; 10(5):1713-1721. doi: 10.1182\/bloodadvances.2025017752","author":"Luo Z, Li M, Primeaux BC, Shah R, Lin R, Iyer SP, Nastoupil LJ, Green MR, Westin JR, Flowers CR, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201381"},{"title01":"Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","title02":"Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","journal":"Blood advances","issue":"2026 March 10; 10(5):1591-1602. doi: 10.1182\/bloodadvances.2025018079","author":"Merryman R, Rutherford SC, Ansell S, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman J, Zelenetz AD, Gutierrez M, Beguelin W, Casulo C, Cerhan J, Green M, Kahl B, Kridel R, Link B, Maurer MJ, Nadel B, Radtke AJ, Luttwak E, Salles G, Sehn L, Pasqualucci L, LaCasce AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337699"},{"title01":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","title02":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","journal":"Blood advances","issue":"2026 March 10; 10(5):1756-1772. doi: 10.1182\/bloodadvances.2025017643","author":"Kong X, Xu-Monette ZY, Xu Z, Hsi ED, Zhao X, Yan H, Nunns H, Au K, Visco C, Tzankov A, Dybkaer K, Yao S, Wu D, Wang C, Xu AM, Pan Z, Parsons BM, Chiu A, Tam W, Montes-Moreno S, Zhan F, Bernal-Mizrachi L, Zu Y, Zhang S, Moller MB, Chen W, Au Q, Merchant A, Bhagat G, Li Y, Young KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346287"},{"title01":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B-cell lymphoma.","title02":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1634-1645. doi: 10.1182\/bloodadvances.2025016858","author":"Yoon SE, Kang W, Cho J, Cho HJ, Chalita M, Oh HS, Hyun DW, Han S, Kim H, Sung H, Lee JY, Park B, Ryu KJ, Kim HY, Cho D, Kim WS, Kim SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364878"},{"title01":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","title02":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1733-1742. doi: 10.1182\/bloodadvances.2025016646","author":"Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej R, Bressel M, Di Iulio J, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380113"},{"title01":"OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R\/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.","title02":"OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R\/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019367. Online ahead of print","author":"Santoro N, Mooyaart JE, Novak U, Protheroe R, Ayuk FA, Dreger P, van Meerten T, Paneesha S, Sanderson R, Ram R, Northend M, Forcade E, Huynh A, Yakoub-Agha I, Hoogenboom JD, Coelho MHM, Pagliuca S, Malard F, Kuball J, Sureda A, Bazarbachi A, Ruggeri A, Rocha V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779968"},{"title01":"Prognostic value of inflammation-based scores in patients with R\/R LBCL treated with CD3xCD20 bispecific T-cell engagers.","title02":"Prognostic value of inflammation-based scores in patients with R\/R LBCL treated with CD3xCD20 bispecific T-cell engagers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1675-1686. doi: 10.1182\/bloodadvances.2025017766","author":"Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Muller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VKJ, Poeck H, Dong N, Holtick U, Ram R, Pabst T, Shumilov E, Lenz G, Iacoboni G, Barba P, Bucklein V, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124666"},{"title01":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","title02":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1722-1732. doi: 10.1182\/bloodadvances.2025016765","author":"Li N, Liu Y, Zhang L, Guo S, Wu Z, Xu Y, Yang M, Kong J, Che Y, Shao K, Yang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428986"},{"title01":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","title02":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1670-1674. doi: 10.1182\/bloodadvances.2025018059","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1773-1782. doi: 10.1182\/bloodadvances.2025018057","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.","title02":"Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025019322. Online ahead of print","author":"Neumann MA, Schneider J, Szameitat M, Schommers P, Borchmann S, Hallek MJ, Borchmann P, Heger JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785308"},{"title01":"Proteogenomic features define subtypes of mantle cell lymphoma.","title02":"Proteogenomic features define subtypes of mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018701. Online ahead of print","author":"Yan Y, Chen W, Ge X, Sun J, Yu L, Garcia-Mansfield K, Zhang X, Yu Y, Xiong W, Zou D, An G, Jia Z, Pirrotte P, Li JJ, Yu Z, Hao M, Qiu L, Qi J, Wang L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785305"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","title02":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025017966. Online ahead of print","author":"Challenger A, McGale P, Probert J, Barrett A, Broggio J, Collins GP, Kayiparambil Harish K, Roden L, Royston D, Wang Z, Darby SC, Cutter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779974"},{"title01":"Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.","title02":"Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.","journal":"Blood advances","issue":"2026 March 10; 10(5):1497-1507. doi: 10.1182\/bloodadvances.2025016361","author":"Kho SJ, Diamond S, Lafeuille P, Schatz JH, Maura F, Aptekar J, Locke FL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201393"},{"title01":"Splitting from a lump: harmonizing ALCL classification.","title02":"Splitting from a lump: harmonizing ALCL classification.","journal":"Blood","issue":"2026 March 12; 147(11):1142-1143. doi: 10.1182\/blood.2025031931","author":"Ng SY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817557"},{"title01":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","title02":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","journal":"Blood","issue":"2026 March 5; 147(10):1058-1069. doi: 10.1182\/blood.2025029329","author":"Rhein S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, Serin N, Leisegang M, Timiliotis S, Ohlmeier L, Freund C, Willimsky G, Konietschke F, Kieback E, Tasian SK, Chapuy B, Keller U, Blankenstein T, Pezzutto A, Busse A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100732"},{"title01":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","title02":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025032050. Online ahead of print","author":"Oertel M, Dabaja BS, Gorlich D, Thomas BR, Sim V, Johnstone P, Hashmi A, Levis M, Ackerson B, Hague C, Weil CR, Plastaras J, Roos DE, Kirova Y, Fietkau R, Fang PQ, Ng AK, Bock F, Tseng YD, Linde P, Dunst J, Terezakis SA, Easwaran T, Peeken JC, Wittig A, Yoon HI, Tao R, Illidge TM, Kelsey CR, Ricardi U, Binkley MS, Campbell BA, Morris SL, Elsayad K, Storck M, Hoppe RT, Eich HT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824381"},{"title01":"Ready, set, GO? Treating older adults with AML.","title02":"Ready, set, GO? Treating older adults with AML.","journal":"Blood","issue":"2026 March 5; 147(10):1007-1008. doi: 10.1182\/blood.2025032119","author":"Jen WY, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785006"},{"title01":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","title02":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031466. Online ahead of print","author":"Mimura K, Kaino A, Ochi Y, Chang YH, Seki M, Takeda J, Katayama S, Niizuma H, Sasahara Y, Mizoguchi Y, Shimomura M, Koyamada R, Ono R, Hasegawa D, Mitani K, Kubota H, Yoshihara S, Hiramoto N, Otsuki A, Okamura Y, Katsuoka F, Kinoshita K, Hasegawa M, Togo-Ohno M, Maeda H, Kakiuchi N, Takeuchi M, Sato-Otsubo A, Kato S, Watanabe K, Katayama K, Imoto S, Shiraishi Y, Koh K, Suenobu S, Hiyama E, Goyama S, Kikuchi A, Ogawa S, Kato M, Nannya Y, Takita J, Yoshida K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790573"},{"title01":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","title02":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02896-4. Online ahead of print","author":"Lonardi S, Cancila V, Morello G, Varano G, Balzarini P, Pellegrini V, Albertini E, Giampaolo S, Pietrini I, Thanasi H, Sindaco P, Piazza F, Manni S, Lorenzini D, Pruneri G, Dei Tos AP, Ponzoni M, Facchetti F, Pizzi M, Lorenzi L, Tripodo C, Casola S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792441"},{"title01":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","title02":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","journal":"Lancet Oncol","issue":"2026 March; 27(3):361-371. doi: 10.1016\/S1470-2045(25)00678-3","author":"Pearson C, Jones DA, Baily G, Cherry R, Gray E, Hiom S, Rous B, Spencer K, Jose S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713471"},{"title01":"CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma.","title02":"CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma.","journal":"Lancet","issue":"2026 March 7; 407(10532):917-919. doi: 10.1016\/S0140-6736(26)00094-2","author":"Zhang S, Zhang H, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41794420"},{"title01":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","title02":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","journal":"Lancet","issue":"2026 March 7; 407(10532):963-975. doi: 10.1016\/S0140-6736(25)02435-3","author":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, Garcia-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692020"},{"title01":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","title02":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300086. Online ahead of print","author":"Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784015"},{"title01":"Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.","title02":"Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.289285. Online ahead of print","author":"Yang J, Villa D, Gerrie AS, Tonseth RP, Wilson DC, Benard F, Slack GW, Venner CP, Lo AC, Scott DW, Sehn LH, Savage KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784019"},{"title01":"Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.","title02":"Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.287782. Online ahead of print","author":"Duan Y, Gao H, Jin L, Yang J, Huang S, Zhang M, Li N, Yang X, Xu H, Wang T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784029"},{"title01":"Prognosis in marginal zone lymphoma: a comprehensive review.","title02":"Prognosis in marginal zone lymphoma: a comprehensive review.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300416. Online ahead of print","author":"Talami A, Nizzoli ME, Cappello E, Luminari S, Arcaini L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784035"},{"title01":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","title02":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 March 1; 111(3):876-891. doi: 10.3324\/haematol.2025.287547","author":"Alhomoud M, Ibrahim R, Demetres M, Rejeski K, Scordo M, Shouval R, Tix T, Martinet J, Foley M, Gomez-Arteaga A, Shore T, Pagnini P, Aljurf M, Guzman ML, Formenti S, Yahalom J, Van Besien K, Imber BS, Chen Z, Yamshon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637750"},{"title01":"The expanding spectrum of CAR-T related T-cell lymphomas.","title02":"The expanding spectrum of CAR-T related T-cell lymphomas.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300499. Online ahead of print","author":"Schonrade T, Braun T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816824"},{"title01":"Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.","title02":"Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300488. Online ahead of print","author":"Noerenberg D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816814"},{"title01":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.","title02":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.","journal":"Haematologica","issue":"2026 March 1; 111(3):1007-1016. doi: 10.3324\/haematol.2025.287919","author":"Chung E, Wang L, Wellard C, Barraclough A, Campbell BA, Chong G, Ciaccio PD, Gregory GP, Hapgood G, Johnston AM, Tam CS, Opat S, Wood EM, McQuilten ZK, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994345"},{"title01":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.","title02":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.","journal":"Haematologica","issue":"2026 March 1; 111(3):1111-1115. doi: 10.3324\/haematol.2025.288699","author":"Yang J, Hayden AR, Villa D, Jiang A, Gerrie AS, Venner CP, Farinha P, Scott DW, Sehn LH, Savage KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035405"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","journal":"Haematologica","issue":"2026 March 1; 111(3):1116-1119. doi: 10.3324\/haematol.2025.288780","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.","title02":"Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300167. Online ahead of print","author":"Picardi M, Vincenzi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816839"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.","title02":"To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300832. Online ahead of print","author":"Russler-Germain DA, Bartlett NL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816825"},{"title01":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 1; 111(3):1029-1033. doi: 10.3324\/haematol.2025.287672","author":"Santoro A, Improta CM, Sarina B, Mannina D, De Philippis C, Taurino D, Mariotti J, Balzarotti M, Bramanti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963380"},{"title01":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","title02":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","journal":"Haematologica","issue":"2026 March 1; 111(3):1120-1124. doi: 10.3324\/haematol.2025.288045","author":"Kiener TA, Schweighofer-Zwink G, Rendl G, Kern JM, Baskova L, Neureiter D, Melchardt T, Raderer M, Greil R, Pirich C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307123"},{"title01":"Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.","title02":"Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300761. Online ahead of print","author":"Avivi I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816813"},{"title01":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","title02":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70424. Online ahead of print","author":"Danesin N, Autore F, Frustaci AM, Favrin G, Cencini E, Noto A, Dogliotti I, Olivieri J, Riva M, Ferrarini I, Barbui AM, Steffanoni S, Marino D, Puccini B, Stefani PM, Rizzi R, Merli M, Ferrari A, Luminari S, Visco C, Trentin L, Visentin A, Conconi A, Ferrero S, Varettoni M, Tedeschi A, Laurenti L, Piazza F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796393"},{"title01":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","title02":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70417. Online ahead of print","author":"Nasibov T, Cunningham A, Sarpong L, Smyth E, O'Brien O, Quinn J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806113"},{"title01":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","title02":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70357. Online ahead of print","author":"O'Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B, Johnson R, Alajangi R, Creasey T, Abdulgawad A, Arias CG, Iyengar S, Ferguson G, Panopoulou K, Delaney A, Pryce A, Rubio L, Jones C, Lambert J, Gupta S, Mathew A, Kasivisvanathan S, Awofisayo O, Hanmantgad S, Collins GP, Besley C, Seymour F, Sanderson R, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796018"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","title02":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","journal":"Br J Haematol","issue":"2026 March 3. doi: 10.1111\/bjh.70410. Online ahead of print","author":"Tuteja SK, Wlodaver A, Kirschmann D, Caparelli E, Yap KL, Schubert J, Zhong Y, Li MM, Leuer K, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773598"},{"title01":"Maneuvering ofCS toward precision medicine for AML?","title02":"Maneuvering ofCS toward precision medicine for AML?","journal":"Blood","issue":"2026 March 12; 147(11):1144-1145. doi: 10.1182\/blood.2025032403","author":"Carlsten M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817556"},{"title01":"Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia.","title02":"Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia.","journal":"Blood","issue":"2026 March 5; 147(10):1083-1097. doi: 10.1182\/blood.2025029875","author":"Zhang L, Kang H, Valerio M, Hoang DH, Pathak K, Garcia-Mansfield K, Lu X, Guo W, Fu YH, He X, Chen YC, Chen Z, Ghoda L, Buettner R, Li Z, Blackmon A, Li L, Zhang B, Pirrotte P, Marcucci G, Kuo YH, Nguyen LXT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397241"},{"title01":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","title02":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2026 March 12; 147(11):1147-1167. doi: 10.1182\/blood.2025031480","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","title02":"Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025031521. Online ahead of print","author":"Suzuki A, Shigehiro T, Hirakawa M, Hirano R, Tamai M, Akahane K, Okamoto K, Takayanagi H, Terashima Y, Ueha S, Kitami T, Takagi M, Keino D, Kawaguchi H, Kato K, Hino M, Inukai T, Yoshimura A, Ikawa T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774513"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"The prevalence and clinical significance of clonal monocytosis.","title02":"The prevalence and clinical significance of clonal monocytosis.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025031883. Online ahead of print","author":"Dunn WG, Sachs MC, Maggi M, Gu M, Quiros PM, Batta K, Andersen CL, Fabre MA, Chevassut TJ, Mohorianu I, Wiseman DH, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802133"},{"title01":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.","title02":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1048-1057. doi: 10.1182\/blood.2025031006","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew G, Dillon R, Gilkes A, Marquez Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne J, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills R, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","title02":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","journal":"Blood","issue":"2026 March 5; 147(10):1058-1069. doi: 10.1182\/blood.2025029329","author":"Rhein S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, Serin N, Leisegang M, Timiliotis S, Ohlmeier L, Freund C, Willimsky G, Konietschke F, Kieback E, Tasian SK, Chapuy B, Keller U, Blankenstein T, Pezzutto A, Busse A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100732"},{"title01":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","title02":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","journal":"Blood","issue":"2026 March 6. doi: 10.1182\/blood.2025031402. Online ahead of print","author":"Di Giacomo D, Polonen P, Bardelli V, Kimura S, Pierini V, Pagliaro L, Arniani S, Chang Y, Gao Q, Montefiori LE, Wu Y, Park CS, Wright WC, Vento F, Wei H, Matteucci C, Lei S, Rosikiewicz W, Nardelli C, Lema Fernandez AG, Ostergaard A, Backhaus EA, Baviskar P, Cerrano M, Leoncin M, Manabe A, Hirabayashi S, Takita J, Hasegawa D, Miyamoto S, Macchiarulo A, Xu J, Teachey DT, Roti G, Iacobucci I, La Starza R, Mecucci C, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791840"},{"title01":"MRD is a new therapeutic target in AML.","title02":"MRD is a new therapeutic target in AML.","journal":"Blood","issue":"2026 March 5; 147(10):1012-1013. doi: 10.1182\/blood.2025032278","author":"Recher C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785005"},{"title01":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","title02":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2024027753. Online ahead of print","author":"Polcik L, Pethe A, Ashok D, Tissino E, Fernandez-Rego A, Pozzo F, Danner DJ, Holst M, Martines C, Hofmann K, Dimovski AJ, Kissel S, Harzschel A, Li L, Bittolo T, Andrieux G, Haslauer T, Hopner JP, Zaborsky N, Greil R, Miething C, Duque-Afonso J, Kohler N, Boerries M, Bomben R, Duyster J, Grosse R, Gaidano G, Zamo A, Zucchetto A, Carrasco YR, Efremov DG, Gattei V, Hartmann TN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790574"},{"title01":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","title02":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):694-697. doi: 10.1038\/s41375-026-02870-0","author":"Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703025"},{"title01":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","title02":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):638-648. doi: 10.1038\/s41375-026-02884-8","author":"Gao J, Zhao X, Yin Q, Hu A, Qiu K, Blackburn L, Lei L, Xiong R, Bi C, Craig JW, Portell CA, Davila ML, Williams ME, Tao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41680300"},{"title01":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):708. doi: 10.1038\/s41375-026-02863-z","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41673334"},{"title01":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","title02":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):685-688. doi: 10.1038\/s41375-026-02872-y","author":"Yang ZZ, Kim HJ, Tang X, Novak JP, Bhardwaj V, Mukherjee P, Villasboas JC, Novak AJ, Mondello P, Ansell SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639205"},{"title01":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","title02":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):681-684. doi: 10.1038\/s41375-026-02861-1","author":"Nikkarinen A, Almlof J, Osterroos A, Ladenvall C, Amini RM, Hollander P, Ayoola Gustafsson K, Baliakas P, Glimelius I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639203"},{"title01":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","title02":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","journal":"Leukemia","issue":"2026 March; 40(3):666-670. doi: 10.1038\/s41375-025-02849-3","author":"Graf CM, Reese M, Vicente-Luque A, Monig N, Bruzeau C, Nadeu F, Latacz M, Bihler J, Meinel J, Cartolano M, Peifer M, Bea S, Campo E, Thelen M, Brockelmann PJ, Jachimowicz RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588054"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):522-539. doi: 10.1038\/s41375-025-02844-8","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","title02":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02869-7. Online ahead of print","author":"Grunenberg A, Schmelzle B, Gokeler J, Mund H, Viardot A, Dreyhaupt J, Nagel G, Reiser M, Gabrysiak T, Braulke F, Dunst J, Schlag R, Gaska T, Runde V, Kraemer D, Weber T, Mueller L, Johansson P, Ziske C, Hess G, Liersch R, Buske C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792439"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018188. Online ahead of print","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Elevated lactate in AML bone marrow contributes to macrophage polarization via GPR81 signaling.","title02":"Elevated lactate in AML bone marrow contributes to macrophage polarization via GPR81 signaling.","journal":"Blood advances","issue":"2026 March 10; 10(5):1614-1629. doi: 10.1182\/bloodadvances.2025016400","author":"Soto CA, Lesch ML, Becker JL, Sharipol A, Khan A, Schafer XL, Li Z, Streeter AR, Becker MW, Munger JC, Frisch BJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364872"},{"title01":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","title02":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","journal":"Blood advances","issue":"2026 March 10; 10(5):1522-1536. doi: 10.1182\/bloodadvances.2025017243","author":"Kuehn HS, Gil Silva AA, Klangkalya N, Esteve-Sole A, Goel S, Niemela JE, Stoddard JL, Chong H, Williams K, Ip W, Framil Seoane M, Loganathan SK, Anantharachagan A, Garcia-Soidan A, Shaffren S, Bindernagel C, Mendez P, Miller RZ, Abolhassani H, Hoytema van Konijnenburg DP, Geerlinks AV, Cabanillas D, Zonneveld-Huijssoon E, Rutgers A, Tangye S, Ma C, Grey A, O'Young P, Aldave Becerra JC, Lyons JJ, White AA, Claiborne M, Doroudchi MA, Modena BD, Milner JD, Solanich X, Farela Neves J, Platt CD, Hammarstrom L, Routes JM, Verbsky J, Butte MJ, Lesmana H, Griffiths WJH, Kumararatne D, Hauck F, Allende LM, Rodriguez-Gallego C, Elfeky R, Rubin T, Boztug K, Fleisher TA, Rosenzweig SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380100"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2026 March 10; 10(5):1537-1547. doi: 10.1182\/bloodadvances.2025018178","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque TZ, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss IT, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","title02":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","journal":"Blood advances","issue":"2026 March 10; 10(5):1576-1586. doi: 10.1182\/bloodadvances.2025017837","author":"Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124669"},{"title01":"The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.","title02":"The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.","journal":"Blood","issue":"2026 March 12; 147(11):1229-1236. doi: 10.1182\/blood.2024028147","author":"Mujollari J, Estruch M, Khadgawat P, Choudhary S, Gustavsson T, Dagil R, Redlinger N, Loppke C, Vidal-Calvo EE, Nordmaj MA, Theander TG, Heidenreich O, Nguyen Y, Qin S, Tolboll Sorensen AL, Gronbaek K, Porse BT, Kircher B, Mueller J, Agerbaek MO, Salanti A, Theilgaard-Monch K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405498"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","title02":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","journal":"Blood","issue":"2026 March 12; 147(11):1199-1214. doi: 10.1182\/blood.2024027700","author":"Feldman AL, Dasari S, Rimsza LM, Scott DW, Oishi N, Hu G, Farinha P, Amador C, Campo E, Chan WC, Cook JR, Delabie J, Fu K, Greiner TC, Hilton LK, Inghirami G, Iqbal J, Jaffe ES, Morin RD, Ondrejka SL, Ott G, Pittaluga S, Raess PW, Rosenwald A, Savage KJ, Slack GW, Slager SL, Song JY, Wright GW, Wang HW, Zeng Y, Yoshino T, Wu X, Wilcox RA, Wang X, Shi M, Satou A, Perry AM, Miranda RN, Medeiros LJ, Maurer MJ, Mou E, Ko YH, Karube K, Kahl BS, Jiang L, Jaye DL, Gru AA, de Leval L, Chen W, Chapman JR, Cerhan JR, Barrionuevo C, Ansell SM, Aljudi AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329859"},{"title01":"The Transposable Element-PARP Axis Underpins Synthetic Lethality and Immunogenic Vulnerability in Blood Cancer.","title02":"The Transposable Element-PARP Axis Underpins Synthetic Lethality and Immunogenic Vulnerability in Blood Cancer.","journal":"Blood","issue":"2026 March 10. doi: 10.1182\/blood.2025032216. Online ahead of print","author":"Zeisig BB, Karimi MM, So CWE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812189"},{"title01":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","title02":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030630. Online ahead of print","author":"Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770817"},{"title01":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","title02":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025032299. Online ahead of print","author":"Becilli M, Merli P, Algeri M, Del Bufalo F, Pagliara D, Bertaina V, Agrati C, Rosignoli C, Cefalo MG, Boccieri E, Di Cecca S, Iaffaldano L, Lee Y, De Angelis B, Meshinchi S, Quintarelli C, Campana D, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774512"},{"title01":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.","title02":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.","journal":"Haematologica","issue":"2026 March 1; 111(3):906-917. doi: 10.3324\/haematol.2025.288249","author":"Yuan M, Zhou L, Li W, Du X, Weng J, Yang L, Ma Y, Liu B, Liu Z, Wen Q, Zhao S, Zhang Y, Bai Q, Feng X, Han Y, Liu C, Meng L, Wang B, Ran X, Wang X, Zhang H, Zeng Y, Leng Q, Yu L, Li Z, Gale RP, Huang X, Jiang Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098110"},{"title01":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","title02":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70407. Online ahead of print","author":"Li J, Lorsbach RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793012"},{"title01":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","title02":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70388. Online ahead of print","author":"Mason G, Hanamshet A, Kim S, Singh N, McIlroy K, Greenwood M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793040"},{"title01":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","title02":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70409. Online ahead of print","author":"Claudiani S, Metelli S, Khan A, Hannah G, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Fernando F, Innes AJ, Apperley JF, Milojkovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797306"},{"title01":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","title02":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70400. Online ahead of print","author":"Yamamoto C, Yamaguchi T, Honda S, Tominaga R, Yokoyama D, Furuki S, Noguchi A, Koyama S, Murahashi R, Nakashima H, Kawaguchi SI, Hyodo K, Toda Y, Umino K, Minakata D, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792981"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Short and complex-Telomeres and genomes in CLL.","title02":"Short and complex-Telomeres and genomes in CLL.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70430. Online ahead of print","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814451"},{"title01":"Sweet’s syndrome in acute myeloid leukaemia.","title02":"Sweet’s syndrome in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70389. Online ahead of print","author":"Mon HT, Han KH, Nicholson E, Aguilar-Duran S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814590"},{"title01":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","title02":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70418. Online ahead of print","author":"Costa A, Scalzulli E, Carmosino I, Bisegna ML, Lagana A, Ielo C, Cappelli L, Martelli M, Breccia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41820245"},{"title01":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","title02":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70386. Online ahead of print","author":"Scott AP, Lo A, Xia Y, Thompson K, Bodimeade H, Fazlollahi A, Weber N, Curley C, Hunt S, Morris K, McNamara C, Perera N, Subramoniapillai E, Lane SW, Kennedy GA, Salvado O, Urriola J, McMahon KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41821185"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","title02":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025017325. Online ahead of print","author":"Wang L, Zhan Q, Luo J, Li J, He C, Zhu Y, Pei CX, Chen Y, Tang NN, Yin J, Su L Sr, Chen J, Xie M, Liu L, Luo XH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824794"},{"title01":"Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.","title02":"Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.","journal":"Blood advances","issue":"2026 March 10; 10(5):1687-1699. doi: 10.1182\/bloodadvances.2025018757","author":"Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A, Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M, Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F, Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis R, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V, Vitale C, Romeo A, Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499776"},{"title01":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","title02":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025017966. Online ahead of print","author":"Challenger A, McGale P, Probert J, Barrett A, Broggio J, Collins GP, Kayiparambil Harish K, Roden L, Royston D, Wang Z, Darby SC, Cutter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779974"},{"title01":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","title02":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","journal":"Blood advances","issue":"2026 March 10; 10(5):1481-1486. doi: 10.1182\/bloodadvances.2025018090","author":"Aquilanti E, Kageler L, Bozinov V, Meyerson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259746"},{"title01":"Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.","title02":"Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1700-1712. doi: 10.1182\/bloodadvances.2025017753","author":"Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411486"},{"title01":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","title02":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1670-1674. doi: 10.1182\/bloodadvances.2025018059","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","title02":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1469-1472. doi: 10.1182\/bloodadvances.2025017795","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.","title02":"Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.","journal":"Blood","issue":"2026 March 12; 147(11):1237. doi: 10.1182\/blood.2025032104","author":"Dermer K, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817552"},{"title01":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","title02":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):843-851. doi: 10.3324\/haematol.2025.287777","author":"Murphy T, Zhang B, Zhang T, King I, Capo-Chichi JM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KWL, Arruda A, Lu Z, Khalaf D, Rockwell C, Leber B, Sabloff M, Tierens A, Stockley TL, Chan SM, Ng SWK, Wang JCY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637740"},{"title01":"Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia.","title02":"Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300442. Online ahead of print","author":"Frisch A, Krayem B, Zuckerman T, Henig I, Yehudai-Ofir D, Glaubach N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784023"},{"title01":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.","title02":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.","journal":"Haematologica","issue":"2026 March 1; 111(3):1044-1048. doi: 10.3324\/haematol.2025.287942","author":"Chevillon F, Labrune E, Clappier E, Lapillonne H, Ballerini P, Lange VB, Fortin A, Itzykson R, Socie G, Buzyn A, Leverger G, Dalle JH, Dhedin N, Boissel N, De Latour RP, Salle B, Roux C, Poirot C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637728"},{"title01":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/beta-catenin pathway.","title02":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/beta-catenin pathway.","journal":"Haematologica","issue":"2026 March 1; 111(3):828-842. doi: 10.3324\/haematol.2025.287651","author":"Veltri G, Peloso A, Cani A, Mariotto E, Corallo D, Aveic S, Russo L, Cescon M, Santinon G, Frasson C, Simon K, Arrighi A, Iorio E, Minuzzo SA, Indraccolo S, Marmiroli S, Ntziachristos P, Biffi A, Pigazzi M, Buldini B, Bresolin S, Serafin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035400"},{"title01":"Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response.","title02":"Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response.","journal":"Haematologica","issue":"2026 March 1; 111(3):1053-1060. doi: 10.3324\/haematol.2025.288054","author":"Barone PD, Dzedzik S, Kleinman AS, Chin CR, Meydan C, Valencia I, Sugita M, Guzman ML, Fein JA, Kaner JD, Desai P, Roboz GJ, Melnick AM, Mason CE, Patel SS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931876"},{"title01":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","title02":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","journal":"Haematologica","issue":"2026 March 1; 111(3):1130-1135. doi: 10.3324\/haematol.2025.288752","author":"Wei Q, Pemmaraju N, Wang SA, Hu S, DiNardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros JL, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262054"},{"title01":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/ refractory acute myeloid leukemia.","title02":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/ refractory acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):1075-1080. doi: 10.3324\/haematol.2025.288178","author":"Verdeyen K, Reuvekamp T, Van der Velden WJFM, Wouters BJ, Von dem Borne PA, Van Rhenen A, Lissenberg-Witte BI, Van Lammeren D, Van Sluis GL, De Jongh E, Fiets RB, Corsten MF, Van der Spek AC, Gerrits AM, Van Bladel ER, Tick LW, De Weerdt O, Van Zaane B, Cruijsen MJ, Posthuma EFM, Van Elssen CHMJ, Klein SK, Van de Loosdrecht AA, De Leeuw DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963393"},{"title01":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.","title02":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.","journal":"Haematologica","issue":"2026 March 1; 111(3):918-926. doi: 10.3324\/haematol.2025.288516","author":"Lokhorst DN, Smit Y, Van den Bemt BJF, Hermens RPMG, Nijziel MR, Jie AK, Daenen LGM, Klein SK, Posthuma EFM, Westerweel PE, Donker M, Hoogendoorn M, Bekker CL, Blijlevens NMA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035410"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","journal":"Haematologica","issue":"2026 March 1; 111(3):1116-1119. doi: 10.3324\/haematol.2025.288780","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.","title02":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):1065-1069. doi: 10.3324\/haematol.2025.288131","author":"Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931864"},{"title01":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.","title02":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.","journal":"Haematologica","issue":"2026 March 1; 111(3):1039-1043. doi: 10.3324\/haematol.2025.287910","author":"Tang X, Zhao L, Li W, Liu S, Li X, Zhu L, Wang D, Chen S, Liu Z, Liu S, Wen F, Abla O, Wang Y, Mai H, Fu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931858"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"Acute leukemia of ambiguous lineage: the known and the uncertain.","title02":"Acute leukemia of ambiguous lineage: the known and the uncertain.","journal":"Haematologica","issue":"2026 March 1; 111(3):813-827. doi: 10.3324\/haematol.2025.287793","author":"Sherban A, Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063702"},{"title01":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","title02":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","journal":"Haematologica","issue":"2026 March 1; 111(3):997-1006. doi: 10.3324\/haematol.2025.288006","author":"Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098096"},{"title01":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","title02":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70420. Online ahead of print","author":"Poirot M, de Medina P, Silvente-Poirot S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41804099"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70401. Online ahead of print","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 March; 40(3):594-608. doi: 10.1038\/s41375-025-02828-8","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):622-629. doi: 10.1038\/s41375-026-02874-w","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e133-e143. doi: 10.1016\/S2352-3026(25)00328-X","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","title02":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e157-e168. doi: 10.1016\/S2352-3026(25)00358-8","author":"Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Hollein A, Kraus S, Schafer-Eckart K, Hanel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Rohnert MA, Oelschlagel U, Wagenfuhr L, Thiede C, Herold S, Poitz D, Stolzel F, Baldus CD, Serve H, Wermke M, Bornhauser M, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791831"},{"title01":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","title02":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e169-e180. doi: 10.1016\/S2352-3026(25)00361-8","author":"Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791832"},{"title01":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","title02":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e144-e156. doi: 10.1016\/S2352-3026(25)00357-6","author":"Gruber TA, Jeha S, Deyell RJ, Lewis V, Chang BH, Lowe EJ, Frediani J, Vezina C, Michon B, Richards M, Breese EH, Tran TH, Lacayo N, Bolen C, Desai S, Pauley JL, Huang M, Ashcraft E, Cheng C, Schultz KR, Stork L, Schlis K, Huynh VT, Gossai N, Messinger YH, Bittencourt H, Horton TM, Athale U, Stearns D, Schiff D, Gaynon PS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692013"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.","title02":"Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.288334. Online ahead of print","author":"Oehler VG, Berman E, Huang IJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816837"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia.","title02":"Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300561. Online ahead of print","author":"Bassan R, Skert C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816828"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","title02":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300199. Online ahead of print","author":"Zadro Y, Lafaurie M, Sommet A, Lapeyre-Mestre M, Moulis G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816826"},{"title01":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","title02":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.288146. Online ahead of print","author":"Feng J, Wang K, Gou J, Wang Y, Hu B, Wei W, Ge J, Feng Y, Feng S, Solary E, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784036"},{"title01":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience.","title02":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience.","journal":"Haematologica","issue":"2026 March 1; 111(3):852-860. doi: 10.3324\/haematol.2025.288246","author":"Arcourt A, Ilan U, Murillo L, Arad-Cohen N, Rubio A, Tasian SK, Baruchel A, Zwaan MC, Ducassou S, Goemans BF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098113"},{"title01":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","title02":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):775-777. doi: 10.3324\/haematol.2025.288928","author":"Sandhu M, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342189"},{"title01":"The sobering reality of fertility preservation in young female patients with acute leukemia.","title02":"The sobering reality of fertility preservation in young female patients with acute leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):791-793. doi: 10.3324\/haematol.2025.288538","author":"Frisch A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994349"},{"title01":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","title02":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):704-707. doi: 10.1038\/s41375-026-02888-4","author":"Wang C, Ge S, Gao J, Yang R, Guo X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703029"},{"title01":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2026 March 5. doi: 10.1038\/s41375-026-02909-2. Online ahead of print","author":"Setiawan T, Muhammad JA, Julianto NM, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787068"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):522-539. doi: 10.1038\/s41375-025-02844-8","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","title02":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","journal":"Leukemia","issue":"2026 March; 40(3):553-561. doi: 10.1038\/s41375-025-02847-5","author":"Rea D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, Illes A, Angona Figueras A, Kiani A, Charbonnier A, Marinakis T, Stenke L, Steegmann JL, Saglio G, Hellmann A, Niederwieser D, Schuld P, Rosti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555010"},{"title01":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","title02":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):577-586. doi: 10.1038\/s41375-025-02855-5","author":"Ansuinelli M, Peragine N, De Propris MS, Puzzolo MC, Di Trani M, Elia L, Skert C, Cairoli R, Sica S, Rambaldi A, Tucci A, Cerrano M, Vallisa D, Cardinali V, Mule A, Chiaretti S, Guarini A, Foa R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571767"},{"title01":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","title02":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","journal":"Leukemia","issue":"2026 March; 40(3):562-576. doi: 10.1038\/s41375-026-02862-0","author":"Wang Y, Wang X, Li M, Song H, Liu C, Shi M, Tao X, Shen S, Li X, Fang H, Zhou Z, Zhang J, Han B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571768"},{"title01":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","title02":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","journal":"Leukemia","issue":"2026 March; 40(3):630-637. doi: 10.1038\/s41375-026-02873-x","author":"Nielsen CG, Als-Nielsen B, Albertsen BK, Davidsson OB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andres-Jensen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41667647"},{"title01":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):708. doi: 10.1038\/s41375-026-02863-z","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41673334"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 March; 40(3):649-660. doi: 10.1038\/s41375-026-02886-6","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","title02":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","journal":"Leukemia","issue":"2026 March; 40(3):540-552. doi: 10.1038\/s41375-025-02856-4","author":"Camiolo G, Gonzalez Silvera D, Leah T, Schwaller J, Ottersbach K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545699"},{"title01":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02898-2. Online ahead of print","author":"Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792440"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","title02":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02901-w. Online ahead of print","author":"Selimoglu-Buet D, Chevret S, Santini V, Thepot S, Morabito M, Ades L, Laplane L, Giagounidis A, Droin N, Lubbert M, Sapena R, Nimubona S, Torregrosa-Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Paul F, Patriarca A, Stamatoullas A, Gotze K, Chermat F, Platzbecker U, Fenaux P, Solary E, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803403"},{"title01":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","title02":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02905-6. Online ahead of print","author":"Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814014"},{"title01":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","title02":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02906-5. Online ahead of print","author":"Parker H, Carr L, Norris K, Nilsson-Takeuchi A, Stevens B, Amarasinghe H, Kadalayil L, Else M, Clifford R, Pettitt A, Munir T, Schuh A, Walewska R, Baird DM, Oscier DG, Pepper C, Bryant D, Gibson J, Strefford JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814015"},{"title01":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02911-8. Online ahead of print","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814016"},{"title01":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","title02":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2026 March 12; 394(11):1084-1096. doi: 10.1056\/NEJMoa2515458","author":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindstrom V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Bottcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfo L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358601"},{"title01":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","title02":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","journal":"Leukemia","issue":"2026 March; 40(3):702-703. doi: 10.1038\/s41375-025-02837-7","author":"Zheng Y, Dong F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571770"},{"title01":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","title02":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","journal":"Leukemia","issue":"2026 March; 40(3):587-593. doi: 10.1038\/s41375-025-02852-8","author":"Oehler VG, Sala-Torra O, Gilderman N, Beppu L, Woolston DW, Namaganda P, Rynning J, Gonzalez IG, Towlerton A, Voutsinas J, Wu Q, Yeung CCS, Radich JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41577999"},{"title01":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","title02":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1082-1093. doi: 10.1182\/bloodadvances.2025017908","author":"Schroeder JC, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733971"},{"title01":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","title02":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300331. Online ahead of print","author":"Chizzoniti D, Ciambelli F, Latargia ML, Canziani L, Godi C, Pavesi F, Zambrotta GMP, Lotesoriere I, Appio L, Bertolli V, Santamaria C, Ballardini F, Cecchetti C, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709740"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","title02":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70382. Online ahead of print","author":"Saini M, Deeksha FNU, Jandial A, Jain A, Prakash G, Khadwal A, Chakraborty R, Malhotra P, Singh C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705773"},{"title01":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","title02":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70373. Online ahead of print","author":"Jamroziak K, Dytfeld D, Kubicki T, Dutka M, Wrobel T, Giannopoulos K, Konska A, Druzd-Sitek A, Tyczynska A, Olszewska-Szopa M, Morawska M, Szeremet A, Kopinska A, Wisniewski K, Czyz J, Helbig G, Gil L, Zaucha JM, Kruk-Kwapisz D, Walewski J, Gorecki T, Pula B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704058"},{"title01":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","title02":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70395. Online ahead of print","author":"Su M, Khan AM, Cowan AJ, Anderson LD Jr, Kaur G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733330"},{"title01":"Patients’, clinicians’ and research’s priorities on important outcomes in multiple myeloma: A mixed-methods study.","title02":"Patients’, clinicians’ and research’s priorities on important outcomes in multiple myeloma: A mixed-methods study.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70396. Online ahead of print","author":"Mainou M, Karagiannis T, Pagkalidou E, Liakos A, Malandrakis P, Hatjiharissi E, Chissan S, Mandala E, Van Oekelen O, Vlachaki E, Papaioannou M, Terpos E, Mohyuddin GR, Tsapas A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747758"},{"title01":"Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.","title02":"Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.","journal":"Blood advances","issue":"2026 February 24; 10(4):1324-1333. doi: 10.1182\/bloodadvances.2025017597","author":"Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733961"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1344-1347. doi: 10.1182\/bloodadvances.2025018021","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733947"},{"title01":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of multiple myeloma.","title02":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):953-959. doi: 10.1182\/bloodadvances.2025017676","author":"Chong PSY, Lim JSL, Tan TZ, Kong LR, de Mel S, Leow ACY, Yap EGS, Chng WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733965"},{"title01":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","title02":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300374. Online ahead of print","author":"Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742869"},{"title01":"Neutrophil extracellular traps, endothelial injury and use of abatacept for graft versus host disease prophylaxis.","title02":"Neutrophil extracellular traps, endothelial injury and use of abatacept for graft versus host disease prophylaxis.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2024.287235. Online ahead of print","author":"Ibrahimova A, Luebbering N, Strecker L, Langenberg L, Abdullah S, Lake KE, Wilhelm J, Lane A, Gloude N, Myers K, Dandoy C, Towe C, Khandelwal P, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709743"},{"title01":"Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial.","title02":"Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300144. Online ahead of print","author":"Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Matos MGAD, Chopra Y, Bhat S, Im HJ, Gungor T, Lu MY, Stefanelli T, Peyrard S, Smith Y, Sinclair K, Diaz-de-Heredia C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709741"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70380. Online ahead of print","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70365. Online ahead of print","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","title02":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70378. Online ahead of print","author":"Alberdi-Lema C, Garcia-Villaronga B, Linzodo-Lopez T, Carcelero E, Riu G, Monge-Escartin I, Suarez-Lledo M, Guardia L, Pedraza A, Sanz C, Charry P, Cid J, Lozano M, Carreras E, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721496"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70381. Online ahead of print","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70379. Online ahead of print","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","title02":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018455. Online ahead of print","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, Wallace DS, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami GG, Pongas GN, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl BS, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","title02":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017456. Online ahead of print","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.","title02":"Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025018519. Online ahead of print","author":"Chan LKL, Nicholson E, Chan LY, Taussig DC, Potter MN, Ethell ME, Easdale S, Garnett C, Anthias C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747186"},{"title01":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","title02":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 24; 10(4):1145-1152. doi: 10.1182\/bloodadvances.2025016648","author":"Farhadfar N, El Jurdi N, Baker KK, Ghosh S, Bat-Erdene M, Chen H, Sahu R, Weiss R, Mi J, Desatnik G, Williams LR, Tkaczyk ER, Lee SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191519"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","title02":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 24; 10(4):1348-1360. doi: 10.1182\/bloodadvances.2025016938","author":"Ulschmid CM, Li X, Wang T, Logan BR, Pidala J, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41498421"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018537. Online ahead of print","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda CJ, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz ML, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone RS, Jurgens EM, Miller KC, Rajeeve S, Giralt SA, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","title02":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018477. Online ahead of print","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth AK, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733975"},{"title01":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","title02":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","journal":"Blood advances","issue":"2026 February 24; 10(4):1114-1125. doi: 10.1182\/bloodadvances.2025017680","author":"Ito S, Martin E, Panousis C, Rowe AM, Stras S, Roy J, Cofano EB, Ventura K, Parr K, Neupane B, Bellesis A, Toki A, Jing R, Jang J, Neves AT, Shlomchik MJ, Shlomchik WD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733935"},{"title01":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","title02":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025030823. Online ahead of print","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","title02":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","journal":"Blood","issue":"2026 February 19; 147(8):848-862. doi: 10.1182\/blood.2025029771","author":"Stewart J, Damania B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105850"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Dysbiosis and gastrointestinal GVHD: to treat or not to treat.","title02":"Dysbiosis and gastrointestinal GVHD: to treat or not to treat.","journal":"Blood","issue":"2026 February 19; 147(8):809-810. doi: 10.1182\/blood.2025031542","author":"Waller EK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712295"},{"title01":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation.","title02":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation.","journal":"Blood","issue":"2026 February 19; 147(8):886-896. doi: 10.1182\/blood.2025029402","author":"Gurer Kluge EE, Meedt E, Feicht J, Cao K, Hiergeist A, Mamilos A, Hirsch D, Hoepting M, Kattner AS, Matos C, Bulow S, Thiele Orberg E, Beckhove P, Kandulski A, Evert M, Hildner K, Kreutz M, Edinger M, Wolff D, Herr W, Poeck H, Gessner A, Weber D, Kehr B, Holler E, Ghimire S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032750"},{"title01":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","title02":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):753-762. doi: 10.1056\/NEJMoa2506431","author":"Barshop BA, Ball ED, Benador N, Trauner D, Phillips S, Dohil R, Afshari NA, Roy S, Campo Fernandes B, Kohn D, Shayan K, Everett JK, Bushman FD, Midgley J, Liang H, Sawyers A, Gangoiti JA, Panchal M, Ahmed I, Cherqui S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707137"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2501591. doi: 10.1200\/JCO-25-01591. Online ahead of print","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"WBC Growth Factors: ASCO Guideline Update.","title02":"WBC Growth Factors: ASCO Guideline Update.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2502938. doi: 10.1200\/JCO-25-02938. Online ahead of print","author":"Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740078"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","title02":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.289302. Online ahead of print","author":"Bonifazi F, Roberto M, Stanghellini MTL, Chiusolo P, Polverelli N, Geromin A, Prezioso L, Algeri M, Mancini G, Prunotto G, Algarotti A, Nozzoli C, Malagola M, Mordini N, Fedele M, Santoro L, Zallio F, Castagna L, Picardi A, Busca A, Giaccone L, Skert C, Elice F, Facchini L, Mariotti J, Pierini A, Spina A, De Marchi R, Salvatore D, Martino M, Tumino M, Rambaldi A, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709738"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70365. Online ahead of print","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70381. Online ahead of print","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","title02":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70378. Online ahead of print","author":"Alberdi-Lema C, Garcia-Villaronga B, Linzodo-Lopez T, Carcelero E, Riu G, Monge-Escartin I, Suarez-Lledo M, Guardia L, Pedraza A, Sanz C, Charry P, Cid J, Lozano M, Carreras E, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721496"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733955"},{"title01":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","title02":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","journal":"Blood advances","issue":"2026 February 24; 10(4):1094-1105. doi: 10.1182\/bloodadvances.2025017838","author":"Murray J, Einhaus T, Radtke S, Bar KJ, Peterson CW, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733968"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733975"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1281-1292. doi: 10.1182\/bloodadvances.2025017433","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733973"},{"title01":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","title02":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017456. Online ahead of print","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2026 February 24; 10(4):1293-1300. doi: 10.1182\/bloodadvances.2024015776","author":"Liu Q, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733938"},{"title01":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","title02":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 24; 10(4):1348-1360. doi: 10.1182\/bloodadvances.2025016938","author":"Ulschmid CM, Li X, Wang T, Logan BR, Pidala J, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41498421"},{"title01":"Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.","title02":"Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.","journal":"Blood","issue":"2026 February 25. doi: 10.1182\/blood.2025032339. Online ahead of print","author":"Kumar R, Li L, Urbut S, Uddin MM, Niroula A, Kanumuri R, Ramdas B, Pasupuleti SK, Palam LR, Wang X, Padam KSR, Kelley MR, Natarajan P, Yu Z, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746260"},{"title01":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","title02":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025030823. Online ahead of print","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031202. Online ahead of print","author":"Parfenova EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.","title02":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.","journal":"N Engl J Med","issue":"2026 February 26; 394(9):872-883. doi: 10.1056\/NEJMoa2508820","author":"Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Shepard DR, LeDuke K, Sheehan L, Alland L, Haque A, Jalota D, Fellous M, Schram AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740031"},{"title01":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","title02":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","journal":"Lancet Oncol","issue":"2026 February 16. doi: 10.1016\/S1470-2045(25)00707-7. Online ahead of print","author":"Louis FM, van der Voort A, van Ramshorst MS, Daletzakis A, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJM, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Egeler MD, van de Poll-Franse LV, Mann RM, Sonke GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713473"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1281-1292. doi: 10.1182\/bloodadvances.2025017433","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2026 February 24; 10(4):1293-1300. doi: 10.1182\/bloodadvances.2024015776","author":"Liu Q, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Regional brain age is decreased in children with sickle cell anemia.","title02":"Regional brain age is decreased in children with sickle cell anemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1035-1044. doi: 10.1182\/bloodadvances.2025017172","author":"Mirro AE, Power LC, Wang J, Germino-Watnick P, Roberts H, Cam Y, Guilliams KP, Fellah S, Chen Y, An H, Lee JM, Ford AL, Fields ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733950"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02886-6. Online ahead of print","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02883-9. Online ahead of print","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","title02":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02865-x. Online ahead of print","author":"Lee NC, Miao R, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703030"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 February 26. doi: 10.1038\/s41375-026-02892-8. Online ahead of print","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","title02":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288081. Online ahead of print","author":"Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Rollig C, Russell N, Dillon R, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742883"},{"title01":"The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.","title02":"The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.300553. Online ahead of print","author":"Chien KS, DeZern AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742893"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","title02":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","journal":"Blood advances","issue":"2026 February 24; 10(4):1114-1125. doi: 10.1182\/bloodadvances.2025017680","author":"Ito S, Martin E, Panousis C, Rowe AM, Stras S, Roy J, Cofano EB, Ventura K, Parr K, Neupane B, Bellesis A, Toki A, Jing R, Jang J, Neves AT, Shlomchik MJ, Shlomchik WD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170916"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 February 24; 10(4):939-950. doi: 10.1182\/bloodadvances.2025018408","author":"Boertjes EL, Grob T, Al Hinai A, Beverloo BHB, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska PL, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2026 February 24; 10(4):1126-1133. doi: 10.1182\/bloodadvances.2025017089","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733942"},{"title01":"Exposure to Agent Orange and Association with Myelodysplastic Syndromes.","title02":"Exposure to Agent Orange and Association with Myelodysplastic Syndromes.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019262. Online ahead of print","author":"Sekeres MA, DeZern AE, Otterstatter M, Padron E, Al Baghdadi T, Foran JM, Komrokji RS, Abel GA, Saber W, Gore SD, Lee C, Bejar R, Liu JJ, Deeg HJ, Sherman S, Lindsley RC, Walter MJ, Gillis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734386"},{"title01":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2026 February 19; 147(8):811-820. doi: 10.1182\/blood.2025029727","author":"Stahl M, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","title02":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","journal":"Leukemia","issue":"2026 February 20. doi: 10.1038\/s41375-026-02893-7. Online ahead of print","author":"Srisuwananukorn A, Loscocco GG, Dolezal JM, Kuykendall AT, Santi R, Zhang L, Singh AM, Guglielmelli P, Vannucchi AM, Salama ME, Pearson AT, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721088"},{"title01":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","title02":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02885-7. Online ahead of print","author":"Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, Schwede M, England J, Luskin MR, DeAngelo DJ, Shimony S, Faiz M, Hillerbrand AC, Kim C, Weeks LD, Waldman L, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Rampal R, Tsai HK, Gotlib J, Gupta V, Stahl M, Mullally A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735484"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 February 26. doi: 10.1038\/s41375-026-02892-8. Online ahead of print","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","title02":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289330. Online ahead of print","author":"Wang Y, Tang D, Cheng Z, Ding L, Zhang Y, Zhang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742887"},{"title01":"A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.","title02":"A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.","journal":"Blood advances","issue":"2026 February 24; 10(4):1250-1259. doi: 10.1182\/bloodadvances.2025017896","author":"Sonmez O, Oyur E, Yonal Hindilerden I, Hindilerden F, Sonmez M, Karismaz A, Atli Z, Soysal T, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733972"},{"title01":"Prime Time for The Use of Statins in MPNs: From Comorbidity Drugs to Disease-Modifying Partners.","title02":"Prime Time for The Use of Statins in MPNs: From Comorbidity Drugs to Disease-Modifying Partners.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2026019625. Online ahead of print","author":"Hasselbalch HC Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747195"},{"title01":"Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.","title02":"Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017575. Online ahead of print","author":"Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758981"},{"title01":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","title02":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","journal":"Blood","issue":"2026 February 26; 147(9):946-959. doi: 10.1182\/blood.2025028703","author":"Yan Y, Liu J, Zhao S, Li F, Yang L, Xu Z, Qin T, Zhu X, An W, Shi Z, Shen W, Zhang P, Huang G, Rampal RK, Xiao Z, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405487"},{"title01":"CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.","title02":"CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.","journal":"Blood","issue":"2026 February 26; 147(9):907-909. doi: 10.1182\/blood.2025032444","author":"Johansson A, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746641"},{"title01":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","title02":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","journal":"Lancet Oncol","issue":"2026 February 16. doi: 10.1016\/S1470-2045(25)00678-3. Online ahead of print","author":"Pearson C, Jones DA, Baily G, Cherry R, Gray E, Hiom S, Rous B, Spencer K, Jose S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713471"},{"title01":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","title02":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02894-6. Online ahead of print","author":"Madiot C, Bellanger C, Dousset C, Decombis S, Thirouard L, Papin A, Baron E, Barc J, Le Bris Y, Gomez-Bougie P, Moreau-Aubry A, Tessoulin B, Pellat-Deceunynck C, Chiron D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714404"},{"title01":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","title02":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02868-8. Online ahead of print","author":"Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714403"},{"title01":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","title02":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02870-0. Online ahead of print","author":"Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703025"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):476-485. doi: 10.1200\/JCO-25-02477","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):466-475. doi: 10.1200\/JCO-25-02380","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","title02":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):449-454. doi: 10.1200\/JCO-25-00203","author":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512237"},{"title01":"Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.000004. Online ahead of print","author":"Koca O, Kucukyurt S, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742899"},{"title01":"Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.","title02":"Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288473. Online ahead of print","author":"Kuchnio A, Yang D, Vloemans N, Cornelissen I, Amorim R, Perova T, Lowenstein C, Janssen L, Suls T, Bekkers M, Lasorsa E, Fontan L, Nemani N, Hojnacki T, Han C, Sukumaran S, Medeiros N, Srinivasan S, Wu B, Chen J, Feldkamp MD, Wu S, Habte H, McRee AJ, Daskalakis N, Krayer J, Holland C, Attar R, DeYoung PM, Singh S, Elsayed Y, Philippar U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742895"},{"title01":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","title02":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288996. Online ahead of print","author":"Tharmaseelan H, Sgonina LM, Buhnen I, Schnetzke U, Meissner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Brockelmann PJ, Kobe C, Borchmann P, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742889"},{"title01":"Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?","title02":"Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289210. Online ahead of print","author":"Dann EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742879"},{"title01":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","title02":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70390. Online ahead of print","author":"Ligia S, Assanto GM, Soriano T, Cappelli LV, Passucci M, Annechini G, D'Elia GM, Pulsoni A, Martelli M, Del Giudice I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721535"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70383. Online ahead of print","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70379. Online ahead of print","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","title02":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70375. Online ahead of print","author":"Miles B, Mao D, Vardhanabhuti S, Bedognetti D, Filosto S, Shen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735224"},{"title01":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","title02":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70402. Online ahead of print","author":"Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Bugane A, Pellegrini C, Broccoli A, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41744197"},{"title01":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","title02":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","journal":"Br J Haematol","issue":"2026 February 27. doi: 10.1111\/bjh.70406. Online ahead of print","author":"Liu Y, Zhang J, Wang L, Liang Z, Gong Y, Gao L, Zhang W, Lu X, Wang C, Yu L, Sun M, Zhuang Y, Miao Y, Ni H, Xie X, Xu J, Zhang Y, Zhao M, Xu M, Zhuang W, Gu W, Lin G, Hua H, Zhu J, Xu M, Jia T, Zhai L, Shan H, Shen Q, Fan L, Xia Y, Li J, Li B, Miao Y, Shi W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41757549"},{"title01":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","title02":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018477. Online ahead of print","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth AK, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma.","title02":"Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019436. Online ahead of print","author":"Craig SM, Okeson KR, Adlowitz DG, Baker C, Rock PJ, Burack R, Fries C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734384"},{"title01":"Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.","title02":"Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.","journal":"Blood advances","issue":"2026 February 24; 10(4):1194-1203. doi: 10.1182\/bloodadvances.2025017530","author":"Neuendorff NR, Pugh K, Juthani R, Soudant C, Mac Eochagain C, Torka P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733959"},{"title01":"Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.","title02":"Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1217-1232. doi: 10.1182\/bloodadvances.2024015689","author":"Ferrant J, Le Gallou S, Padonou F, Dubec-Fleury C, Leonard S, Papa I, Brottier C, Pangault C, Barthel A, Launay V, Manson G, Hoareau B, Deleurme L, Monvoisin C, Albaud B, Shipp MA, Van Acker N, Laurent C, Llamas Gutierrez F, Michaud HA, Bonnefoy N, Pecot T, Tarte K, Roussel M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733976"},{"title01":"Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults.","title02":"Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults.","journal":"Blood advances","issue":"2026 February 24; 10(4):1134-1144. doi: 10.1182\/bloodadvances.2024015763","author":"Xie Y, Zhou KS, Li LF, Liang AB, Mei H, Zou DH, Li WY, Jin J, Jin ZM, Jing HM, Yang HY, Chen T, Huang HQ, He PC, Cao JN, Xia Z, Gu YE, Zang YB, Zhou ZS, Tian ZZ, Zhu J, Song YQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811825"},{"title01":"Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.","title02":"Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1023-1034. doi: 10.1182\/bloodadvances.2025018137","author":"Darnell EP, Gallagher KME, Kanska J, Scarfo I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41686452"},{"title01":"A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.","title02":"A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.","journal":"Blood advances","issue":"2026 February 24; 10(4):1153-1162. doi: 10.1182\/bloodadvances.2025016845","author":"Tuscano JM, Othman T, Frankel P, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde EL, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, William BM, Holland HK, Sharon E, Streicher H, Danilov A, Newman E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213001"},{"title01":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.","title02":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1381-1394. doi: 10.1182\/bloodadvances.2025017760","author":"Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang J, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami G, Chen-Kiang S, Elemento O, Maddocks K, Leonard JP, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289154"},{"title01":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.","title02":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1372-1380. doi: 10.1182\/bloodadvances.2025018527","author":"Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov A, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun AM, Ayyappan S, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz JL, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta A, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380101"},{"title01":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","title02":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025019303. Online ahead of print","author":"Kamdar M, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Ribrag V, Lin Y, Bhatnagar R, Braun R, Montheard S, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707107"},{"title01":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","title02":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018455. Online ahead of print","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, Wallace DS, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami GG, Pongas GN, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl BS, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2026 February 24; 10(4):1012-1022. doi: 10.1182\/bloodadvances.2025017165","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733951"},{"title01":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","title02":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","journal":"Blood","issue":"2026 February 17. doi: 10.1182\/blood.2025032307. Online ahead of print","author":"Dowling MR, Cliff ERS, Jeffrey A, Cashion C, Boyle S, Li J, Buss T, MacDonald R, Edelkina A, Scott HW MD, O'Leary N, Keir MW, Belbachir S, Westerman DA, Tam CS, Ho PJ, Harrison SJ, Barraclough A, Inam S, Blyth E, Henden AS, Vanguru V, Dickinson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701973"},{"title01":"A viral Achilles’ heel for EBV-positive lymphomas.","title02":"A viral Achilles’ heel for EBV-positive lymphomas.","journal":"Blood","issue":"2026 February 19; 147(8):804-806. doi: 10.1182\/blood.2025031851","author":"Yarchoan R, Tosato G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712297"},{"title01":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","title02":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031181. Online ahead of print","author":"Yu C, Holloman M, Kim A, Chang Y, Meyer S, Holmes AB, Cai B, Mo T, Basso K, Dreval K, Morin RD, Bhagat G, Mullighan CG, Dalla-Favera R, Pasqualucci L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746257"},{"title01":"Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed\/Refractory B-NHL.","title02":"Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed\/Refractory B-NHL.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031309. Online ahead of print","author":"Marcoux P, Gava F, Tosolini M, Gravelle P, Schniederjohann C, Quertinmont S, Serrat N, Bouquet F, Herter S, Tarte K, Roussel M, Sesques P, Bret C, Rossi C, Aubert P, Morschhauser F, Cartron G, Huber W, Dietrich S, Ysebaert L, Brousset P, Bruch PM, Perez-Galan P, Bezombes C, Laurent C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746860"},{"title01":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","title02":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","journal":"Blood","issue":"2026 February 19; 147(8):848-862. doi: 10.1182\/blood.2025029771","author":"Stewart J, Damania B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105850"},{"title01":"CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.","title02":"CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031156. Online ahead of print","author":"Li X, Liu M, Shi Q, Du ZS, Fu D, Fang Y, Zhao LJ, Dai Y, Zhang MC, Zhang F, Zhao Y, Yi HM, He Y, Cheng S, Xu PP, Wang L, Chen J, Zhao W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758931"},{"title01":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","title02":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):739-752. doi: 10.1056\/NEJMoa2514663","author":"Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363801"},{"title01":"Biting the Tail of CAR-T for Relapsed Multiple Myeloma.","title02":"Biting the Tail of CAR-T for Relapsed Multiple Myeloma.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):807-809. doi: 10.1056\/NEJMe2517627","author":"Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707143"},{"title01":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","title02":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02880-y. Online ahead of print","author":"Spataro F, Armentaro G, Di Gioia G, Meloni P, Rossi I, Williams M, Romiti GF, Talerico R, Villani R, Desantis V, Einsele H, Bencivenga L, Solimando AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703031"},{"title01":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","title02":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02889-3. Online ahead of print","author":"Riedhammer C, Truger M, Lee H, Leypoldt LB, Meggendorfer M, Hutter S, Muller H, Mersi J, Kadel SK, Buchwald T, Kosch R, Helal M, Afrin N, Rosenwald A, Gerhard-Hartmann E, Brioli A, Kronke J, Haferlach T, Haferlach C, Weisel KC, Neri P, Einsele H, Kortum KM, Waldschmidt JM, Bahlis N, Weinhold N, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703032"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 February 27; JCO2501969. doi: 10.1200\/JCO-25-01969. Online ahead of print","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.","title02":"Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300309. Online ahead of print","author":"Nakagawa M, Hiasa M, Teramachi J, Harada T, Oda A, Nishino G, Matsuki S, Hanawa M, Bat-Erdene A, Taniguchi T, Taniguchi H, Tsuneyama K, Tominaga T, Tanaka E, Hiyama TY, Matsuoka KI, Katayama Y, Abe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742871"},{"title01":"Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.","title02":"Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019231. Online ahead of print","author":"Tan CR, Usmani SZ, Derkach A, De Menezes Silva Corraes A, Parrondo RD, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Martinez-Lopez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso AC, Lin Y, Martin TG, Mian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734378"},{"title01":"Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.","title02":"Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018598. Online ahead of print","author":"Sester LS, Galeeva I, de Castilhos J, Borisov V, Gambihler A, Kilian M, Vonhoren D, Friedrich MJ, Poschet G, Steiger S, Chechenina A, Lettau K, Kohlberger CP, Prokoph N, Frenking JH, John L, Huhn S, Reichert P, Mai EK, Rippe K, Sauer S, Muller-Tidow C, Weinhold N, Platten M, Goldschmidt H, Raab MS, Stein-Thoeringer CK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734379"},{"title01":"Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.","title02":"Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018963. Online ahead of print","author":"Wood WA, Kumar SK, Semmel E, James S, Schroeder MA, Chung DJ, Rosenberg AS, Zonder JA, Rubinstein SM, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson LD, Derkach A, Geyer S, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734388"},{"title01":"Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma.","title02":"Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1405-1408. doi: 10.1182\/bloodadvances.2025018655","author":"Mian H, Arribas M, Fonseca R, Mutterback E, Shahid O, Gouda R, Pond GR, Visram A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733956"},{"title01":"Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed\/refractory multiple myeloma.","title02":"Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1395-1399. doi: 10.1182\/bloodadvances.2025017939","author":"Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733964"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018537. Online ahead of print","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda CJ, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz ML, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone RS, Jurgens EM, Miller KC, Rajeeve S, Giralt SA, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.","title02":"Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018974. Online ahead of print","author":"Di Palma-Grisi J, Biran N, Phull P, Vesole DH, Siegel DS, Parmar H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701974"},{"title01":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","title02":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","journal":"Blood advances","issue":"2026 February 24; 10(4):1400-1404. doi: 10.1182\/bloodadvances.2025018342","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","title02":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","journal":"Blood advances","issue":"2026 February 24; 10(4):1312-1323. doi: 10.1182\/bloodadvances.2025018133","author":"Fang B, Zhu Z, Chang Y, He X, Li S, Li M, Yan S, Zhu D, Li Z, Mao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385406"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1344-1347. doi: 10.1182\/bloodadvances.2025018021","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380108"},{"title01":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","title02":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025019050. Online ahead of print","author":"Atrash S, Symanowski J, Robinson M, Flynn C, Norek S, Cox R, Plott M, Bumgarner K, Rhinehardt D, Begic X, Ndiaye AP, Robinson JD, Friend R, Paul BA, Varga C, Ferreri CJ, Pineda-Roman M, Foureau DM, Bhutani M, Voorhees PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719502"},{"title01":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.","title02":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.","journal":"Blood","issue":"2026 February 19; 147(8):834-847. doi: 10.1182\/blood.2025030027","author":"Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, Testa JS, Ponticiello R, Brodeur S, Heidrich B, Packman K, Singh S, Attar R, Elsayed Y, Philippar U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100731"},{"title01":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","title02":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","journal":"Blood","issue":"2026 February 26; 147(9):932-945. doi: 10.1182\/blood.2025030083","author":"Fokkema C, Bertamini L, de Jong MME, Tahri S, Hofste Op Bruinink D, Kellermayer Z, Papazian N, den Hollander C, Vermeulen MPW, Stoetman ECG, van Beek G, Hoogenboezem R, van der Velden VHJ, Hulin C, Perrot A, Moreau P, Rowe M, Vieyra D, Carson R, van Duin M, Sanders MA, Broijl A, Sonneveld P, Cupedo T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411148"},{"title01":"At a crossroads: circulating tumor cells in myeloma.","title02":"At a crossroads: circulating tumor cells in myeloma.","journal":"Blood","issue":"2026 February 26; 147(9):906-907. doi: 10.1182\/blood.2025032333","author":"Alberge JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746637"},{"title01":"Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study.","title02":"Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025030120. Online ahead of print","author":"Orlowski RZ, Dimopoulos MA, Leleu X, Facon T, Ishida T, Hajek R, Spicka I, Romejko-Jarosinska J, Vorobyev VI, Besemer B, Kalayoglu Besisik S, Robak P, Jelinek T, Goldschmidt H, Martin T, Mohty M, Mace S, Kodas E, Tekle C, Shafer AT, Moreau P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758929"},{"title01":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","title02":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031663. Online ahead of print","author":"Wang Y, Liu S, Ghamlouch H, Gagler DC, Blaney P, Nabet B, Davies FE, Morgan GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758961"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 February 27; JCO2501969. doi: 10.1200\/JCO-25-01969. Online ahead of print","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2501591. doi: 10.1200\/JCO-25-01591. Online ahead of print","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","title02":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.289302. Online ahead of print","author":"Bonifazi F, Roberto M, Stanghellini MTL, Chiusolo P, Polverelli N, Geromin A, Prezioso L, Algeri M, Mancini G, Prunotto G, Algarotti A, Nozzoli C, Malagola M, Mordini N, Fedele M, Santoro L, Zallio F, Castagna L, Picardi A, Busca A, Giaccone L, Skert C, Elice F, Facchini L, Mariotti J, Pierini A, Spina A, De Marchi R, Salvatore D, Martino M, Tumino M, Rambaldi A, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709738"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","title02":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288996. Online ahead of print","author":"Tharmaseelan H, Sgonina LM, Buhnen I, Schnetzke U, Meissner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Brockelmann PJ, Kobe C, Borchmann P, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742889"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02883-9. Online ahead of print","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","title02":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02888-4. Online ahead of print","author":"Wang C, Ge S, Gao J, Yang R, Guo X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703029"},{"title01":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","title02":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02875-9. Online ahead of print","author":"Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbuhl K, Zupan I, Voskanyan A, Golos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Sudhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714405"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02886-6. Online ahead of print","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):476-485. doi: 10.1200\/JCO-25-02477","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","title02":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):435-439. doi: 10.1200\/JCO-25-02691","author":"Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363770"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):466-475. doi: 10.1200\/JCO-25-02380","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","title02":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):440-444. doi: 10.1200\/JCO-25-02879","author":"Braunstein MJ, Williams ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557975"},{"title01":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","title02":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289330. Online ahead of print","author":"Wang Y, Tang D, Cheng Z, Ding L, Zhang Y, Zhang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742887"},{"title01":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","title02":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288081. Online ahead of print","author":"Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Rollig C, Russell N, Dillon R, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742883"},{"title01":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","title02":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70405. Online ahead of print","author":"Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, Ebrahimi-Fakhari D, Bodmer N, Conter V, Elitzur S, Moricke A, Schrappe M, Stary J, Zapotocka E, Zimmermann M, Lehrnbecher T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733132"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70380. Online ahead of print","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.","title02":"FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.","journal":"Blood advances","issue":"2026 February 24; 10(4):1179-1193. doi: 10.1182\/bloodadvances.2025018168","author":"Rohrbacher L, Nixdorf D, Stadler H, Brauchle B, Markl F, Gottschlich A, Hoffmann GV, Philipp N, Hanel G, Kirmaier ME, Marcinek A, Kazerani M, Richter D, Magno G, Goldstein RL, Theurich S, Straub T, Kobold S, Arvedson T, Bucklein V, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733953"},{"title01":"Interpreting Next-Generation Immunosequencing Results in Children and Young Adults with Acute Lymphoblastic Leukemia.","title02":"Interpreting Next-Generation Immunosequencing Results in Children and Young Adults with Acute Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025018923. Online ahead of print","author":"Hamidi R, Kirsch IR, Schultz LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747190"},{"title01":"Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?","title02":"Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?","journal":"Blood advances","issue":"2026 February 24; 10(4):999-1011. doi: 10.1182\/bloodadvances.2025015936","author":"Datta S, Litzow MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115238"},{"title01":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","title02":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","journal":"Blood advances","issue":"2026 February 24; 10(4):1301-1311. doi: 10.1182\/bloodadvances.2024015408","author":"Lefeivre T, Grosu TI, Tudose C, Jones L, Leon TE, Wynne K, Oliviero G, Smith OP, Trinquand A, Mansour MR, Ryan CJ, Bond J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337688"},{"title01":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","title02":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","journal":"Blood advances","issue":"2026 February 24; 10(4):1400-1404. doi: 10.1182\/bloodadvances.2025018342","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","title02":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1082-1093. doi: 10.1182\/bloodadvances.2025017908","author":"Schroeder JC, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2026 February 24; 10(4):1012-1022. doi: 10.1182\/bloodadvances.2025017165","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Low Flow Cytometry Events in Detecting CNS Involvement in Pediatric BCP-ALL: NGS Validation and Prognostic Significance.","title02":"Low Flow Cytometry Events in Detecting CNS Involvement in Pediatric BCP-ALL: NGS Validation and Prognostic Significance.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025018288. Online ahead of print","author":"Chou SW, Su YH, Lu MY, Chang HH, Yang YL, Du CJ, Yen HJ, Li MJ, Lee CY, Liew PT, Lin DT, Lin KH, Lin SW, Jou ST","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719456"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2026 February 24; 10(4):1126-1133. doi: 10.1182\/bloodadvances.2025017089","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","title02":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","journal":"Blood advances","issue":"2026 February 24; 10(4):1272-1277. doi: 10.1182\/bloodadvances.2025016618","author":"Mayerhofer C, Crompton E, Mayerhofer E, Kristiansen T, Fukushima T, Keyes S, Sharda A, Li D, Da Silva C, Shrestha D, Kiem A, Feuchtinger T, Scadden DT, Miller PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351481"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 February 24; 10(4):939-950. doi: 10.1182\/bloodadvances.2025018408","author":"Boertjes EL, Grob T, Al Hinai A, Beverloo BHB, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska PL, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site, retrospective cohort review.","title02":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site, retrospective cohort review.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018604. Online ahead of print","author":"Rankin AW, Myers RM, Lamble AJ, Hsieh EM, Sankaran H, Chen L, Annesley C, DiNofia AM, Grupp SA, Pulsipher MA, Dolan JG, Bhojwani D, Gardner RA, Shah NN, Rheingold SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701972"},{"title01":"CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?","title02":"CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018480. Online ahead of print","author":"Gava F, Yates B, Sun Z, Li G, O'Koren C, Adhikari B, Luger SM, Shalabi HN, Mattison RJ, Turkbey EB, Yuan CM, Paietta E, Wang HW, Mullighan CG, Silbert SK, Litzow MR, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707115"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172235"},{"title01":"Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study.","title02":"Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025019447. Online ahead of print","author":"Crossette-Thambiah CK, Rajakaruna I, Odho Z, Doyle AJ, Breen KA, Laffan MA, J Arachchillage D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719455"},{"title01":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","title02":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","journal":"Blood advances","issue":"2026 February 24; 10(4):987-998. doi: 10.1182\/bloodadvances.2025017083","author":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269778"},{"title01":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","title02":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","journal":"Blood","issue":"2026 February 19; 147(8):863-876. doi: 10.1182\/blood.2025028933","author":"Ling T, O'Brien C, St-Germain JR, Rondeau V, Shi M, Berman JM, Cepa A, Saez Raez P, Wunderlich M, Carter KM, Stillwell C, Sexton C, Culp-Hill R, Reisz JA, Adeel SA, Zeng AGX, Bansal S, Tsao E, Chen HT, Dick JE, Minden MD, Arruda A, Amaya ML, Tikhonova AN, Hope KJ, D'Alessandro A, Raught B, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237364"},{"title01":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2026 February 19; 147(8):811-820. doi: 10.1182\/blood.2025029727","author":"Stahl M, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031202. Online ahead of print","author":"Parfenova EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","title02":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031663. Online ahead of print","author":"Wang Y, Liu S, Ghamlouch H, Gagler DC, Blaney P, Nabet B, Davies FE, Morgan GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758961"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.","title02":"Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.","journal":"Blood","issue":"2026 February 19; 147(8):897-901. doi: 10.1182\/blood.2024028042","author":"Attardi E, Gray N, Lewis S, Boals M, Shaker P, Kotmayer L, Sahoo SS, Li P, Andersen EF, Zhao J, Pizzo L, Oved JH, Jesudas R, Reiss UM, Sharma R, Christakopoulos GE, Bhoopalan SV, Takemoto CM, Kennedy A, Voso MT, Kang G, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41335385"},{"title01":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","title02":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","journal":"Blood","issue":"2026 February 24. doi: 10.1182\/blood.2024027853. Online ahead of print","author":"Himonas E, de Beauchamp L, Zerbst D, Desmares-Romain E, Sarnello D, Kalkman ER, Rattigan KM, James D, Shokry E, Copland M, Griessinger E, Recher C, Mansat-De Mas V, Vergez F, Sumpton D, Schimmer AD, Minden MD, Gottlieb E, Shanks E, Sarry JE, Helgason V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734389"},{"title01":"Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1\/BRM inhibitor.","title02":"Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1\/BRM inhibitor.","journal":"Blood","issue":"2026 February 24. doi: 10.1182\/blood.2025031486. Online ahead of print","author":"Fiskus W, Mill CP, Issa GC, Piel J, Collins MP, Hentemann M, Cuglievan B, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Senapati J, Loghavi S, Flores L, Su X, DiNardo CD, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734382"},{"title01":"De novo CD19- B-ALL: awareness of a rare entity in initial diagnosis.","title02":"De novo CD19- B-ALL: awareness of a rare entity in initial diagnosis.","journal":"Blood","issue":"2026 February 19; 147(8):902. doi: 10.1182\/blood.2025031848","author":"Hagos T, Zhao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712292"},{"title01":"Incremental changes to improve outcomes in ALL.","title02":"Incremental changes to improve outcomes in ALL.","journal":"Blood","issue":"2026 February 19; 147(8):801-802. doi: 10.1182\/blood.2025031878","author":"Litzow MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712294"},{"title01":"Glutathionylated leaky mitochondrial pores as target in AML.","title02":"Glutathionylated leaky mitochondrial pores as target in AML.","journal":"Blood","issue":"2026 February 19; 147(8):806-807. doi: 10.1182\/blood.2025032167","author":"Pereira-Martins D, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712296"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL.","title02":"Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025019273. Online ahead of print","author":"Armitage JO, Lunning MA, Vose JM, Longo DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747191"},{"title01":"Real-World Outcomes and Toxicities of CAR-T in Relapsed\/Refractory Follicular Lymphoma: A Multicenter Cohort Study.","title02":"Real-World Outcomes and Toxicities of CAR-T in Relapsed\/Refractory Follicular Lymphoma: A Multicenter Cohort Study.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025019115. Online ahead of print","author":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Reef D, Gorzewski AM, Wang JS, Shouse G, Reinert C, Teferra A, Toro Velez E, Pelcovits A, Ollila TA, Clark WB, Yazbeck V, Maakaron JE, Kamdar M, Fitzgerald LA, Danilov AV, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747197"},{"title01":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","title02":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","journal":"Leukemia","issue":"2026 February 25. doi: 10.1038\/s41375-026-02897-3. Online ahead of print","author":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41741799"},{"title01":"Exploiting metabolic dependencies in acute myeloid leukemia: DHODH inhibition meets lipid and cholesterol metabolism.","title02":"Exploiting metabolic dependencies in acute myeloid leukemia: DHODH inhibition meets lipid and cholesterol metabolism.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.300677. Online ahead of print","author":"Cruz-Rodriguez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742882"},{"title01":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","title02":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300374. Online ahead of print","author":"Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742869"},{"title01":"Platelet glycoprotein V autoantibodies and complement C3 are associated with thrombosis in systemic lupus erythematosus.","title02":"Platelet glycoprotein V autoantibodies and complement C3 are associated with thrombosis in systemic lupus erythematosus.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300094. Online ahead of print","author":"Bengtsson AA, Grenmyr E, Jonsen A, Kahn R, Semple JW, Porcelijn L, Kapur R, Linge CP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742868"},{"title01":"Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.","title02":"Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300427. Online ahead of print","author":"Baden D, Wolgast N, Ruhnke L, Metzeler K, Beder T, Pohlmann A, Steinhauser S, Muller-Nordhorn J, Katalinic A, Voso MT, Baldus CD, Fransecky L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742888"},{"title01":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300417. Online ahead of print","author":"Mohetaer A, Hao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742890"},{"title01":"Extracellular microvesicles from patients with antiphospholipid syndrome carry antigenic targets and promote endothelial cell activation in vitro.","title02":"Extracellular microvesicles from patients with antiphospholipid syndrome carry antigenic targets and promote endothelial cell activation in vitro.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.288860. Online ahead of print","author":"Capozzi A, Riitano G, Recalchi S, Longo A, Manganelli V, Mancuso S, Alessandri C, Misasi R, Garofalo T, Sorice M, Truglia S, Conti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709746"},{"title01":"CML-like biology is a unifying feature of myeloid\/lymphoid neoplasms with tyrosine kinase fusions in lymphoid blast phase. Comment on: Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology.","title02":"CML-like biology is a unifying feature of myeloid\/lymphoid neoplasms with tyrosine kinase fusions in lymphoid blast phase. Comment on: Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300254. Online ahead of print","author":"Wang WJ, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709742"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70383. Online ahead of print","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","title02":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70393. Online ahead of print","author":"Eriksen JVN, de Pietri S, Rathe M, Hasle H, Enevold C, Nielsen CH, Schmigelow K, Moser C, Muller K, Weischendorff S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733102"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","title02":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February; 40(2):360-372. doi: 10.1038\/s41375-025-02836-8","author":"Guy A, Mansier O, Decilap M, Catherineau A, Garcia G, Labrouche-Colomer S, Bats ML, Boyer F, Ianotto JC, Lippert E, Roy L, Tavitian S, Slama B, Girault S, Etienne G, Parry A, Saint-Lezer A, Denis G, Mediavilla C, Viallard JF, Legros L, Ranta D, Wemeau M, Nicolini FE, Lifermann F, Cambier N, Darnige L, Girodon F, Soret-Dulphy J, Cayssials E, Vacheret F, Sureau L, Paz DL, Ugo V, Kiladjian JJ, Thiebaut R, James C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436639"},{"title01":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","title02":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February 2. doi: 10.1038\/s41375-025-02843-9. Online ahead of print","author":"Kealy D, Ellerington R, Bansal S, Medeiros JJF, Hawley CA, Zeng AGX, Lukaszonek J, West KA, Sinha AD, Caalim G, Gawne RT, Pope J, Ferreira BL, Blacknell NM, Drylie B, Chatzigerou J, Khoo HM, Wilkinson AC, Fielding AK, Wang G, Psaila B, Kent DG, Hitchcock IS, Holding AN, Mason AS, Gupta V, Dick JE, Bridge KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41629621"},{"title01":"Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.","title02":"Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300028. Online ahead of print","author":"Barbui T, Ghirardi A, Condorelli A, Sobas M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641637"},{"title01":"Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.","title02":"Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 February 10; 10(3):775-778. doi: 10.1182\/bloodadvances.2025016344","author":"Ghosh S, Miklosz J, Trebak F, Tourn J, Grover SP, Pawlinski R, Reeves BN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191539"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.","title02":"Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018818. Online ahead of print","author":"Chowdhury SR, Sirotich E, Guyatt GH, Modi D, Cuker A, Breakey V, Grace RF, Pai M, Beck CE, Yan JW, Porter S, Kang M, Webert KE, O'Connor C, Pruitt B, DiRaimo J, Paynter D, Strachan G, St John M, Molnar L, Arnold DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637560"},{"title01":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","title02":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025018690. Online ahead of print","author":"Gunn E, Angulo PA, Badawy SM, Davini M, Elkus H, Hillier K, Kaicker S, Lebensburger J, Luke N, Scott KE, Nakano TA, Remiker AS, Rifkin-Zenenberg S, Schultz CL, Buissereth T, Carrier K, Durney J, Dekermanji A, Grace RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643186"},{"title01":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.","title02":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.","journal":"Blood","issue":"2026 February 12; 147(7):783-799. doi: 10.1182\/blood.2025029769","author":"Mei H, Xu M, Shu J, Tang L, Xie Q, Luo L, Wei Q, Jiang H, Ming Z, Hu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237341"},{"title01":"Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model.","title02":"Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model.","journal":"Blood","issue":"2026 February 3. doi: 10.1182\/blood.2025028563. Online ahead of print","author":"Hillier K, Zobeck M, MacMath D, Chumsky J, Kirk SE, O'Farrell C, Lucari B, Ngwerume F, Gaerlan S, Konde P, Wang KG, Lambert MP, Grace RF, Grimes AB, Kim TO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632829"},{"title01":"Stuck on you: Tregs, alphavbeta8, TGF-beta1, and platelets in ITP.","title02":"Stuck on you: Tregs, alphavbeta8, TGF-beta1, and platelets in ITP.","journal":"Blood","issue":"2026 February 12; 147(7):709-711. doi: 10.1182\/blood.2025031893","author":"Ragni MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678206"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025017945. Online ahead of print","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?","title02":"Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?","journal":"Blood advances","issue":"2026 February 10; 10(3):608-617. doi: 10.1182\/bloodadvances.2025017015","author":"Krishnamurti L, Olafimihan A, Hsu LL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092461"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","title02":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","journal":"Blood advances","issue":"2026 February 10; 10(3):887-900. doi: 10.1182\/bloodadvances.2025016812","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin NJ, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo L, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","title02":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","journal":"Blood advances","issue":"2026 February 10; 10(3):759-773. doi: 10.1182\/bloodadvances.2025017705","author":"Tanaka-Yano M, Sugden WW, Wang D, Falchetti M, Badalamenti B, Cote P, Chin D, Goldstein J, George S, Rodrigues-Luiz GF, Lummertz da Rocha E, Li H, North TE, Gryder BE, Rowe RG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191516"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Antibiotic risk score for acute graft-versus-host disease.","title02":"Antibiotic risk score for acute graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 10; 10(3):555-561. doi: 10.1182\/bloodadvances.2025018317","author":"Rashidi A, Gao F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160804"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2025018651. Online ahead of print","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S Phd, Valero-Arrese L, Ruano D, Andres M, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Marec-Berard P, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P Sr, Hessissen L, Golan M, Elitzur S, Ben Arush M, Ashkenazi Lustig D, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia GA Sr, Braier JL, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti PC, Todesco A, Papadakis V, Luz I, Costa V, Osipova DS, Lyudovskikh E, Maschan MA, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.","title02":"Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.","journal":"Blood","issue":"2026 February 5; 147(6):613-632. doi: 10.1182\/blood.2024027948","author":"Turkalj S, Radtke FA, Stoilova B, Mecklenbrauck R, Groom AJ, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa G, Kadia T, Symeonidou V, de Groot AP, Kantarjian H, Takahashi K, Konopleva M, DiNardo CD, Vyas P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191518"},{"title01":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","title02":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","journal":"Blood","issue":"2026 February 11. doi: 10.1182\/blood.2025031247. Online ahead of print","author":"Chen Y, Shen J, Lin Z, Ding Q, Zhang X, Zhang M, Yang H, Yao H, Liu S, Wan J, Liu S, Jia X, Wang X, Yu U, Hao S, Cao M, Jiang H, Guo B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671478"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.","title02":"Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.","journal":"J Clin Oncol","issue":"2026 February; 44(4):261-273. doi: 10.1200\/JCO-25-02142","author":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, Hu H, Qian M, Singh J, Godard J, Tang M, Ahn MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41086386"},{"title01":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","title02":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","journal":"Haematologica","issue":"2026 February 1; 111(2):646-655. doi: 10.3324\/haematol.2024.287055","author":"Mei C, Xu G, Zheng C, Xie Y, Li M, Shao Y, Yao R, Tao S, Jiang W, Guo J, Zheng Z, Wang W, Zhou X, Ma L, Ye L, Luo Y, Yang C, Yu W, Xie W, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501398"},{"title01":"Increasing daily step counts improves physical fitness, reduces pain and arterial stiffness in sickle cell patients.","title02":"Increasing daily step counts improves physical fitness, reduces pain and arterial stiffness in sickle cell patients.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300290. Online ahead of print","author":"De Lima F, Diaw M, Nader E, Carin R, Ducray M, Coly MS, Charlot K, Marano M, Gallou-Guyot M, Diop S, Miyachi M, Yoshida T, Seck M, Samb A, Ranque B, Tripette J, Connes P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641647"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","title02":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","journal":"Blood advances","issue":"2026 February 10; 10(3):563-574. doi: 10.1182\/bloodadvances.2025017536","author":"Pincez T, Fernandes H, Leverger G, Barlogis V, Fahd M, Garnier N, Paillard C, Guitton C, Abou Chahla W, Pasquet M, Jeziorski E, Castelle M, Bayart S, Pellier I, Thomas C, Pagnier A, Benadiba J, Li Thiao Te V, Cheikh N, Lejeune J, Deparis M, Marie-Cardine A, Chastagner P, Desplantes C, Millot F, Vic P, Thouvenin S, Piguet C, Pluchart C, Leblanc T, Heritier S, Aladjidi N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092477"},{"title01":"Heme and hemozoin induce platelet cell death through UPR-induced apoptosis and ferroptosis in vivax malaria.","title02":"Heme and hemozoin induce platelet cell death through UPR-induced apoptosis and ferroptosis in vivax malaria.","journal":"Blood advances","issue":"2026 February 10; 10(3):575-592. doi: 10.1182\/bloodadvances.2024015623","author":"Gomes MT, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Azevedo-Quintanilha IG, Fontes TM, de Brito Carneiro A, Azambuja P, Tolley ND, Rowley JW, Carpinter BA, Ferreira MU, Goncalves RM, Rocha VN, Rosa Nascimento AL, Carvalho WA, Scopel KKG, Campbell RA, Bozza PT, Weyrich AS, Zimmerman GA, Lacerda MVG, Castro-Faria-Neto HC, Hottz ED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115249"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2026 February 10; 10(3):821-836. doi: 10.1182\/bloodadvances.2025017217","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy V, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice.","title02":"Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025017943. Online ahead of print","author":"Leal S, Denardo A, Van Echten A, Jungnickel H, Nelson CB, Sandoval D, Salvador JA, Shin J, Chung A, Brush M, Bennett CP, Piermatteo A, Secrest P, Jung CL, Ganz T, Poli M, Gordts P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671472"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2026 February; 40(2):279-292. doi: 10.1038\/s41375-025-02839-5","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","title02":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","journal":"Leukemia","issue":"2026 February; 40(2):397-409. doi: 10.1038\/s41375-025-02831-z","author":"Santini V, Zeidan AM, Van Eygen K, Fenaux P, Germing U, Madanat YF, Raza A, Savona MR, Sekeres MA, Thepot S, Raddi MG, Boyer T, Sun L, Wan Y, Berry T, Xia Q, Huang F, Dougherty S, Navada S, Feller F, Komrokji RS, Platzbecker U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526614"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 9. doi: 10.1038\/s41375-026-02874-w. Online ahead of print","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","title02":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","journal":"Haematologica","issue":"2026 February 1; 111(2):646-655. doi: 10.3324\/haematol.2024.287055","author":"Mei C, Xu G, Zheng C, Xie Y, Li M, Shao Y, Yao R, Tao S, Jiang W, Guo J, Zheng Z, Wang W, Zhou X, Ma L, Ye L, Luo Y, Yang C, Yu W, Xie W, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501398"},{"title01":"Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?","title02":"Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?","journal":"Haematologica","issue":"2026 February 1; 111(2):451-453. doi: 10.3324\/haematol.2025.288157","author":"Mozessohn L, Buckstein R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568724"},{"title01":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","title02":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","journal":"Haematologica","issue":"2026 February 1; 111(2):518-534. doi: 10.3324\/haematol.2025.288080","author":"Yuen LD, Hasserjian RP, Fathi AT, Luskin MR, Winer ES, Dal Cin P, Kim AS, Lindsley RC, Tsai HK, Nardi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820841"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","title02":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70358. Online ahead of print","author":"MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, Morrissey O, Neofytos D, Buetti N, Parker C, Slavin MA, Craddock C, Stanworth SJ, McQuilten Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41677362"},{"title01":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","title02":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","journal":"Blood advances","issue":"2026 February 10; 10(3):881-886. doi: 10.1182\/bloodadvances.2025017745","author":"Urrutia S, Sasaki K, Bataller A, Kantarjian H, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee K, Zeidan A, Savona M, Oganesian A, Sano Y, Keer HN, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170912"},{"title01":"UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes.","title02":"UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes.","journal":"Blood advances","issue":"2026 February 10; 10(3):782-793. doi: 10.1182\/bloodadvances.2025017340","author":"Maffeo B, Panuzzo C, Savi A, Itri F, Piccioli S, Danzero AC, Maglione A, Marini S, Voso MT, Fava C, Bracco E, Pergolizzi B, Cilloni D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191526"},{"title01":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","title02":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","journal":"Blood advances","issue":"2026 February 10; 10(3):710-724. doi: 10.1182\/bloodadvances.2025017005","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AYH, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Thrombosis in Primary Myelofibrosis: The Influence of Cohort Composition and Disease Biology.","title02":"Thrombosis in Primary Myelofibrosis: The Influence of Cohort Composition and Disease Biology.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2026019668. Online ahead of print","author":"Barbui T, De Stefano V, Tefferi A, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678834"},{"title01":"Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.","title02":"Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.","journal":"N Engl J Med","issue":"2026 February 12; 394(7):669-683. doi: 10.1056\/NEJMoa2514824","author":"Wang JJ, Schonborn L, Warkentin TE, Muller L, Thiele T, Ulm L, Volker U, Ameling S, Franzenburg S, Kaderali L, Tzvetkova A, Colella A, Chataway T, Tan CW, Armour B, Troelnikov A, Rutten L, McCluskey J, Zahn R, Gordon TP, Greinacher A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671482"},{"title01":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","title02":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","journal":"Blood advances","issue":"2026 February 10; 10(3):563-574. doi: 10.1182\/bloodadvances.2025017536","author":"Pincez T, Fernandes H, Leverger G, Barlogis V, Fahd M, Garnier N, Paillard C, Guitton C, Abou Chahla W, Pasquet M, Jeziorski E, Castelle M, Bayart S, Pellier I, Thomas C, Pagnier A, Benadiba J, Li Thiao Te V, Cheikh N, Lejeune J, Deparis M, Marie-Cardine A, Chastagner P, Desplantes C, Millot F, Vic P, Thouvenin S, Piguet C, Pluchart C, Leblanc T, Heritier S, Aladjidi N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092477"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","title02":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70359. Online ahead of print","author":"Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693283"},{"title01":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","title02":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018667. Online ahead of print","author":"Stedema FG, Brink M, Huisman F, Van Rijn R, Sijs-Szabo A, Nijhof IS, Diepstra A, Vergote VKJ, van Gorkom G, Flinsenberg TWH, Huls GA, van Meerten T, Doorduijn J, Plattel WJ, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","title02":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017996. Online ahead of print","author":"Soares MV, Escamilla Gomez V, Azevedo RI, Pereira PNG, Caballero-Velazquez T, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Rodriguez-Gil A, Espada ELDS, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach HR, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P Sr, Caldas CMF, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos AM, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Pinho Vaz C, Perez-Simon JAA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2025018651. Online ahead of print","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S Phd, Valero-Arrese L, Ruano D, Andres M, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Marec-Berard P, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P Sr, Hessissen L, Golan M, Elitzur S, Ben Arush M, Ashkenazi Lustig D, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia GA Sr, Braier JL, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti PC, Todesco A, Papadakis V, Luz I, Costa V, Osipova DS, Lyudovskikh E, Maschan MA, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","title02":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019065. Online ahead of print","author":"Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025017945. Online ahead of print","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"Antibiotic risk score for acute graft-versus-host disease.","title02":"Antibiotic risk score for acute graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 10; 10(3):555-561. doi: 10.1182\/bloodadvances.2025018317","author":"Rashidi A, Gao F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160804"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","title02":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","journal":"Blood advances","issue":"2026 February 10; 10(3):887-900. doi: 10.1182\/bloodadvances.2025016812","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin NJ, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo L, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next?","title02":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next?","journal":"Blood","issue":"2026 February 5; 147(6):633-638. doi: 10.1182\/blood.2025030416","author":"Curtis DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411147"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","title02":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029546. Online ahead of print","author":"Diefenbach C, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen JB, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly KM, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1 and Th17-dependent GVHD within the Gastrointestinal Tract.","title02":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1 and Th17-dependent GVHD within the Gastrointestinal Tract.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029431. Online ahead of print","author":"Takahashi S, Inoue T, Ensbey KS, Legg SR, Sekiguchi T, Nelson EL, Nemychenkov NS, Joshi T, Minnie S, Yeh AC, Zhang P, Headley M, Paik J, Amory JK, Hill GR, Koyama M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662631"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","title02":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","journal":"Blood","issue":"2026 February 12; 147(7):755-767. doi: 10.1182\/blood.2025030149","author":"Sorial MN, Malpica Castillo LE, Chiattone C, Julia E, Bachy E, Barta SK, Stuver R, Jacobsen E, Federico M, Jain H, Prince HM, Foss F, Zinzani PL, Okatani T, Kim WS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shen C, Jain S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41347825"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February 3. doi: 10.1016\/S2352-3026(25)00328-X. Online ahead of print","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","title02":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","journal":"Lancet","issue":"2026 February 7; 407(10528):637-648. doi: 10.1016\/S0140-6736(25)02164-6","author":"Groarke EM, Turturice B, Patel BA, Quinn KA, Fike A, Grayson PC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41520673"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","title02":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","journal":"Haematologica","issue":"2026 February 1; 111(2):448-450. doi: 10.3324\/haematol.2025.288704","author":"Hayal TB, Wu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063708"},{"title01":"Elevated levels of Ube2g1 in hematopoietic stem cells lead to segmental aging of the hematopoietic system.","title02":"Elevated levels of Ube2g1 in hematopoietic stem cells lead to segmental aging of the hematopoietic system.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288847. Online ahead of print","author":"Niemann J, Schuster T, Sakk V, Soller K, Brown A, Wiese S, Eiwen K, Hoenicka M, Liebold A, Oltmanns M, Reichel H, Mulaw MA, Geiger H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641641"},{"title01":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","title02":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):632-645. doi: 10.3324\/haematol.2025.287897","author":"Shamie I, Bliss-Moreau M, Lee JC, Mathieu R, Hoffman HM, Geng B, Lewis NE, Zhu YP, Croker BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671503"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):546-557. doi: 10.3324\/haematol.2024.287157","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.","title02":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.","journal":"Haematologica","issue":"2026 February 1; 111(2):457-469. doi: 10.3324\/haematol.2023.283896","author":"Wong CK, McDonald A, Buttigieg MM, Rauh MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905074"},{"title01":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","title02":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","journal":"Haematologica","issue":"2026 February 1; 111(2):493-507. doi: 10.3324\/haematol.2025.287740","author":"Naji NS, Pasca S, Chatzilygeroudi T, Toledano-Sanz P, Rimando J, An Y, Hemani Y, Perkins B, Zeng X, Talbot C Jr, Paun B, Abdulmalik A, Lossos C, Boronina TR, Sinanidis I, Tsakiroglou P, Fernandes P, Esteb C, Ambinder AJ, Cole RN, Xian R, Gojo I, Paul S, Levis MJ, DeZern AE, Luznik L, Karanika S, Resar LS, Jones RJ, Bunz F, Gondek L, Arvanitis M, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874324"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","journal":"Haematologica","issue":"2026 February 1; 111(2):620-631. doi: 10.3324\/haematol.2025.288279","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","title02":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017996. Online ahead of print","author":"Soares MV, Escamilla Gomez V, Azevedo RI, Pereira PNG, Caballero-Velazquez T, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Rodriguez-Gil A, Espada ELDS, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach HR, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P Sr, Caldas CMF, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos AM, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Pinho Vaz C, Perez-Simon JAA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","title02":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019065. Online ahead of print","author":"Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017189. Online ahead of print","author":"Utrero-Rico A, Kapoor U, Berrios BJ, Morales G, Levine JE, Prado-Acosta MP, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","title02":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025017065. Online ahead of print","author":"Hagen MW, Setiawan NJ, Dexter SL, Woodruff KA, Gaerlan FLK, Billings TM, Orozco JJ, Termini CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671449"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2026 February 10; 10(3):821-836. doi: 10.1182\/bloodadvances.2025017217","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy V, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","journal":"Haematologica","issue":"2026 February 1; 111(2):693-697. doi: 10.3324\/haematol.2025.287344","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitekenaite V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH, Study Group NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Dreaming of a better future: drug development in myeloma.","title02":"Dreaming of a better future: drug development in myeloma.","journal":"Blood advances","issue":"2026 February 10; 10(3):779-781. doi: 10.1182\/bloodadvances.2024015740","author":"Parikh R, Lonial S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269780"},{"title01":"Smoldering multiple myeloma in the United States: a population-based analysis.","title02":"Smoldering multiple myeloma in the United States: a population-based analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):661-664. doi: 10.1182\/bloodadvances.2025017817","author":"Wang SY, Wang R, Schoen M, Huber JH, Feuer EJ, Ruhl J, Neparidze N, Ma X, Davidoff AJ, Chang SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213002"},{"title01":"Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.","title02":"Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.","journal":"Blood advances","issue":"2026 February 10; 10(3):604-607. doi: 10.1182\/bloodadvances.2025018078","author":"Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko V, Kim-Schulze S, Rahman A, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez L, Rossi A, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Lagana A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191534"},{"title01":"Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.","title02":"Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.","journal":"Blood","issue":"2026 February 3. doi: 10.1182\/blood.2025029358. Online ahead of print","author":"Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632828"},{"title01":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2026 February 5; 147(6):650-661. doi: 10.1182\/blood.2025030061","author":"Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"PIKfyve blockade exposes lysosomal vulnerability in myeloma.","title02":"PIKfyve blockade exposes lysosomal vulnerability in myeloma.","journal":"Blood","issue":"2026 February 5; 147(6):605-607. doi: 10.1182\/blood.2025032023","author":"Fulciniti M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642608"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","title02":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","journal":"J Clin Oncol","issue":"2026 February 11; JCO2502083. doi: 10.1200\/JCO-25-02083. Online ahead of print","author":"Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671533"},{"title01":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","title02":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","journal":"J Clin Oncol","issue":"2026 February 11; JCO2502087. doi: 10.1200\/JCO-25-02087. Online ahead of print","author":"Faramand RG, Xie Z, Jain MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671523"},{"title01":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","title02":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):558-571. doi: 10.3324\/haematol.2025.287554","author":"Ma R, Zhu XY, Lu Y, Chen J, Xuan L, Yuan HL, Cao Y, Cao WJ, Fang XS, Miao KR, Hu XX, Yi H, Zhao YM, Wu YB, Yang T, Wang HT, Yin Y, Zhang ZM, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Sun YQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671492"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):546-557. doi: 10.3324\/haematol.2024.287157","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","journal":"Haematologica","issue":"2026 February 1; 111(2):693-697. doi: 10.3324\/haematol.2025.287344","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitekenaite V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH, Study Group NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","journal":"Haematologica","issue":"2026 February 1; 111(2):620-631. doi: 10.3324\/haematol.2025.288279","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.","title02":"Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.","journal":"Blood advances","issue":"2026 February 10; 10(3):682-693. doi: 10.1182\/bloodadvances.2025015832","author":"Hall K, Lazaryan A, van der Laan M, Lee C, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota L, Nikai E, Ponomareva E, Koumas A, Waller EK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875591"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017189. Online ahead of print","author":"Utrero-Rico A, Kapoor U, Berrios BJ, Morales G, Levine JE, Prado-Acosta MP, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","title02":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70361. Online ahead of print","author":"Poh C, Zain J, Godfrey J, Querfeld C, Puverel S, Chen L, Allen P, Herrera AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693089"},{"title01":"Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.","title02":"Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029012. Online ahead of print","author":"Dorando HK, Andrews JM, Khatavkar OU, Borcherding N, Korshunova Y, Hakeman G, Panigassi RB, Vo PM, Tu RY, Tran D, Quinn CC, Schmidt JA, Aluri J, Harmon MT, Watkins MP, Frank A, Cooper MA, Musiek A, Mehta-Shah N, Payton JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662591"},{"title01":"Follicular lymphoma transformed to classic Hodgkin lymphoma.","title02":"Follicular lymphoma transformed to classic Hodgkin lymphoma.","journal":"Blood","issue":"2026 February 12; 147(7):800. doi: 10.1182\/blood.2025031906","author":"Yenwongfai LN, Francischetti IMB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678203"},{"title01":"The ticking clock of relapse in T-cell lymphomas.","title02":"The ticking clock of relapse in T-cell lymphomas.","journal":"Blood","issue":"2026 February 12; 147(7):707-708. doi: 10.1182\/blood.2025032024","author":"Jiang Q, Herling M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678205"},{"title01":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","title02":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","journal":"Blood","issue":"2026 February 12; 147(7):755-767. doi: 10.1182\/blood.2025030149","author":"Sorial MN, Malpica Castillo LE, Chiattone C, Julia E, Bachy E, Barta SK, Stuver R, Jacobsen E, Federico M, Jain H, Prince HM, Foss F, Zinzani PL, Okatani T, Kim WS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shen C, Jain S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41347825"},{"title01":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","title02":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029546. Online ahead of print","author":"Diefenbach C, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen JB, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly KM, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma – Authors’ reply.","title02":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma – Authors’ reply.","journal":"Lancet Oncol","issue":"2026 February; 27(2):e65. doi: 10.1016\/S1470-2045(26)00019-7","author":"Manier S, Lambert J, Hulin C, Macro M, Leleu X, Facon T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643703"},{"title01":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma.","title02":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma.","journal":"Lancet Oncol","issue":"2026 February; 27(2):e64. doi: 10.1016\/S1470-2045(25)00728-4","author":"Fu Y, Zhang J, Xu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643702"},{"title01":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","title02":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 February; 27(2):254-268. doi: 10.1016\/S1470-2045(25)00653-9","author":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martinez-Lopez J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519141"},{"title01":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","title02":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","journal":"Leukemia","issue":"2026 February; 40(2):339-347. doi: 10.1038\/s41375-025-02834-w","author":"Grozinger M, Schlanke M, Grone J, Erdmann S, Hajiyianni M, Poos AM, Thierjung H, Mai EK, Sauer S, Kaudewitz D, Veelken K, Michel CS, Frenking JH, Sester LS, Weber TF, Sedaghat S, Wennmann M, Muller-Tidow C, Schlemmer HP, Delorme S, Raab MS, Goldschmidt H, Weinhold N, John L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430398"},{"title01":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","title02":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","journal":"Leukemia","issue":"2026 February; 40(2):440-443. doi: 10.1038\/s41375-025-02819-9","author":"Gustine JN, Scaringi JA, Bauer F, Cirstea DD, Branagan AR, Puliafito BR, Maus MV, Frigault MJ, Yee AJ, Mahmood U, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419604"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","title02":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","journal":"J Clin Oncol","issue":"2026 February; 44(4):321-334. doi: 10.1200\/JCO-25-00289","author":"Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380103"},{"title01":"EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.","title02":"EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288024. Online ahead of print","author":"Li Y, Wilson A, Chrisochoidou Y, Martin S, Bird S, Morales S, Leiro M, Kozik Z, Crump NT, Roumeliotis TI, Choudhary J, Pawlyn C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676914"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300240. Online ahead of print","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"High-cholesterol diet fuels myeloma progression, dysregulates adipokine expression in vivo, and impairs treatment response ex vivo.","title02":"High-cholesterol diet fuels myeloma progression, dysregulates adipokine expression in vivo, and impairs treatment response ex vivo.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288286. Online ahead of print","author":"Gamez B, Whipp DJ, Rao SR, Morris EV, Park YE, Kaya Z, Edwards CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676897"},{"title01":"Second primary malignancy in multiple myeloma: does a prior malignancy matter?","title02":"Second primary malignancy in multiple myeloma: does a prior malignancy matter?","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300320. Online ahead of print","author":"Visram A, Seow H, Chakraborty R, Pond G, Gayowsky A, Mohyuddin GR, Hadidi SA, Hansen DK, Sidana S, Gouda R, Garcia-Horton A, Fonseca R, Mian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641642"},{"title01":"Post-CAR-T lymphocytosis in multiple myeloma: too much of a good thing?","title02":"Post-CAR-T lymphocytosis in multiple myeloma: too much of a good thing?","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300428. Online ahead of print","author":"Chen G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641636"},{"title01":"Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States.","title02":"Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States.","journal":"Haematologica","issue":"2026 February 1; 111(2):703-706. doi: 10.3324\/haematol.2025.287724","author":"Anuraj A, Rath D, Derkach A, Usmani SZ, Shah UA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836775"},{"title01":"Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis.","title02":"Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 1; 111(2):745-750. doi: 10.3324\/haematol.2025.288174","author":"Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D'Souza A, Pasquini M, Dhakal B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820831"},{"title01":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.","title02":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.","journal":"Haematologica","issue":"2026 February 1; 111(2):656-664. doi: 10.3324\/haematol.2025.288187","author":"Cani L, Scott SA, Roberts D, Joseph NS, Hofmeister CC, Gupta VA, Dhodapkar MV, Lonial S, Nooka AK, Kaufman JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905083"},{"title01":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes – insights from a single-site study.","title02":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes – insights from a single-site study.","journal":"Haematologica","issue":"2026 February 1; 111(2):713-717. doi: 10.3324\/haematol.2025.287760","author":"Bauer MA, Farmer P, Su JL, Schootman M, Li C, Van Rhee F, Al Hadidi S, Schinke C, Shaughnessy JD, Zhan F, Ashby C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905079"},{"title01":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.","title02":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.","journal":"Haematologica","issue":"2026 February 1; 111(2):665-678. doi: 10.3324\/haematol.2025.288203","author":"Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Patel S, Suchindran S, Zhou X, Richardson PG, Cohen AD, Lowther DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874339"},{"title01":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study.","title02":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study.","journal":"Haematologica","issue":"2026 February 1; 111(2):728-732. doi: 10.3324\/haematol.2025.287954","author":"Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874328"},{"title01":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","title02":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70356. Online ahead of print","author":"Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622574"},{"title01":"High-throughput monoclonal gammopathy community monitoring programme.","title02":"High-throughput monoclonal gammopathy community monitoring programme.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70366. Online ahead of print","author":"Agarwal G, Campbell L, Carty O, Larham J, Knight E, Moore S, Gooding S, Kothari J, Browning J, Evans J, Ferguson L, Vieira A, Swanborough L, Roberts P, Bateman E, Sadler R, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41674337"},{"title01":"Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.","title02":"Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70352. Online ahead of print","author":"Rieu JB, Schavgoulidze A, Canali A, Largeaud L, Perrot A, Syrykh C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693048"},{"title01":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","title02":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70359. Online ahead of print","author":"Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693283"},{"title01":"Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.","title02":"Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.","journal":"Blood advances","issue":"2026 February 10; 10(3):593-603. doi: 10.1182\/bloodadvances.2025017862","author":"Anderson DR, Gangaraju R, Sedhom WG, Hamulyak EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170879"},{"title01":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","title02":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","journal":"Blood","issue":"2026 February 12; 147(7):768-782. doi: 10.1182\/blood.2025030209","author":"Kawano G, Ikeda R, Ishihara D, Shima T, Sakoda T, Yamamoto S, Kochi Y, Semba Y, Ashitani S, Mori Y, Kato K, Maeda T, Miyamoto T, Soga T, Akashi K, Kikushige Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191529"},{"title01":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2026 February 5; 147(6):650-661. doi: 10.1182\/blood.2025030061","author":"Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.","title02":"Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.","journal":"Blood","issue":"2026 February 5. doi: 10.1182\/blood.2025031734. Online ahead of print","author":"Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu KS, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand RG, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine JP, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran M, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock WA, Schwartz MS, Byrd K, Yalniz FF, Bachanova V, Tracy SI, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai C, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643192"},{"title01":"MMF unlocks a new path to venetoclax sensitivity in AML.","title02":"MMF unlocks a new path to venetoclax sensitivity in AML.","journal":"Blood","issue":"2026 February 12; 147(7):708-709. doi: 10.1182\/blood.2025032116","author":"Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678204"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","title02":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","journal":"Leukemia","issue":"2026 February 4. doi: 10.1038\/s41375-026-02872-y. Online ahead of print","author":"Yang ZZ, Kim HJ, Tang X, Novak JP, Bhardwaj V, Mukherjee P, Villasboas JC, Novak AJ, Mondello P, Ansell SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639205"},{"title01":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","title02":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","journal":"Leukemia","issue":"2026 February 4. doi: 10.1038\/s41375-026-02861-1. Online ahead of print","author":"Nikkarinen A, Almlof J, Osterroos A, Ladenvall C, Amini RM, Hollander P, Ayoola Gustafsson K, Baliakas P, Glimelius I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639203"},{"title01":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","title02":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","journal":"Leukemia","issue":"2026 February 12. doi: 10.1038\/s41375-026-02884-8. Online ahead of print","author":"Gao J, Zhao X, Yin Q, Hu A, Qiu K, Blackburn L, Lei L, Xiong R, Bi C, Craig JW, Portell CA, Davila ML, Williams ME, Tao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41680300"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","title02":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e86-e97. doi: 10.1016\/S2352-3026(25)00318-7","author":"Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, Brailovski E, Assouline S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448213"},{"title01":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","title02":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e56-e57. doi: 10.1016\/S2352-3026(25)00342-4","author":"Karmali R, Gordon LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448214"},{"title01":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sezary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.","title02":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sezary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e98-e109. doi: 10.1016\/S2352-3026(25)00322-9","author":"Stadler R, Quaglino P, Woei-A-Jin FJSH, Dummer R, Mitteldorf C, Papadavid E, Ortiz Romero PL, Guenova E, Abe R, Cowan R, Bagot M, Dalle S, Fujimura T, Gambichler T, Morris S, Wehkamp U, Terheyden P, Cozzio A, Dippel E, Alberti-Violetti S, Romejko-Jarosinska J, Wozniacka A, Gonzalez Barca E, Pujol Vallverdu R, Ramelyte E, Bechter O, Suzuki K, Knobler R, Danhauser-Riedl S, Scarisbrick J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651641"},{"title01":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","title02":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","journal":"Lancet","issue":"2026 February 12. doi: 10.1016\/S0140-6736(25)02435-3. Online ahead of print","author":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, Garcia-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692020"},{"title01":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","title02":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):400-409. doi: 10.1200\/JCO-25-01712","author":"Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385760"},{"title01":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","title02":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):410-420. doi: 10.1200\/JCO-25-01587","author":"Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, Kaji F, Raso-Barnett L, Cheow H, Elzubeir L, Smith J, Kamil A, Barbara RR, Price J, Elston K, Kolodziejczyk A, Tarantino S, Mariscotti F, Barry P, Frost S, Demiris N, Thomas MG, Hassane D, Munugalavadla V, Nagumantry SK, Karanth MJ, Ahearne M, Shah N, Fox CP, Anand S, Hodson DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428995"},{"title01":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","title02":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):429. doi: 10.1200\/JCO-25-02779","author":"Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490480"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","title02":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","journal":"Br J Haematol","issue":"2026 February 11. doi: 10.1111\/bjh.70363. Online ahead of print","author":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41668589"},{"title01":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","title02":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018667. Online ahead of print","author":"Stedema FG, Brink M, Huisman F, Van Rijn R, Sijs-Szabo A, Nijhof IS, Diepstra A, Vergote VKJ, van Gorkom G, Flinsenberg TWH, Huls GA, van Meerten T, Doorduijn J, Plattel WJ, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","title02":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018515. Online ahead of print","author":"Godtfredsen SJ, Bergstrom F, Harrysson S, Kragholm KH, El-Galaly TC, Smedby KE, Eloranta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637561"},{"title01":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.","title02":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.","journal":"Blood advances","issue":"2026 February 10; 10(3):725-732. doi: 10.1182\/bloodadvances.2025017120","author":"Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201962"},{"title01":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","title02":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","journal":"Blood advances","issue":"2026 February 10; 10(3):850-863. doi: 10.1182\/bloodadvances.2025016492","author":"Galtier J, Peanne R, Le Morvan V, Blondy T, Melane M, Bidon A, Chopin A, Prochazkova-Carlotti M, Poglio S, Merlio JP, Chevret E, Gros A, Pham-Ledard A, Beylot-Barry M, Bresson-Bepoldin L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358745"},{"title01":"Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy.","title02":"Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018042. Online ahead of print","author":"Saleh N, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671456"},{"title01":"Long-term outcomes of 40Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","title02":"Long-term outcomes of 40Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019130. Online ahead of print","author":"Yoon SE, Oh D, Ryu G, Cho J, Kim SJ, Kim WS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628317"},{"title01":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","title02":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","journal":"Blood advances","issue":"2026 February 10; 10(3):694-706. doi: 10.1182\/bloodadvances.2025015986","author":"Tam CS, Anderson MA, Simkovic M, Ghia P, Flinn IW, Laribi K, Opat S, Cull G, Munir T, Osterborg A, Tedeschi A, Wang M, Szeto A, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829104"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Exploring the Role of Blinatumomab in Pediatric B-Lymphoblastic Lymphoma (B-LLy).","title02":"Exploring the Role of Blinatumomab in Pediatric B-Lymphoblastic Lymphoma (B-LLy).","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025019473. Online ahead of print","author":"Devine KJ, Fries C, Wistinghausen B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643198"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.","title02":"Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 February 10; 10(3):620-626. doi: 10.1182\/bloodadvances.2025017620","author":"Champagne JN, Villa D, Gerrie AS, Venner CP, Slack GW, Farinha P, Craig JW, Hilton LK, Savage KJ, Scott DW, Sehn LH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170907"},{"title01":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","title02":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025031089. Online ahead of print","author":"Heger JM, Mattlener J, Kaul H, Ferdinandus J, Schneider J, Schleifenbaum JK, Schneider G, Schaub V, Haenel M, Hellmuth JC, Dierlamm J, Martin S, Mathas S, Meissner J, Pegtel DM, Zijlstra JM, Ossowski A, Becker K, Hallek MJ, von Tresckow B, Borchmann P, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662627"},{"title01":"Stable, thus in critical condition: m6A-methylated fusion transcripts in B-cell acute lymphoblastic leukemia.","title02":"Stable, thus in critical condition: m6A-methylated fusion transcripts in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300292. Online ahead of print","author":"De Kesel J, Ntziachristos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676904"},{"title01":"Genomic proximity mapping: a promising next generation cytogenomic assay for comprehensive assessment of acute myeloid leukemia.","title02":"Genomic proximity mapping: a promising next generation cytogenomic assay for comprehensive assessment of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2026.000003. Online ahead of print","author":"Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676907"},{"title01":"A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia.","title02":"A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300161. Online ahead of print","author":"Zhang Y, Fan Y, Xu M, Xue S, Tang X, Qiu H, Miao M, Chen S, Zhou H, Zhang J, Yang X, Xu Y, Zhang X, Wu D, Chen J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676908"},{"title01":"Body mass index during and early after therapy for pediatric acute lymphoblastic leukemia is associated with obesity in survivors.","title02":"Body mass index during and early after therapy for pediatric acute lymphoblastic leukemia is associated with obesity in survivors.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288529. Online ahead of print","author":"Suwannaying K, Zhou GC, Lertvivatpong N, Neupane A, Petrykey K, Yoshida T, Baedke JL, Rujkijyanont P, Wilson CL, Dixon SB, Delaney A, Sapkota Y, Kaste SC, Armstrong GT, Pui CH, Hudson MM, Srivastava D, Ness KK, Inaba H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676909"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300240. Online ahead of print","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"Intrinsic cellular resistance to BCR::ABL1 inhibitors.","title02":"Intrinsic cellular resistance to BCR::ABL1 inhibitors.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.287814. Online ahead of print","author":"Cruz-Rodriguez N, Torres-Llanos Y, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676916"},{"title01":"FLT3-ITD measurable residual disease from the QuANTUM-First trial.","title02":"FLT3-ITD measurable residual disease from the QuANTUM-First trial.","journal":"Blood advances","issue":"2026 February 10; 10(3):917-928. doi: 10.1182\/bloodadvances.2025016444","author":"Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Zak P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052406"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Metformin induces ferroptosis associated with lipidomic remodeling in AML.","title02":"Metformin induces ferroptosis associated with lipidomic remodeling in AML.","journal":"Blood advances","issue":"2026 February 10; 10(3):733-747. doi: 10.1182\/bloodadvances.2025016155","author":"Sternadt D, Pereira-Martins DA, Chatzikyriakou P, Albuquerque-Simoes L, Yang M, Silveira DRA, Wierenga ATJ, Weinhauser I, Hogeling SM, Oudejans LL, Casares Alaez P, Sarry JE, Frezza C, Huls GA, Quek L, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172231"},{"title01":"Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.","title02":"Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.","journal":"Blood advances","issue":"2026 February 10; 10(3):642-653. doi: 10.1182\/bloodadvances.2025016509","author":"Pastoret C, Yang J, Feith DJ, Roussel M, Moignet A, Dighe S, Solga MD, Marchand T, Visser G, Gasparini VR, Teramo A, Zambello R, Loughran TP Jr, Lamy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191533"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","title02":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","journal":"Blood advances","issue":"2026 February 10; 10(3):710-724. doi: 10.1182\/bloodadvances.2025017005","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AYH, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Reassessing IgRT in CLL: evidence still unconvincing.","title02":"Reassessing IgRT in CLL: evidence still unconvincing.","journal":"Blood advances","issue":"2026 February 10; 10(3):533-534. doi: 10.1182\/bloodadvances.2025018312","author":"Lesan V, Munteanu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150822"},{"title01":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","title02":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018600. Online ahead of print","author":"Xu J, McCoy M, Martinez Z, Sussman JH, Gao D, Vincent TL, Wang H, Ma C, Elghawy O, Chen GM, Yang AG, Polonen P, Natan K, Shraim R, Newman H, Hofmann TJ, Scoma S, DiNofia AM, Hunger SP, Yang JJ, Mullighan CG, Bernt KM, Hexner EO, Grupp SA, Watanabe K, June CH, Tan K, Teachey DT, Diorio C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671457"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"Conventional Therapy vs HMA or LDAC +\/- Venetoclax in Older Adults With AML: Systematic Review and Meta-analysis.","title02":"Conventional Therapy vs HMA or LDAC +\/- Venetoclax in Older Adults With AML: Systematic Review and Meta-analysis.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025016877. Online ahead of print","author":"Ibrahim S, Burgos-Mansilla B, Roldan Y, Oliveros MJ, Bhogal G, Bravo-Soto G, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Mulazzani F, Taj TK, Hadeiy SK, Qureshi M, Chowdhury SR, Couban R, Artz AS, Fletcher L, Gilberto L, Mattison RJ, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671437"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis.","title02":"Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis.","journal":"Blood advances","issue":"2026 February 10; 10(3):627-641. doi: 10.1182\/bloodadvances.2025016507","author":"van Bergen T, Bosch DA, Bellanne-Chantelot C, Mulet-Lazaro R, Bledsoe JR, Chen L, de Looper HWJ, van Dijk C, Ter Borg MND, Bindels EMJ, Hoogenboezem RM, Roovers O, Olofsen PA, Bartels M, van Montfrans J, Breed P, Salzer E, Holierhoek MG, Nelken B, Beaupain B, Fleming MD, Shimamura A, Raaijmakers MHGP, Donadieu J, Newburger PE, Touw IP, Aalbers AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056520"},{"title01":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","title02":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","journal":"Blood advances","issue":"2026 February 10; 10(3):694-706. doi: 10.1182\/bloodadvances.2025015986","author":"Tam CS, Anderson MA, Simkovic M, Ghia P, Flinn IW, Laribi K, Opat S, Cull G, Munir T, Osterborg A, Tedeschi A, Wang M, Szeto A, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829104"},{"title01":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","title02":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018688. Online ahead of print","author":"Chiu SK, Furlong E, Fox A, McKinnon EJ, Sanchez-Ovando S, Mclean-Tooke A, Oommen J, Yeoh DK, Cheung LC, Gottardo NG, Kotecha RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628313"},{"title01":"Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.","title02":"Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019153. Online ahead of print","author":"Zeidner JF, Jain J, Welkie RL, Huang Y, Swords R, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH Jr, Baer MR, Duong VH, Blum W, Arellano ML, Stock WA, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Handa S, Heerema NA, Chen TL, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate UM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632633"},{"title01":"TP53-aberrated CLL: is BTK inhibitor monotherapy enough?","title02":"TP53-aberrated CLL: is BTK inhibitor monotherapy enough?","journal":"Blood advances","issue":"2026 February 10; 10(3):707-709. doi: 10.1182\/bloodadvances.2025017954","author":"Niemann CU","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41615766"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow Cytometry.","title02":"Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow Cytometry.","journal":"Blood advances","issue":"2026 February 6. doi: 10.1182\/bloodadvances.2025018607. Online ahead of print","author":"Li S, Short NJ, Wang W, Ling J, Qiu L, Xu J, Wang WJ, Jia F, Tang G, Karrar O, Maroun MM, Medeiros LJJ, Ravandi F, Wang SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41649796"},{"title01":"Clonal cacophony of AML relapse.","title02":"Clonal cacophony of AML relapse.","journal":"Blood","issue":"2026 February 5; 147(6):603-604. doi: 10.1182\/blood.2025032092","author":"Wang ES","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642609"},{"title01":"Inclusion as innovation: broadening trial criteria in AML.","title02":"Inclusion as innovation: broadening trial criteria in AML.","journal":"Blood","issue":"2026 February 5; 147(6):604-605. doi: 10.1182\/blood.2025031718","author":"Kennedy VE, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642607"},{"title01":"Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.","title02":"Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.","journal":"Blood","issue":"2026 February 5; 147(6):639-649. doi: 10.1182\/blood.2025030741","author":"Hantel A, Wang Y, Cronin A, Khan I, Abraham I, Eisfeld AK, Patel AA, Stock W, Monick S, Walsh TP, Gallagher E, Luskin MR, Avila Rodriguez AM, Galvez C, Doukas P, Altman JK, Burkart M, Erra A, Zia M, Larson ML, Dave A, Tsai SB, Aleen A, Raptis N, Lathan CS, Uno H, DeAngelo DJ, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100728"},{"title01":"TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.","title02":"TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.","journal":"Blood","issue":"2026 February 5; 147(6):607-609. doi: 10.1182\/blood.2025032009","author":"Skwarska A, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642606"},{"title01":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.","title02":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.","journal":"Blood","issue":"2026 February 12; 147(7):725-738. doi: 10.1182\/blood.2025031243","author":"Schroeder B, Yuan C, Wang HW, Mohindroo C, Zhou H, Raffeld M, Xi L, Arons E, Feurtado J, James-Echenique L, Calvo KR, Maric I, Kreitman RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060318"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","title02":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e74-e85. doi: 10.1016\/S2352-3026(25)00323-0","author":"Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Metzger A, Krolla C, Andrieux G, Kohler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Bruggemann M, Rammensee HG, Salih HR, Walz JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41547362"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February 3. doi: 10.1016\/S2352-3026(25)00328-X. Online ahead of print","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Jorge Cortes: building a network of leukaemia expertise in Latin America.","title02":"Jorge Cortes: building a network of leukaemia expertise in Latin America.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e61. doi: 10.1016\/S2352-3026(26)00003-7","author":"Wilkinson E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651639"},{"title01":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","title02":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","journal":"Lancet Haematol","issue":"2026 February 12. doi: 10.1016\/S2352-3026(25)00357-6. Online ahead of print","author":"Gruber TA, Jeha S, Deyell RJ, Lewis V, Chang BH, Lowe EJ, Frediani J, Vezina C, Michon B, Richards M, Breese EH, Tran TH, Lacayo N, Bolen C, Desai S, Pauley JL, Huang M, Ashcraft E, Cheng C, Schultz KR, Stork L, Schlis K, Huynh VT, Gossai N, Messinger YH, Bittencourt H, Horton TM, Athale U, Stearns D, Schiff D, Gaynon PS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692013"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","title02":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):370-374. doi: 10.1200\/JCO-25-01806","author":"Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Huitema ADR, Pieters R, van der Sluis IM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505662"},{"title01":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells.","title02":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):481-492. doi: 10.3324\/haematol.2025.287352","author":"Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, Showers W, Grier A, D'Alessandro A, Smith C, McMahon C, Pollyea DA, Gillen AE, Amaya ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534505"},{"title01":"Interleukin signaling mitigates the inhibitory effects of combined Src\/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Interleukin signaling mitigates the inhibitory effects of combined Src\/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288829. Online ahead of print","author":"Naeemikia F, Reynolds J, Dong C, Pritchard JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641639"},{"title01":"Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.","title02":"Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300277. Online ahead of print","author":"Barzilai-Birenboim S, Arad-Cohen N, Bardi E, Heldrup J, Kovacs G, Mateos M, Moericke A, Oosterom N, Sonnenberg S, Steinhauer F, Vaitkeviciene GE, Van der Sluis IM, Weinreb SM, Zapotocka E, Zucker D, Schmiegelow K, Mikkelsen TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641640"},{"title01":"Beating the STATs: targeting the metabolome in acute myeloid leukemia.","title02":"Beating the STATs: targeting the metabolome in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):439-441. doi: 10.3324\/haematol.2025.288349","author":"Nachmias B, Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905076"},{"title01":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.","title02":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):718-723. doi: 10.3324\/haematol.2025.287794","author":"Ahn JS, Park JH, Lee C, Song IC, Kim MY, Sohn SK, Yhim HY, Park Y, Kim I, Shin HJ, Park SK, Kim SH, Cheong JW, Lee HS, Lee H, Bae SH, Choi Y, Lee HG, Do YR, Han JJ, Kim MK, Park S, Kim HJ, Kim HJ, Working Party KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605710"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia.","title02":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):679-686. doi: 10.3324\/haematol.2024.287099","author":"Chan WK, Tan L, Martinez SA, Du D, Horvath TD, Pontikos M, Rusling LA, Chiu Y, Tran BQ, Rempe SB, Sukharev S, Weinstein JN, Lorenzi PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931860"},{"title01":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.","title02":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):583-596. doi: 10.3324\/haematol.2025.287934","author":"Holl NJ, Fearnow A, Christodoulou I, Vorri SC, Rahnama R, Choe J, Ghosal A, Ng WI, Vyas V, Song HW, Varadhan R, Bonifant CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931866"},{"title01":"CCRL2 and who? An important driver in TP53-mutant myeloid leukemias.","title02":"CCRL2 and who? An important driver in TP53-mutant myeloid leukemias.","journal":"Haematologica","issue":"2026 February 1; 111(2):442-443. doi: 10.3324\/haematol.2025.288631","author":"Arnold O, Saygin C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931868"},{"title01":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.","title02":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):572-582. doi: 10.3324\/haematol.2025.287697","author":"Fischer C, Chen SS, Nimmerfroh J, Eugster A, Stucheli S, Schultheiss C, Widmer C, Heim D, Kasenda B, Passweg J, Kobold S, Egli L, Coianiz N, Chijioke O, Chiorazzi N, Follo M, Laubli H, Peipp M, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931870"},{"title01":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","title02":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","journal":"Haematologica","issue":"2026 February 1; 111(2):518-534. doi: 10.3324\/haematol.2025.288080","author":"Yuen LD, Hasserjian RP, Fathi AT, Luskin MR, Winer ES, Dal Cin P, Kim AS, Lindsley RC, Tsai HK, Nardi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820841"},{"title01":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.","title02":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.","journal":"Haematologica","issue":"2026 February 1; 111(2):597-608. doi: 10.3324\/haematol.2025.287772","author":"Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L, Takahashi N, Moon SH, Grigg A, Borowczak C, Schuld P, Frank P, Constantinescu C, Boquimpani C, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637752"},{"title01":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.","title02":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.","journal":"Haematologica","issue":"2026 February 1; 111(2):764-767. doi: 10.3324\/haematol.2025.288776","author":"Jung BK, Weissmann S, Schock C, Meggendorfer M, Haferlach T, Dicker F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098098"},{"title01":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","title02":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","journal":"Haematologica","issue":"2026 February 1; 111(2):446-447. doi: 10.3324\/haematol.2025.288391","author":"Lipton JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637736"},{"title01":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","title02":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300345. Online ahead of print","author":"Lucini C, Lion T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676918"},{"title01":"Modern treatment of acute promyelocytic leukemia.","title02":"Modern treatment of acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):437-438. doi: 10.3324\/haematol.2025.289382","author":"Russell N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622919"},{"title01":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","title02":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70358. Online ahead of print","author":"MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, Morrissey O, Neofytos D, Buetti N, Parker C, Slavin MA, Craddock C, Stanworth SJ, McQuilten Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41677362"},{"title01":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","title02":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","journal":"Br J Haematol","issue":"2026 February 3. doi: 10.1111\/bjh.70355. Online ahead of print","author":"Komori T, Kawai T, Okuno Y, Tsujimoto S, Kato S, Kamitori T, Saida S, Ikeda J, Ohki K, Kato M, Tomizawa D, Taga T, Takita J, Horibe K, Adachi S, Hayashi Y, Ito S, Shiba N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41631723"},{"title01":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","title02":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70349. Online ahead of print","author":"Bidet A, Laharanne E, Dos Santos M, De Grande AC, Leguay T, Pigneux A, Frison E, Achard S, Dupont-Moufakkir S, Klein E, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622767"},{"title01":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","title02":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70351. Online ahead of print","author":"Monaghan L, Bunschoten RP, Bittencourt-Silvestre J, Park T, Gannon S, Pirvan PA, Hoose A, Wheadon H, Liskamp RMJ, Huang X, Jorgensen HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622589"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","title02":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","journal":"Leukemia","issue":"2026 February; 40(2):454-458. doi: 10.1038\/s41375-025-02797-y","author":"Agathangelidis A, Iatrou A, Pechlivanis N, Karakatsoulis G, Zaragoza-Infante L, Galigalidou C, Maity PC, Ranghetti P, Almeida J, Fuentes-Herrero B, Navarro A, Alcoceba M, Rabbani L, Thorvaldsdottir B, Scarfo L, Orfao A, Psomopoulos F, Jumaa H, Rosenquist R, Chatzidimitriou A, Ghia P, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501505"},{"title01":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","title02":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):435-439. doi: 10.1038\/s41375-025-02825-x","author":"Haaksma LH, Palmieri R, Reuvekamp T, Tettero JM, Ngai LL, Bachas C, Kelder A, Scholten WJ, Gradowska P, Arena V, Joao Simione A, Maurillo L, Venditti A, Lowenberg B, Ossenkoppele GJ, de Leeuw DC, Ikoma-Colturato MRV, Buccisano F, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372597"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2026 February; 40(2):279-292. doi: 10.1038\/s41375-025-02839-5","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","title02":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):444-448. doi: 10.1038\/s41375-025-02835-9","author":"Fedenko A, Czapinska H, Kramer A, Stolzel F, Bochtler T, Bochtler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419603"},{"title01":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","title02":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","journal":"Leukemia","issue":"2026 February; 40(2):293-303. doi: 10.1038\/s41375-025-02816-y","author":"Ho TC, LaMere MW, Kawano H, Byun DK, LaMere EA, Chiu YC, Chen C, Wang LJ, Wang J, Ramdas B, Dokholyan NV, Calvi LM, Liesveld JL, Jordan CT, Singh RK, Kapur R, Becker MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419607"},{"title01":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 February; 40(2):304-313. doi: 10.1038\/s41375-025-02842-w","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419608"},{"title01":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","title02":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):325-338. doi: 10.1038\/s41375-025-02829-7","author":"Dinh TTT, Lordo MR, Zhang AY, Goda C, Shilo N, Altynova E, Ruesch M, Kronen P, Broughton M, Jeremy E, Sellers VL, Zhang X, Larkin KT, Collins PL, Dorrance AM, Freud AG, Oakes CC, Mundy-Bosse BL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430399"},{"title01":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","title02":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):348-359. doi: 10.1038\/s41375-025-02832-y","author":"Yang Y, Liu X, Wei J, Qin J, Tan Q, Ji J, Guo F, Zheng Y, Bi F, Liu M, Wang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436638"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","title02":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","journal":"Leukemia","issue":"2026 February; 40(2):449-453. doi: 10.1038\/s41375-025-02846-6","author":"Ayoub M, Hitier C, Dehgane L, Mallet E, Tannoury M, Nemazanyy I, Roos-Weil D, Maloum K, Ringshausen I, Chapiro E, Nguyen-Khac F, Garnier D, Lagouge M, Lerner LK, Susin SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501504"},{"title01":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","title02":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):265-278. doi: 10.1038\/s41375-025-02817-x","author":"Struckman NE, Koutsoumpli G, de Jong RCM, van der Lee DI, Remst DFG, Smith SI, Honders MW, Hagedoorn RS, de Ru AH, Matsuda M, Ishikawa F, Tak T, Valk PJM, Heemskerk MHM, van Veelen PA, Falkenburg JHF, Griffioen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41388195"},{"title01":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","title02":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):383-396. doi: 10.1038\/s41375-025-02845-7","author":"Gonzales F, Schneider C, Alexe G, Lin S, Khalid D, Alvarez M, Basanthakumar A, Ellegast JM, Merickel L, Salhotra S, Taillon A, Giaimo M, Wunderlich M, Ansari M, Perry JA, Degar B, Pikman Y, Stegmaier K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41507381"},{"title01":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","title02":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","journal":"Leukemia","issue":"2026 February; 40(2):410-417. doi: 10.1038\/s41375-025-02859-1","author":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Mohle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuss A, Gothert JR, Ernst T, Abu-Samra M, Hoffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526617"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 9. doi: 10.1038\/s41375-026-02874-w. Online ahead of print","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","title02":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","journal":"Leukemia","issue":"2026 February 10. doi: 10.1038\/s41375-026-02873-x. Online ahead of print","author":"Nielsen CG, Als-Nielsen B, Albertsen BK, Davidsson OB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andres-Jensen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41667647"},{"title01":"Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.","title02":"Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.289170. Online ahead of print","author":"Fan L, Gao L, Zhang W, Yang L, Liu H, Wang H, Xiao P, Liao N, Zhuang Y, Xu X, Luo J, He Y, Zhang Y, Han X, Hu Y, Li J, He H, Wang Y, Cheng C, Zhai X, Ju X, Wang N, Lu J, Jiang H, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641646"},{"title01":"FLAG-IDA-Venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.","title02":"FLAG-IDA-Venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288866. Online ahead of print","author":"Krayem B, Frisch A, Yehudai-Ofir D, Henig I, Glaubach N, Zuckerman T, Haran A, Nachmias B, Aumann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641653"},{"title01":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","title02":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","journal":"Haematologica","issue":"2026 February 1; 111(2):493-507. doi: 10.3324\/haematol.2025.287740","author":"Naji NS, Pasca S, Chatzilygeroudi T, Toledano-Sanz P, Rimando J, An Y, Hemani Y, Perkins B, Zeng X, Talbot C Jr, Paun B, Abdulmalik A, Lossos C, Boronina TR, Sinanidis I, Tsakiroglou P, Fernandes P, Esteb C, Ambinder AJ, Cole RN, Xian R, Gojo I, Paul S, Levis MJ, DeZern AE, Luznik L, Karanika S, Resar LS, Jones RJ, Bunz F, Gondek L, Arvanitis M, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874324"},{"title01":"The immunophenotypic and genetic characterization of pediatric T-lymphoblastic leukemia with a mature immunophenotype.","title02":"The immunophenotypic and genetic characterization of pediatric T-lymphoblastic leukemia with a mature immunophenotype.","journal":"Haematologica","issue":"2026 February 1; 111(2):751-755. doi: 10.3324\/haematol.2025.288233","author":"Khanlari M, Wang W, Tizro P, Eldomery MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874330"},{"title01":"Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia.","title02":"Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):454-456. doi: 10.3324\/haematol.2025.288448","author":"Loghavi S, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874334"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.","title02":"Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288855. Online ahead of print","author":"Najar W, Barette L, Penther D, Maarek O, Stamatoullas A, Penichoux J, Veresezan EL, Daliphard S, Buchonnet G, Bobee V, Jardin F, De Botton S, Fenaux P, Camus V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609063"},{"title01":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","title02":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70330. Online ahead of print","author":"Pedraza A, Castano S, Pereira A, Nomdedeu M, Ruiz C, Esteva M, Diaz-Beya M, Sanz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560464"},{"title01":"Faulty antibody editing permits antiplatelet B cells in ITP.","title02":"Faulty antibody editing permits antiplatelet B cells in ITP.","journal":"Blood","issue":"2026 January 22; 147(4):323-325. doi: 10.1182\/blood.2025031605","author":"Bednarski JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569624"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","title02":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025016977. Online ahead of print","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli AA, Apperley JF, Akhtar S, Bourhis JH, Maertens JA, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola AM, Schaap M, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak GW, Peric Z, Penack O, Schoemans HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","title02":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025017559. Online ahead of print","author":"Lu B, Troyer J, Krause KJ, Lapite A, Aviles MM, Della-Moretta S, Dobson D, Farrokhi K, Hasanali ZS, Pillai PM, Taborda C, Villagomez L, Vo P, Wangondu R, Yui JC, Weyand AC, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587417"},{"title01":"HCT Pre-App Program: A Telemedicine-based Prehabilitation for Allogeneic Hematopoietic Cell Transplant candidates.","title02":"HCT Pre-App Program: A Telemedicine-based Prehabilitation for Allogeneic Hematopoietic Cell Transplant candidates.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025018378. Online ahead of print","author":"Salinas Gonzalez R, Guardia L, Sole B, Moreno C, de Llobet N, Cascos E, Martinez-Sanchez J, Diaz-Ricart M, Carreras E, Antonio M, Suarez-Lledo M, Rosinol L, Closa C, Sebio R, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544211"},{"title01":"Acquired non-permissive BM microenvironment impairs HSCs proliferation and maintenance and B-cell development post-HSCT.","title02":"Acquired non-permissive BM microenvironment impairs HSCs proliferation and maintenance and B-cell development post-HSCT.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025015915. Online ahead of print","author":"de Gier M, Korzhenevich J, Schmidt F, Janowska I, van Ostaijen-Ten Dam MM, Pico-Knijnenburg I, Cats D, Keller F, Hadlova P, Kunze M, Markfeld-Erol F, Mei H, Reising K, Bredius RG, Lankester AC, van der Burg M, Rizzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544216"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025016780. Online ahead of print","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania AV, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","title02":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025031370. Online ahead of print","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar S, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"Dynamic rRNA methylation regulates translation in the hematopoietic system and is essential for stem cell fitness.","title02":"Dynamic rRNA methylation regulates translation in the hematopoietic system and is essential for stem cell fitness.","journal":"Blood","issue":"2026 January 29; 147(5):520-533. doi: 10.1182\/blood.2024028300","author":"Rabany O, Ben Dror S, Arafat M, Aharoni Levitanus H, Halperin Y, Marchand V, Romanovski N, Ussishkin N, Livneh Golany M, Reches A, Wexler J, Mayorek N, Monderer-Rothkoff G, Shifman S, Bouhou WM, VanInsberghe M, Pauli C, Muller-Tidow C, Karmi O, Livneh Y, van Oudenaarden A, Motorin Y, Nachmani D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191530"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02860-2. Online ahead of print","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia.","title02":"Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300002. Online ahead of print","author":"Pool ES, Pothast CR, Gennesse SM, Van Egmond EHM, Giezen JM, Veld SAJ, Toes REM, Koning F, Halkes CJM, Heemskerk MHM, Moes DJAR, Tjon JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609027"},{"title01":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","title02":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300131. Online ahead of print","author":"Kanezaki R, Toki T, Okuse R, Kobayashi A, Sato M, Kimura S, Kudo K, Sato T, Tanaka T, Yoshida K, Kawai Y, Tokunaga K, Takita J, Ogawa S, Terui K, Ito E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568468"},{"title01":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","title02":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288956. Online ahead of print","author":"Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcarcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Diez-Campelo M, Oliva EN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568521"},{"title01":"Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis.","title02":"Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288981. Online ahead of print","author":"Fattizzo B, Abbatista M, Cecchi N, Novembrino C, Boscolo-Anzoletti M, Pedone GL, Bortolotti M, Artoni A, Giannotta JA, Peyvandi F, Passamonti F, Barcellini W, Capecchi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568533"},{"title01":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","title02":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","journal":"Br J Haematol","issue":"2026 January 27. doi: 10.1111\/bjh.70348. Online ahead of print","author":"Alam AU, Kaul P, Jain V, Wu C, Sun HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41589617"},{"title01":"Medical haematology: Repositioning haematology at the centre of medicine.","title02":"Medical haematology: Repositioning haematology at the centre of medicine.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70340. Online ahead of print","author":"Toh CH, Bates I, Pavord S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41556724"},{"title01":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","title02":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025017519. Online ahead of print","author":"Gotlib J, Reiter A, Radia DH, Alvarez-Twose I, Deininger MW, George TI, Panse JP, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu C, Mesa RA, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lubke J, Bidollari I, Lin HM, Rylova SN, Dimitrijevic S, Munoz-Gonzalez JI, DeAngelo DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604606"},{"title01":"Cold clues in pediatric autoimmune hemolytic anemia.","title02":"Cold clues in pediatric autoimmune hemolytic anemia.","journal":"Blood advances","issue":"2026 January 27; 10(2):531-532. doi: 10.1182\/bloodadvances.2025018452","author":"Jacobs JW, Bloch EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41591772"},{"title01":"Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.","title02":"Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.","journal":"Blood advances","issue":"2026 January 27; 10(2):418-427. doi: 10.1182\/bloodadvances.2025017254","author":"Power-Hays A, McElhinney KE, Williams TN, Mochamah G, Olupot-Olupot P, Paasi G, Reid ME, Rankine-Mullings AE, Opoka RO, John CC, McGann PT, Quinn CT, Punt NC, Smart LR, Stuber SE, Latham TS, Vinks AA, Ware RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026975"},{"title01":"Lipid Metabolism Transcriptomic Signature of Defective Erythropoiesis in Diamond Blackfan Anemia syndrome.","title02":"Lipid Metabolism Transcriptomic Signature of Defective Erythropoiesis in Diamond Blackfan Anemia syndrome.","journal":"Blood advances","issue":"2026 January 23. doi: 10.1182\/bloodadvances.2025017318. Online ahead of print","author":"Deng K, Wang Y, Min JC, Liu X, Ueharu H, Myers G, Yu L, Hammoud SB, Adam A, Saba R, Natogi V, Drysdale C, Chen B, Yee JL, Kitzman J, Lyssiotis CA, Mishina Y, Jones MA, Kaartinen V, Guan Y, Khoriaty R, Engel JD, Singh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576344"},{"title01":"Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency.","title02":"Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency.","journal":"Blood advances","issue":"2026 January 27; 10(2):521-530. doi: 10.1182\/bloodadvances.2025017309","author":"Blachez M, Aladjidi N, Modot T, Fernandes H, Garnier N, Chastagner P, Bayart S, Armari-Alla C, Piguet C, Pasquet M, Paillard C, Pluchart C, Guitton C, Thomas C, Barlogis V, Pellier I, Stephan JL, Benadiba J, Jeziorski E, Deparis M, Carausu L, Cheikh N, Li-Thiao Te V, Lejeune J, Marie-Cardine A, Millot F, Abou Chahla W, Gay S, Alimi A, Petit A, Castelle M, Moshous D, Picard C, Rieux-Laucat F, Leblanc T, Ducassou S, Leverger G, Fahd M, Heritier S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118608"},{"title01":"Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.","title02":"Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025017577. Online ahead of print","author":"Di Stefano V, Gianesin B, Orecchia V, Longo F, Susanna B, Barone A, Culcasi M, Denotti AR, Costantini S, Ferrara F, Foggetti I, Gigante A, Manca MR, Mazzi F, Pasanisi A, Pisaniello M, Ricchi P, Serra M, Origa R, Bertini M, Motta I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569798"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Hematologic malignancies in pediatric patients with RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy.","title02":"Hematologic malignancies in pediatric patients with RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy.","journal":"Blood advances","issue":"2026 January 30. doi: 10.1182\/bloodadvances.2025017808. Online ahead of print","author":"Kajdic A, Deuitch NT, Bresciani E, Chong SN, Craft KM, Davis J, Bashtawi R, McReynolds LJ, Giri N, Young DJ, Liu PP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41616279"},{"title01":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","title02":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025030464. Online ahead of print","author":"Ling T, Bezavada L, Mehmood R, Zhang K, Cotton A, Crawford JC, Jin H, Sona S, Li L, Ju Y, Han L, Liu N, Tran T, Vu H, Jin Y, Zhai J, Pruett-Miller SM, Bhoopalan SV, Xu J, Ni M, Crispino JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587073"},{"title01":"A Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection.","title02":"A Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031965. Online ahead of print","author":"Sohail H, Collins JE, Chan KH, Alamgir MA, Kamran AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592284"},{"title01":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","title02":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02858-2. Online ahead of print","author":"Zhao LP, Kosmider O, Heiblig M, Moulinet T, Lacombe V, Comont T, Lobbes H, Karam JD, Terriou L, Ardois S, Le Guenno G, Jachiet V, Wolff L, Vertenoeil G, Hadjadj J, Bouaziz JD, Lemaire P, Fain O, Terrier B, Georgin-Lavialle S, Larcher L, Clappier E, Sebert M, Ades L, Mekinian A, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545701"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","title02":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288956. Online ahead of print","author":"Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcarcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Diez-Campelo M, Oliva EN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568521"},{"title01":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","title02":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300405. Online ahead of print","author":"Oster H, Mittelman M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568531"},{"title01":"Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker.","title02":"Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300022. Online ahead of print","author":"Israel A, Gat R, Oster H, Moshe Y, Raz I, Mittelman M, Merzon E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609028"},{"title01":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","title02":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70345. Online ahead of print","author":"Furumoto T, Ando K, Toriyama E, Hata T, Sakamoto H, Chiwata M, Kitanosono H, Nakashima J, Kato T, Taguchi M, Horai M, Itonaga H, Sato S, Sawayama Y, Imanishi D, Imaizumi Y, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582419"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","title02":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018431. Online ahead of print","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho VT, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al-Ali N, Sallman DA, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02860-2. Online ahead of print","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","title02":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288948. Online ahead of print","author":"Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568522"},{"title01":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","title02":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","journal":"Blood advances","issue":"2026 January 27; 10(2):315-319. doi: 10.1182\/bloodadvances.2025017168","author":"Lee MH, Wang Y, Cronin A, Tramontano AC, Weeks LD, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056521"},{"title01":"Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.","title02":"Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.","journal":"Blood advances","issue":"2026 January 27; 10(2):507-510. doi: 10.1182\/bloodadvances.2025017938","author":"Suo S, Fu R, Qin A, Shao Z, Bai J, Zhou H, Xu N, Chen S, Zuo X, Du X, Duan M, Wang L, Li P, Zhang X, Zhang S, Wu D, Zhang J, Xiao Z, Zhang L, Jin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172233"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018811. Online ahead of print","author":"Tashi T, Shih LY, Yo YT, Sullivan A, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia.","title02":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia.","journal":"Lancet","issue":"2026 January 31; 407(10527):489-491. doi: 10.1016\/S0140-6736(25)02515-2","author":"Duque-Afonso J, Rummelt C, Forster K, Zeiser R, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587555"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288558. Online ahead of print","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609024"},{"title01":"Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.","title02":"Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70309. Online ahead of print","author":"Wang JH, Yang Q, Duan SQ, Yang L, Zhou Y, Fang CL, Xiao ZG, Yang CH, Xiong YC, Tian X, Huang TL, Zhang XW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41554292"},{"title01":"Immune repertoire profiling in immune thrombocytopenia: A path towards biomarkers, for The British Journal of Haematology.","title02":"Immune repertoire profiling in immune thrombocytopenia: A path towards biomarkers, for The British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70341. Online ahead of print","author":"Malik A, Hart A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560569"},{"title01":"A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.","title02":"A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.","journal":"Blood","issue":"2026 January 22; 147(4):416-430. doi: 10.1182\/blood.2025028960","author":"Sheng Z, Jiang N, Gao Y, Zhang Y, Zhang X, Li N, Feng Q, Zhang Y, Wang L, Semple JW, Wang S, Li S, Peng J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032749"},{"title01":"Immune biomarkers of increased infection risk in multiple myeloma.","title02":"Immune biomarkers of increased infection risk in multiple myeloma.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031744. Online ahead of print","author":"Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, Sklavenitis Pistofidis R, Smits F, Rodriguez-Otero P, Roncal C, Aranha MP, Zihala D, Machu M, Tsakirakis N, Bakouros P, Tsitsilonis O, Solia I, Moreno C, Maia C, Martin-Sanchez E, Perez JJ Sr, Encinas C, Rios-Tamayo R, Oriol A, Blanchard MJ, de Arriba F, Gonzalez-Garcia E, Lakhwani S, Sureda A, Cabanas V, Escalante F, Carrillo-Cruz E, Perez-Montana A, Ocio EMM, Bargay J, Orfao A, Jelinek T, Ghobrial IM, Mutis T, Zweegman S, Terpos E, Kastritis E, Martinez-Lopez J, Lahuerta JJ, Fernandez de Larrea C, Rosinol L, Blade J, Mateos MV, San-Miguel JF, Cedena MT, Puig N, Paiva B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610428"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 January 21; JCO2502130. doi: 10.1200\/JCO-25-02130. Online ahead of print","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","title02":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289266. Online ahead of print","author":"Canto PA, Montoro J, Balaguer-Rosello A, Villalba M, Chorao P, Louro A, Granados P, Eiris J, Bataller A, Gomez-Segui I, Solves P, Leon G, Lamas B, Eritzpokhoff L, Vallejo N, Hervas A, Hurtado M, Lopez J, Mansilla-Polo M, Reig JP, Valero MGG, De la Rubia M, Satorres C, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568541"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","title02":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018431. Online ahead of print","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho VT, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al-Ali N, Sallman DA, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025016780. Online ahead of print","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania AV, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","title02":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 27; 10(2):479-491. doi: 10.1182\/bloodadvances.2025017127","author":"Haydu JE, Redd RA, Lei MM, Hochberg EP, Barnes JA, Armand P, Soumerai JD, Eichler AF, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany I, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170917"},{"title01":"Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.","title02":"Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.","journal":"Blood advances","issue":"2026 January 27; 10(2):379-391. doi: 10.1182\/bloodadvances.2025017980","author":"Diaz-Gonzalez A, Mora E, Garrote M, Carreno-Tarragona G, Salido M, Pastor-Galan I, Stuckey R, Cisneros A, Domingo-Monfort JA, Uresandi-Iruin N, Argoitia-Ituarte N, Avetisyan G, Garcia-Ruiz C, Torres-Hernandez N, Furio S, Arellano-Rodrigo E, Alvarez N, Velez P, Villamon E, Segura-Diaz A, Ayala R, Espinet B, Alvarez-Larran A, Hernandez-Boluda JC, Such E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150842"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","title02":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025031370. Online ahead of print","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar S, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"How I treat advanced phases of CML.","title02":"How I treat advanced phases of CML.","journal":"Blood","issue":"2026 January 22; 147(4):369-378. doi: 10.1182\/blood.2024026510","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031952. Online ahead of print","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria B, Giri S, Godby K, Silbermann R, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","title02":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025032347. Online ahead of print","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02828-8. Online ahead of print","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 January 21; JCO2502130. doi: 10.1200\/JCO-25-02130. Online ahead of print","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications – inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","title02":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications – inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.287480. Online ahead of print","author":"Bachrach T, Duek A, Shlush LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609026"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","title02":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289266. Online ahead of print","author":"Canto PA, Montoro J, Balaguer-Rosello A, Villalba M, Chorao P, Louro A, Granados P, Eiris J, Bataller A, Gomez-Segui I, Solves P, Leon G, Lamas B, Eritzpokhoff L, Vallejo N, Hervas A, Hurtado M, Lopez J, Mansilla-Polo M, Reig JP, Valero MGG, De la Rubia M, Satorres C, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568541"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","title02":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288948. Online ahead of print","author":"Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568522"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.287609. Online ahead of print","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Ligature-induced periodontitis promotes Dnmt3a R878H-driven clonal hematopoiesis.","title02":"Ligature-induced periodontitis promotes Dnmt3a R878H-driven clonal hematopoiesis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288827. Online ahead of print","author":"Yuan Q, Liao M, Zhuang Z, Huang C, Chen R, Song Y, Wu Y, Zou P, Li L, Nie H, Zhang M, Song S, Li Y, Yan F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568536"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"Ribosomal RNA methylation in HSCs: it’s so “good for you”.","title02":"Ribosomal RNA methylation in HSCs: it’s so “good for you”.","journal":"Blood","issue":"2026 January 29; 147(5):476-478. doi: 10.1182\/blood.2025032073","author":"Lopez J, Tzelepis K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609808"},{"title01":"Remodelling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","title02":"Remodelling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025030055. Online ahead of print","author":"Ngo S, D'Agostino GA, Papazoglou D, Mohamad Nor F, Finsterbusch K, Habel K, Ferrelli A, Anjos-Afonso F, Bonnet D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610429"},{"title01":"Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.","title02":"Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.","journal":"Blood advances","issue":"2026 January 27; 10(2):392-401. doi: 10.1182\/bloodadvances.2025016727","author":"Erbella F, Bachy E, Cartron G, Gat E, Manson G, Morschhauser F, Gros FX, Roulin L, Tessoulin B, Bories P, Tournilhac O, Ricard L, Guidez S, Choquet S, Casasnovas RO, Brisou G, Campidelli A, Castilla-Llorente C, Jardin F, Gyan E, Guffroy B, Abraham J, Decroocq J, Chauchet A, Joris M, Claves F, Carras S, Guillerm G, Loschi M, Hermine O, Taguy-Schimidt A, Le Gouill S, Houot R, Di Blasi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124667"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.","title02":"DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.","journal":"Blood","issue":"2026 January 20. doi: 10.1182\/blood.2025030049. Online ahead of print","author":"Chiodin G, Tatterton DJ, Rock PJ, Del Rio L, Snook E, James S, Duriez PJ, Di Re M, Verdoes M, Lanham S, Hodson DJ, Burack R, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557914"},{"title01":"Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.","title02":"Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.","journal":"Blood","issue":"2026 January 29; 147(5):602. doi: 10.1182\/blood.2025031040","author":"Urano Y, Satou A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609805"},{"title01":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","title02":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):164-175. doi: 10.1200\/JCO-25-00924","author":"Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370738"},{"title01":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","title02":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","journal":"J Clin Oncol","issue":"2026 January 27; JCO2501713. doi: 10.1200\/JCO-25-01713. Online ahead of print","author":"Banerjee R, King T, Faiman B, Harding S, Rosenberg AS, Sanchorawala V, Mikhael JR, Cowan AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592262"},{"title01":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions.","title02":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):188-199. doi: 10.1200\/JCO-25-01733","author":"Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Via MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061199"},{"title01":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma.","title02":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):139-142. doi: 10.1200\/JCO-25-01088","author":"Kaiser MF, Cliff ERS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40929614"},{"title01":"Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed\/refractory multiple myeloma.","title02":"Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed\/refractory multiple myeloma.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.289079. Online ahead of print","author":"Chai JN, Simonson PD, Gulgar K, Costanzo F, Jayabalan DS, Bustoros M, Inghirami GG, Geyer JT, Saldarriaga MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609029"},{"title01":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma treated in Europe.","title02":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma treated in Europe.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289034. Online ahead of print","author":"Cavo M, Schjesvold F, Dimopoulos M, Delforge M, Escalante F, Kleinman D, Lee HC, Vij R, Greil R, Melchardt T, Antonioli E, Lysen A, Camadoo-O'Byrne L, Bitetti J, D'Estrube T, Fry M, Byrne J, Vossen CY, Sapra S, Benson VS, Mouro J, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568469"},{"title01":"Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.","title02":"Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.289200. Online ahead of print","author":"Roman E, Bagguley T, Crouch S, Smith A, Painter D, Howell D, Patmore R, Tooze R, Cargo C, De Tute R, Rawstron A, Cook G, Parrish C, Seymour F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609031"},{"title01":"Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study.","title02":"Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300043. Online ahead of print","author":"Lee JY, Jung EJ, Kwon S, Kim SA, Lee JO, Han K, Bang SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609060"},{"title01":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.","title02":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025018951. Online ahead of print","author":"Oswald LB, Li X, Ferraris CE, DeAvila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue BJ, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini OA, Nishihori T, Liu HD, Locke FL, Jim HS, Hansen DK, Peres LC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564433"},{"title01":"Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.","title02":"Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025018945. Online ahead of print","author":"Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J, Fan L, Chen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564431"},{"title01":"Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.","title02":"Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):439-451. doi: 10.1182\/bloodadvances.2025018024","author":"Arnold KD, Ong KL, Ravi G, Wessel MC, Davies FE, Costa LJ, Deshpande A, Morgan GJ, Birmann BM, Brown EE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150833"},{"title01":"Vaccination during bispecific antibody treatment for myeloma.","title02":"Vaccination during bispecific antibody treatment for myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):519-520. doi: 10.1182\/bloodadvances.2025018225","author":"Banerjee R, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061155"},{"title01":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.","title02":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025017889. Online ahead of print","author":"Mersi J, Burow L, Zhou X, Eisele F, Fante M, Riedhammer C, Stich A, Isberner N, Afrin N, Duell J, Topp MS, Einsele H, Waldschmidt JM, Kortum KM, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610311"},{"title01":"Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.","title02":"Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.","journal":"Blood advances","issue":"2026 January 27; 10(2):343-355. doi: 10.1182\/bloodadvances.2025017296","author":"Dyer MR, Zheleznyak A, Teubner EN, Prior JL, Manion B, Jing Z, Sharma AK, Du J, Tang R, Fiala MA, DiPersio JF, Veis D, O'Neal J, Berezin MY, Shokeen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056513"},{"title01":"Long-term follow-up of zevor-cel in patients with relapsed\/refractory multiple myeloma.","title02":"Long-term follow-up of zevor-cel in patients with relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):468-478. doi: 10.1182\/bloodadvances.2025017365","author":"Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, Wu Y, Yan S, Gao W, Shi X, Han X, Tang F, Zheng G, Wen Y, Meng X, Yuan D, Wang H, Li Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160798"},{"title01":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","title02":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025032347. Online ahead of print","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"A myeloma identity crisis yields daratumumab resistance.","title02":"A myeloma identity crisis yields daratumumab resistance.","journal":"Blood","issue":"2026 January 29; 147(5):473-474. doi: 10.1182\/blood.2025031281","author":"Pandey A, Diamond B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609806"},{"title01":"The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma.","title02":"The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma.","journal":"Blood","issue":"2026 January 29; 147(5):474-476. doi: 10.1182\/blood.2025031961","author":"Al Hadidi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609812"},{"title01":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","title02":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025032536. Online ahead of print","author":"van de Donk NWCJ, Sonneveld P, Einsele H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610427"},{"title01":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.","title02":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.","journal":"Blood","issue":"2026 January 29; 147(5):534-546. doi: 10.1182\/blood.2024027616","author":"Rieger L, Irlinger K, Fuchsl F, Tietje M, Purcarea A, Barbian N, Faber M, Vogelsang C, Pfeuffer L, Stotz S, Karpiuk O, Schulze T, Augsburger A, Glaisner N, Konetzki V, Friedel S, Besse A, Besse L, Driessen C, Buchner M, Schwamborn K, Steiger K, Giansanti P, Theurich S, Waldschmidt J, Kortum KM, Hudecek M, Einsele H, Hogner M, Kuster B, Krackhardt AM, Hecker JS, Bassermann F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40638685"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031952. Online ahead of print","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria B, Giri S, Godby K, Silbermann R, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Time to Revise Myeloma Diagnostic Criteria? A Decade of Accumulated Evidence on Serum Free Light Chain Ratio >\/=100.","title02":"Time to Revise Myeloma Diagnostic Criteria? A Decade of Accumulated Evidence on Serum Free Light Chain Ratio >\/=100.","journal":"Blood","issue":"2026 January 20. doi: 10.1182\/blood.2025031907. Online ahead of print","author":"Chakraborty R, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557896"},{"title01":"The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma.","title02":"The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma.","journal":"Blood","issue":"2026 January 29; 147(5):513-519. doi: 10.1182\/blood.2025030559","author":"Pan M, Wang D, Xu J, Jin S, Wang Y, Tao Y, Liu Y, Ouyang W, Weng X, Yi H, Huang Y, Cao X, Li S, Zhang F, Zhang W, Li C, Mi JQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118600"},{"title01":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.","title02":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.","journal":"Blood","issue":"2026 January 22; 147(4):431-442. doi: 10.1182\/blood.2025030113","author":"Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted A, Vieyra D, Attar R, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060326"},{"title01":"Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.","title02":"Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.","journal":"Blood","issue":"2026 January 29; 147(5):497-512. doi: 10.1182\/blood.2025029921","author":"Meads MB, Zhao X, Noyes D, Sudalagunta PR, Achille A, Zhang C, Canevarolo RR, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil SS, Yoder SJ, Grajales-Cruz AF, Blue B, Freeman CL, Kim J, Alsina M, Brayer J, Silva AS, Song X, Shain KH, Baz R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983035"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70347. Online ahead of print","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI.","title02":"Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025017413. Online ahead of print","author":"Goldenberg M, Varadhan R, Gamper CJ, Cooke KR, Ambinder AJ, Symons HJ, Pecker LH, Jones RJ, Brodsky RA, Bolanos-Meade J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569644"},{"title01":"Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.","title02":"Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025019253. Online ahead of print","author":"Hochsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, Kalhammer U, Opitz SA, Marx-Hoffmann A, Knight DB, Brodsky RA, Marvaki A, Lalayanni C, Korper S, Babushok DV, Schrezenmeier H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610317"},{"title01":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","title02":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025016977. Online ahead of print","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli AA, Apperley JF, Akhtar S, Bourhis JH, Maertens JA, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola AM, Schaap M, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak GW, Peric Z, Penack O, Schoemans HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018811. Online ahead of print","author":"Tashi T, Shih LY, Yo YT, Sullivan A, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"How I treat advanced phases of CML.","title02":"How I treat advanced phases of CML.","journal":"Blood","issue":"2026 January 22; 147(4):369-378. doi: 10.1182\/blood.2024026510","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.","title02":"Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):547-556. doi: 10.1182\/blood.2025030498","author":"Azevedo RS, Jabbour E, Kantarjian HM, Lavu S, Loghavi S, Jain N, Sasaki K, Garris RS, Takahashi K, Ravandi F, Short NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41335402"},{"title01":"The proteostasis network is a therapeutic target in acute myeloid leukemia.","title02":"The proteostasis network is a therapeutic target in acute myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):557-572. doi: 10.1182\/blood.2024026749","author":"Lam K, Kim YJ, Tan EL, Ong CM, Liu AZ, Zhou FJ, Sunshine MJ, Chua BA, Vicenzi S, Chen K, Yu H, Ford PW, Zhou JH, Hong Y, Bennett EJ, Crews LA, Ball ED, Signer RAJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111393"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","title02":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025030464. Online ahead of print","author":"Ling T, Bezavada L, Mehmood R, Zhang K, Cotton A, Crawford JC, Jin H, Sona S, Li L, Ju Y, Han L, Liu N, Tran T, Vu H, Jin Y, Zhai J, Pruett-Miller SM, Bhoopalan SV, Xu J, Ni M, Crispino JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587073"},{"title01":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","title02":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025029972. Online ahead of print","author":"Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen VW, Zhou C, Wallace JA, Tanaka KL, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TYY, Greenberg PL, Gotlib J, Mannis GN, Shomali W, Salmasi GG, Kuo CJ, Shanafelt TD, Singh I, Inoue D, Hansen FK, Gray NS, Van Rechem C, Fakhri B, Zhang X, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587094"},{"title01":"How I treat chronic myeloid leukemia in children and adolescents.","title02":"How I treat chronic myeloid leukemia in children and adolescents.","journal":"Blood","issue":"2026 January 22; 147(4):379-389. doi: 10.1182\/blood.2024026514","author":"Chen J, Suttorp M, Hijiya N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40132166"},{"title01":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","title02":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02849-3. Online ahead of print","author":"Graf CM, Reese M, Vicente-Luque A, Monig N, Bruzeau C, Nadeu F, Latacz M, Bihler J, Meinel J, Cartolano M, Peifer M, Bea S, Campo E, Thelen M, Brockelmann PJ, Jachimowicz RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588054"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02844-8. Online ahead of print","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Transforming mantle cell lymphoma: the journey across eras.","title02":"Transforming mantle cell lymphoma: the journey across eras.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300275. Online ahead of print","author":"Castonguay M, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609054"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","title02":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","journal":"Br J Haematol","issue":"2026 January 22. doi: 10.1111\/bjh.70334. Online ahead of print","author":"Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571607"},{"title01":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","title02":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70344. Online ahead of print","author":"Fleischmann M, Hansen O, Voigtlander D, Bechwar J, Schwietzer LJ, Bahr S, Schnetzke U, Fischer M, Heidel FH, Schnoder TM, Muller JP, Hochhaus A, Scholl S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608989"},{"title01":"How I manage mycosis fungoides and Sezary syndrome: Current controversies and unmet needs.","title02":"How I manage mycosis fungoides and Sezary syndrome: Current controversies and unmet needs.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70308. Online ahead of print","author":"Stadler R, Quaglino P, Roccuzzo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555738"},{"title01":"Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.","title02":"Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70298. Online ahead of print","author":"Angel S, Marc B, Victor N, Patricia LP, David Q, Juan-Manuel S, Adolfo S, Ana JU, Carlos CJ, Raul C, Maria C, la Cruz Beatriz D, Samuel R, Ainara F, Tomas G, Teresa V, Andrea R, Sofia V, Paola V, Carmen H, Miguel C, Miguel A, Alejandro MG, Javier M, Cristina G, Ana MN, Gloria I, Francesc B, Pau A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560431"},{"title01":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","title02":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","journal":"Br J Haematol","issue":"2026 January 26. doi: 10.1111\/bjh.70335. Online ahead of print","author":"Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582824"},{"title01":"Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","title02":"Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025018719. Online ahead of print","author":"Heger JM, Mattlener J, Herhaus P, Meissner J, Trautmann-Grill K, Voltin CA, Schneider J, Schleifenbaum JK, Heidenreich SJ, Kobe C, Kaul H, Klapper W, von Tresckow B, Borchmann P, Brockelmann PJ, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592288"},{"title01":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","title02":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018536. Online ahead of print","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","title02":"Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018491. Online ahead of print","author":"Gong IY, Kuruvilla J, Prica A, Olney HJ, Fraser GA, Buckstein RJ, Skrabek P, Keating MM, Hay AE, Shepherd L, Chen BE, Crump M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587423"},{"title01":"Treatment and Survival Outcomes in Follicular Lymphoma Patients with POD24: A Systematic Review and Meta-Analysis.","title02":"Treatment and Survival Outcomes in Follicular Lymphoma Patients with POD24: A Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018474. Online ahead of print","author":"Shen J, Zhang J, Zhu Z, Ma H, Zhang J, Zhou F, Tian H, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587420"},{"title01":"Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.","title02":"Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.","journal":"Blood advances","issue":"2026 January 27; 10(2):358-366. doi: 10.1182\/bloodadvances.2025017248","author":"Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquieres H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Oberic L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056515"},{"title01":"Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.","title02":"Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025016925. Online ahead of print","author":"Schmeing S, Nassiri S, Leclercq-Cohen G, Yanguez E, Husser T, Alberti Servera L, Schlenker R, Sam J, Klein C, Umana P, Herter S, Bottos A, Bacac M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569641"},{"title01":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC\/BCL2 rearrangements, DLBCL morphology.","title02":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC\/BCL2 rearrangements, DLBCL morphology.","journal":"Blood advances","issue":"2026 January 27; 10(2):320-333. doi: 10.1182\/bloodadvances.2025017282","author":"Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Savage KJ, Villa D, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071951"},{"title01":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","title02":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025017682. Online ahead of print","author":"Qin Y, Xia PH, Huang YH, Cheng S, Liu JY, Gao X, Cai MC, Wang C, Qiu YR, Hu S, Shi Q, Yang HX, Zhao JY, Wang L, Xiong J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564436"},{"title01":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","title02":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017049. Online ahead of print","author":"Yim J, Lee S, Kim S, Han B, Lim S, Song YK, Youk J, Bae JM, Koh J, Lee C, Kim YA, Paik JH, Kim TMM, Yun H, Jeon YK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544233"},{"title01":"Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.","title02":"Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017401. Online ahead of print","author":"Kordbacheh T, Chan KK, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544221"},{"title01":"Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R\/R Marginal Zone Lymphoma: Phase 1\/2 BRUIN Study.","title02":"Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R\/R Marginal Zone Lymphoma: Phase 1\/2 BRUIN Study.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017489. Online ahead of print","author":"Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani CS, Hoffmann MS, Cheah CY, Munir T, Lewis DJ, Scarfo L, Eyre TA, Alencar AJ, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada PB, Balbas M, Zinzani PLL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544219"},{"title01":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","title02":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 27; 10(2):479-491. doi: 10.1182\/bloodadvances.2025017127","author":"Haydu JE, Redd RA, Lei MM, Hochberg EP, Barnes JA, Armand P, Soumerai JD, Eichler AF, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany I, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170917"},{"title01":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","title02":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","journal":"Blood advances","issue":"2026 January 27; 10(2):289-300. doi: 10.1182\/bloodadvances.2025017321","author":"Butt H, Sathish S, London E, Le A, Li Q, Gudmundsdottir B, Lee DY, Burke EV, Yates BP, Liu DR, Hsieh M, Leonard A, Eaton WA, Uchida N, Pierciey FJ Jr, Newby GA, Tisdale JF, Demirci S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150843"},{"title01":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","title02":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):135-138. doi: 10.1200\/JCO-25-02305","author":"Saldarriaga MM, Bellman P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385751"},{"title01":"National-level dietary patterns and acute myeloid leukemia: a global ecological analysis.","title02":"National-level dietary patterns and acute myeloid leukemia: a global ecological analysis.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288955. Online ahead of print","author":"Wen D, Peng Z, Deng J, National-Level Dietary Patterns And Acute Myeloid Leukemia A Global Ecological, Analysis NNSFOCN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609059"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288558. Online ahead of print","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609024"},{"title01":"Exploring the synergy between telomere length and genomic complexity in CLL.","title02":"Exploring the synergy between telomere length and genomic complexity in CLL.","journal":"Br J Haematol","issue":"2026 January 23. doi: 10.1111\/bjh.70317. Online ahead of print","author":"Ramos-Campoy S, Puiggros A, Kamaso J, Parker H, Rigolin GM, Haferlach C, Larrayoz MJ, Collado R, Salgado R, Calasanz MJ, Etter L, Valiente A, Abrisqueta P, Bosch F, Gimeno E, Cuneo A, Nguyen-Khac F, Schoumans J, Strefford JC, Espinet B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41574981"},{"title01":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","title02":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70353. Online ahead of print","author":"Lee YW, Chiang CJ, Lin YC, Tzeng HE, Chuang YT, Yang YW, Lee WC, Wu SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608915"},{"title01":"The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.","title02":"The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70336. Online ahead of print","author":"Verbeek MWC, Sanders MA, Grashof DGB, Hoogenboezem RM, van Zuijen I, Bos A, van Gulck T, Olsman R, Mukhopadhyay R, Bindels EMJ, Valk PJM, van de Werken HJG, van der Velden VHJ, Erkeland SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41550039"},{"title01":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","title02":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018536. Online ahead of print","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.","title02":"Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025018771. Online ahead of print","author":"Vainer N, Brieghel C, Rostgaard K, Davidsson OB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Curovic Rotbain E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604617"},{"title01":"Advancing Precision Therapy in Pediatric Acute Myeloid Leukemia Through PDX Models and Mitochondrial Targeting.","title02":"Advancing Precision Therapy in Pediatric Acute Myeloid Leukemia Through PDX Models and Mitochondrial Targeting.","journal":"Blood advances","issue":"2026 January 23. doi: 10.1182\/bloodadvances.2025018002. Online ahead of print","author":"Da Ros A, Peloso A, Longo G, Benetton M, Indio V, Cairo S, Sandri M, Buldini B, Bresolin S, Rosato A, Pession A, Tregnago C, Locatelli F, Pigazzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576348"},{"title01":"Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia.","title02":"Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 27; 10(2):452-465. doi: 10.1182\/bloodadvances.2024015174","author":"Quessada J, Nozais M, Grosjean C, Savey C, Pankaew S, Allelova S, Potier D, Loosveld M, Payet-Bornet D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811813"},{"title01":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","title02":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018369. Online ahead of print","author":"Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton NM, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610325"},{"title01":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","title02":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","journal":"Blood advances","issue":"2026 January 27; 10(2):289-300. doi: 10.1182\/bloodadvances.2025017321","author":"Butt H, Sathish S, London E, Le A, Li Q, Gudmundsdottir B, Lee DY, Burke EV, Yates BP, Liu DR, Hsieh M, Leonard A, Eaton WA, Uchida N, Pierciey FJ Jr, Newby GA, Tisdale JF, Demirci S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150843"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression.","title02":"High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025029824. Online ahead of print","author":"Li L, Rottmann I, Saeed BR, Ivison G, Wei H, Schroeder JC, Dunkel G, Greif K, Zhang Y, Makky A, Ochsenbein AF, Riether C, Goltsev Y, Nolan G, Mayer AT, Weigelin B, Schurch CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592325"},{"title01":"Menin inhibitors: a 2-in-1 defense versus AML immune evasion.","title02":"Menin inhibitors: a 2-in-1 defense versus AML immune evasion.","journal":"Blood","issue":"2026 January 29; 147(5):482-483. doi: 10.1182\/blood.2025031975","author":"Chakraverty R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609810"},{"title01":"Targeting proteostasis addiction in AML.","title02":"Targeting proteostasis addiction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):479-480. doi: 10.1182\/blood.2025031546","author":"Clarke ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609811"},{"title01":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.","title02":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031266. Online ahead of print","author":"Ranasinghe D, Lin WY, Fordham SE, Alharbi AA, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol AD, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop HS, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem BC, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok MH, Preudhomme C, Gale RE, Linch DC, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes AF, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Parkin BL, Malek SN, Stolzel F, Onel K, Allan JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610418"},{"title01":"circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","title02":"circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031129. Online ahead of print","author":"Papaioannou D, Urs AP, Buisson R, Petri A, Liu M, Woodward L, Kulkarni R, Weislamle X, Ivashkiv O, Nicolet D, Goda C, Paraskevopoulou V, Bustos Y, Mrozek K, Eisfeld AK, Chandrasekharan MB, Behbehani GK, Kauppinen S, Aifantis I, Singh G, Dorrance AM, Garzon R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610425"},{"title01":"Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.","title02":"Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025030626. Online ahead of print","author":"Pinton A, Courtois L, Delafoy M, Bonnet MF, Cieslak A, Lhermitte L, Simonin M, Dourthe ME, Touzart A, Andrieu GP, Dombret H, Baruchel A, Spicuglia S, Payet-Bornet D, Boissel N, Macintyre EA, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592282"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Introduction to a How I Treat series on chronic myeloid leukemia.","title02":"Introduction to a How I Treat series on chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 22; 147(4):319-320. doi: 10.1182\/blood.2025031933","author":"Gotlib J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569619"},{"title01":"TP53-mutated AML with salmon-colored globules, a single Auer rod, pseudo-Chediak-Higashi granules, and micronuclei.","title02":"TP53-mutated AML with salmon-colored globules, a single Auer rod, pseudo-Chediak-Higashi granules, and micronuclei.","journal":"Blood","issue":"2026 January 22; 147(4):471. doi: 10.1182\/blood.2025031282","author":"Xu Z, Medvedev N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569620"},{"title01":"How I individualize frontline treatment for chronic-phase CML.","title02":"How I individualize frontline treatment for chronic-phase CML.","journal":"Blood","issue":"2026 January 22; 147(4):329-336. doi: 10.1182\/blood.2024026508","author":"Leyte-Vidal A, Shah NP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40239150"},{"title01":"How I manage chronic myeloid leukemia during pregnancy.","title02":"How I manage chronic myeloid leukemia during pregnancy.","journal":"Blood","issue":"2026 January 22; 147(4):347-356. doi: 10.1182\/blood.2024026513","author":"Abruzzese E, Chelysheva E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758938"},{"title01":"DHODH as a Targetable Metabolic Achilles’ Heel for chemo-resistant B-ALL.","title02":"DHODH as a Targetable Metabolic Achilles’ Heel for chemo-resistant B-ALL.","journal":"Blood","issue":"2026 January 23. doi: 10.1182\/blood.2025029264. Online ahead of print","author":"Liu Y, Jiang H, Liu J, Stuani L, Merchant MJ, Jager A, Koladiya A, Chang TC, Domizi P, Sarno J, Wang A, Keyes T, Jedoui D, Meng J, Hartmann F, Hou R, Fries C, Pirillo C, Gao Q, Iacobucci I, Bendall SC, Huang M, Lacayo NJ, Sakamoto KM, Mullighan CG, Loh ML, Yu J, Yang JJ, Ye J, Davis KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576347"},{"title01":"How I evaluate and treat resistance and relapse in CML.","title02":"How I evaluate and treat resistance and relapse in CML.","journal":"Blood","issue":"2026 January 22; 147(4):337-346. doi: 10.1182\/blood.2024026511","author":"Soverini S, Castagnetti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373278"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02828-8. Online ahead of print","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","title02":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","journal":"Leukemia","issue":"2026 January 23. doi: 10.1038\/s41375-025-02852-8. Online ahead of print","author":"Oehler VG, Sala-Torra O, Gilderman N, Beppu L, Woolston DW, Namaganda P, Rynning J, Gonzalez IG, Towlerton A, Voutsinas J, Wu Q, Yeung CCS, Radich JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41577999"},{"title01":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","title02":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-025-02837-7. Online ahead of print","author":"Zheng Y, Dong F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571770"},{"title01":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","title02":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02862-0. Online ahead of print","author":"Wang Y, Wang X, Li M, Song H, Liu C, Shi M, Tao X, Shen S, Li X, Fang H, Zhou Z, Zhang J, Han B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571768"},{"title01":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","title02":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","journal":"Leukemia","issue":"2026 January 19. doi: 10.1038\/s41375-025-02847-5. Online ahead of print","author":"Rea D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, Illes A, Angona Figueras A, Kiani A, Charbonnier A, Marinakis T, Stenke L, Steegmann JL, Saglio G, Hellmann A, Niederwieser D, Schuld P, Rosti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555010"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02844-8. Online ahead of print","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","title02":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","journal":"J Clin Oncol","issue":"2026 January 20; JCO2502879. doi: 10.1200\/JCO-25-02879. Online ahead of print","author":"Braunstein MJ, Williams ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557975"},{"title01":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):254-256. doi: 10.1200\/JCO-25-01695","author":"Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270246"},{"title01":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):256-257. doi: 10.1200\/JCO-25-02231","author":"Sharman JP, Liu B, Wang DY, Leow CC, Barr PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270260"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.","title02":"Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300099. Online ahead of print","author":"Yoon JH, Min KI, Kwag D, Min GJ, Park SS, Park S, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Lee S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609055"},{"title01":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300390. Online ahead of print","author":"Hochberg J, Cairo MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568543"},{"title01":"Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.","title02":"Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288274. Online ahead of print","author":"Chavana AN, Mason EJ, Woodhouse JP, Taylor OA, Gramatges MM, Yi JS, Pruitt S, Bernhardt BM, Ludwig K, Klesse L, Heym K, Griffin T, Roberts M, Erana R, Bernini JC, Zhu H, Lupo PJ, Rabin KR, Scheurer ME, Mittelman SD, Huynh V, Orgel E, Brown AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568528"},{"title01":"Optimal management of elderly\/old Ph+ acute lymphoblastic leukemia patients.","title02":"Optimal management of elderly\/old Ph+ acute lymphoblastic leukemia patients.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300060. Online ahead of print","author":"Foa R, Chiaretti S, Ferrara F, Pizzolo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568523"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.287609. Online ahead of print","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70347. Online ahead of print","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","title02":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70346. Online ahead of print","author":"Dai X, Wu Z, Zhang W, Chen S, Zhao X, Lu Y, Ma Y, Zheng W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608869"},{"title01":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","title02":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 January 28. doi: 10.1111\/bjh.70339. Online ahead of print","author":"Crespo-Garcia E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41606290"},{"title01":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","title02":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","journal":"Br J Haematol","issue":"2026 January 22. doi: 10.1111\/bjh.70334. Online ahead of print","author":"Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571607"},{"title01":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","title02":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70344. Online ahead of print","author":"Fleischmann M, Hansen O, Voigtlander D, Bechwar J, Schwietzer LJ, Bahr S, Schnetzke U, Fischer M, Heidel FH, Schnoder TM, Muller JP, Hochhaus A, Scholl S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608989"},{"title01":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","title02":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70330. Online ahead of print","author":"Pedraza A, Castano S, Pereira A, Nomdedeu M, Ruiz C, Esteva M, Diaz-Beya M, Sanz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560464"},{"title01":"Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.","title02":"Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.","journal":"Blood advances","issue":"2026 January 27; 10(2):428-438. doi: 10.1182\/bloodadvances.2025017755","author":"Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, Besikli-Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer-Lores B, Garcia Vela JA, Gentile M, Vazquez EG, Gutwein O, Herishanu Y, Jablonowska-Babij P, Jaksic O, Josefsson P, Kalicinska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Mela Osorio MJ, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Savas EM, Scarfo L, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtzi P, Tranidou A, Visentin A, Vrachiolias G, Wasik-Szczepanek E, Wrobel T, Yagci M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren-Michowitz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135013"},{"title01":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","title02":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-025-02855-5. Online ahead of print","author":"Ansuinelli M, Peragine N, De Propris MS, Puzzolo MC, Di Trani M, Elia L, Skert C, Cairoli R, Sica S, Rambaldi A, Tucci A, Cerrano M, Vallisa D, Cardinali V, Mule A, Chiaretti S, Guarini A, Foa R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571767"},{"title01":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","title02":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02856-4. Online ahead of print","author":"Camiolo G, Gonzalez Silvera D, Leah T, Schwaller J, Ottersbach K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545699"},{"title01":"Correspondence to “Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis”.","title02":"Correspondence to “Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis”.","journal":"Leukemia","issue":"2026 January; 40(1):245-246. doi: 10.1038\/s41375-025-02812-2","author":"Zheng H, Zhang L, Li L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225181"},{"title01":"Correction: Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”.","title02":"Correction: Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”.","journal":"Leukemia","issue":"2026 January; 40(1):260. doi: 10.1038\/s41375-025-02813-1","author":"Wang X, Yao H, Chen J, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41272183"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Erratum to: “Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model”.","title02":"Erratum to: “Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model”.","journal":"Haematologica","issue":"2026 January 1; 111(1):436. doi: 10.3324\/haematol.2025.288211","author":"Daniels DE, Hawksworth J, El Hoss S, Oyawoye FO, Ferrer-Vicens I, Wilson MC, Frayne J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496706"},{"title01":"The landmark contribution by Erik von Willebrand.","title02":"The landmark contribution by Erik von Willebrand.","journal":"Haematologica","issue":"2026 January 1; 111(1):1-9. doi: 10.3324\/haematol.2024.286012","author":"Lassila R, Berntorp E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496698"},{"title01":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","title02":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","journal":"Haematologica","issue":"2026 January 1; 111(1):314-328. doi: 10.3324\/haematol.2025.287720","author":"Bernaudin F, Arnaud C, Kamdem A, Youn J, Vasile M, Hau I, Madhi F, Malterre A, Delestrain C, Epaud R, Jung C, Verlhac S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568713"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","title02":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.289268. Online ahead of print","author":"Aldapt M, Wang YH, Shah KJ, El Kettani M, Foran J, Kharfan-Dabaja M, Murthy H, Al-Kali A, Shah MV, Alkhateeb H, Saliba AN, Hogan W, Yi CA, Sproat L, Punwani N, Khera N, Palmer J, Litzow M, Tefferi A, Gangat N, Patnaik MM, Badar T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504247"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.","title02":"Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70302. Online ahead of print","author":"Hoff FW, Trikha R, Groarke EM, Patel BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41531276"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","title02":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","journal":"Blood advances","issue":"2026 January 13; 10(1):262-272. doi: 10.1182\/bloodadvances.2025017601","author":"Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda R, Miyake H, Yamamoto N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056522"},{"title01":"More than CLK bait? Rogocekib for MDS and AML.","title02":"More than CLK bait? Rogocekib for MDS and AML.","journal":"Blood advances","issue":"2026 January 13; 10(1):260-261. doi: 10.1182\/bloodadvances.2025018552","author":"Chen EC, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528737"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018408. Online ahead of print","author":"Boertjes EL, Grob T, Al Hinai ASA, Beverloo BH, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck-Verschueren CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska P, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","title02":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","journal":"Blood","issue":"2026 January 8; 147(2):197-208. doi: 10.1182\/blood.2025028644","author":"Guarnera L, Wahida A, Gurnari C, Hutter S, Stainczyk SA, Williams ND, Durmaz A, Kubota Y, Bravo-Perez C, Kawashima N, Orland M, Pagliuca S, Huang Y, LaFramboise T, Visconte V, Walter W, Meggendorfer M, Kern W, Westermann F, Feuerbach L, Haferlach T, Maciejewski JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983034"},{"title01":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","title02":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","journal":"Blood","issue":"2026 January 15. doi: 10.1182\/blood.2025030760. Online ahead of print","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N Jr, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti SML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","title02":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 January; 40(1):224-229. doi: 10.1038\/s41375-025-02798-x","author":"Lisle TL, Holmstrom MO, Penco MP, Ruders JH, Riley CH, Grauslund JH, Jensen EB, Sorensen AL, Skov V, Kjaer L, Hasselbalch H, Andersen MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214139"},{"title01":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","title02":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018682. Online ahead of print","author":"Ouellet M, Rizzolo A, Venne C, Moussa H, Bilodeau K, Mollica L, Chabot-Roy G, Huynh-Trudeau G, Lesage S, Harnois M, Busque L, Sirhan S, Szuber N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499761"},{"title01":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","title02":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018724. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.","title02":"Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2024027897. Online ahead of print","author":"Thompson-Peach CA, Thomas D, Dottore M, Lim K, Stomski F, Panagopoulos R, Fosselteder J, Reinisch A, Chandrakanthan V, Jenkner S, Bland L, Paton S, Gronthos S, Hercus T, Wardill H, Kan WL, Kamel M, Moretti PA, Pitson SM, Burbury K, Ross DM, Nair P, Lopez AF, Tvorogov D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481383"},{"title01":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","title02":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025028645. Online ahead of print","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome.","title02":"Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome.","journal":"Blood","issue":"2026 January 15; 147(3):316. doi: 10.1182\/blood.2025031930","author":"Gummadi YK, Trottier AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538207"},{"title01":"Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience.","title02":"Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70306. Online ahead of print","author":"Mingot-Castellano ME, Alcalde-Mellado P, Entrena-Urena L, Pascual-Izquierdo C, Zafra-Torres D, Canaro Hirnyk M, Bastida JM, Bernat-Pablo S, Martinez-Carballeira D, Caparros-Miranda IS, Cuesta-Garcia A, Lakhwani S, Sanchez-Gonzalez B, Canet-Maldonado M, Gomez-Del-Castillo-Solano MD, Garcia-Culebras M, Chiclana-Rodriguez B, Fernandez-Villalobos M, Sanchez-Llorca P, Piquer-Monsonis D, Puerta-Vazquez C, Perez-Montes R, Garcia-Pallarols F, Poza-Santaella M, Pedrote-Amador B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41480972"},{"title01":"High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology.","title02":"High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70310. Online ahead of print","author":"Schmidt-Barbo P, Schultheiss C, Jauch AJ, Simnica D, Silling G, Hanel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41486630"},{"title01":"Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia (ITP): A systematic review and meta-analysis of randomised clinical trials.","title02":"Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia (ITP): A systematic review and meta-analysis of randomised clinical trials.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70316. Online ahead of print","author":"Mustafa MT, Abushanab AK, Mousa MT, Ismaeel R, Alshamasneh F, Khalaileh Y, Alkhalaileh RM, Zaina RFA, Sa'ed A, Mahfouz EA, Sitta ZAA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41486786"},{"title01":"Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of Haematology.","title02":"Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 6. doi: 10.1111\/bjh.70312. Online ahead of print","author":"Jauch AJ, Schmidt-Barbo P, Schultheiss C, Silling G, Hanel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Bignucolo O, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496604"},{"title01":"Safety and efficacy of daratumumab in immune thrombocytopenia.","title02":"Safety and efficacy of daratumumab in immune thrombocytopenia.","journal":"Blood advances","issue":"2026 January 13; 10(1):143-154. doi: 10.1182\/bloodadvances.2025017279","author":"Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjonnfjord E, Munthe LA, Drivet E, Kared H, Sorvoll IH, Ahlen MT, Mahevas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763272"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","title02":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","journal":"Lancet","issue":"2026 January 8. doi: 10.1016\/S0140-6736(25)02164-6. Online ahead of print","author":"Groarke EM, Turturice B, Patel BA, Quinn KA, Fike A, Grayson PC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41520673"},{"title01":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","title02":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288892. Online ahead of print","author":"Park-Egan B, Hough CL, Lyons PG, Newell LF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537342"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288371. Online ahead of print","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","title02":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2026 January 1; 111(1):286-299. doi: 10.3324\/haematol.2025.288041","author":"Mizuno S, Gras L, Baaij LGA, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Kawamura K, Kodera Y, Hamad N, Ko BS, Liam C, Ho KW, Goh AS, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry BQUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Verburgh E, Galeano S, Bass F, Mian H, McCurdy A, Wang FR, Neumann D, Koh MBC, Snowden JA, Schonland S, McLornan DP, Hayden PJ, Balari AMS, Greinix HT, Aljurf M, Atsuta Y, Rondelli D, Niederwieser DW, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820767"},{"title01":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","title02":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","journal":"Haematologica","issue":"2026 January 1; 111(1):230-244. doi: 10.3324\/haematol.2024.287114","author":"Gao M, Zhang K, Li S, Guo H, Sun Y, Kong J, Han T, Chang Y, Huang X, Zhao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820727"},{"title01":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop.","title02":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop.","journal":"Haematologica","issue":"2026 January 1; 111(1):245-258. doi: 10.3324\/haematol.2025.287765","author":"Chen R, Dong Q, Zhou L, He H, Du Y, Sun Q, Suda T, Cheng T, Wang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605703"},{"title01":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","title02":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","journal":"Blood advances","issue":"2026 January 13; 10(1):111-120. doi: 10.1182\/bloodadvances.2025017540","author":"Matsui H, Arai Y, Kanda J, Kondo T, Schoettler ML, Mohty M, Perales MA, Duarte RF, Rambaldi A, Takaori-Kondo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071950"},{"title01":"MicroRNA-223-3p is a determinant of platelet procoagulant activity.","title02":"MicroRNA-223-3p is a determinant of platelet procoagulant activity.","journal":"Blood advances","issue":"2026 January 13; 10(1):83-94. doi: 10.1182\/bloodadvances.2024015290","author":"Charlon-Gay J, Nolli S, Dunoyer-Geindre S, Ciepla P, Reny JL, Fontana P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056510"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","title02":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","journal":"Blood advances","issue":"2026 January 13; 10(1):168-180. doi: 10.1182\/bloodadvances.2025016624","author":"Ferreira AC, Dutta D, Rowan CM, Renbarger J, Cooke KR, Carpenter PA, Krance R, Duncan C, Cruz CRY, Jacobsohn D, Bollard CM, Hill E, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966416"},{"title01":"Induction of moderate DNA damage enhances megakaryopoiesis and platelet production.","title02":"Induction of moderate DNA damage enhances megakaryopoiesis and platelet production.","journal":"Blood advances","issue":"2026 January 13; 10(1):155-167. doi: 10.1182\/bloodadvances.2025017375","author":"Camacho V, Bekendam RH, Stone AP, Barrachina MN, Branfield S, Carminita E, Becker IC, Lee DH, Walsey E, Payne C, Kaplan J, Tilburg J, Pal S, Batista LFZ, Italiano JE Jr, Machlus KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938731"},{"title01":"BK virus kinetics and associated cystitis\/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant.","title02":"BK virus kinetics and associated cystitis\/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant.","journal":"Blood advances","issue":"2026 January 13; 10(1):1-13. doi: 10.1182\/bloodadvances.2025016589","author":"Dimitrova D, Xue E, Hyder MA, Choo-Wosoba H, Rechache K, Flomerfelt FA, Das S, McKeown C, Cusmano A, Sabina R, Kanakry JA, Kanakry CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864202"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025031080. Online ahead of print","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk FA, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","title02":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2025028762. Online ahead of print","author":"Verkamp B, Jordan MB, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481377"},{"title01":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","title02":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 January 12. doi: 10.1182\/blood.2024028031. Online ahead of print","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","title02":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2024028063. Online ahead of print","author":"Castiglioni C, Piussi R, Ditadi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481376"},{"title01":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","title02":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","journal":"Blood","issue":"2026 January 15; 147(3):241-253. doi: 10.1182\/blood.2025028625","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa R, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin L, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Savasan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging.","title02":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging.","journal":"Blood","issue":"2026 January 8; 147(2):164-179. doi: 10.1182\/blood.2024026505","author":"Matteini F, Thambyrajah R, Montserrat-Vazquez S, Jung S, Ferrer-Perez A, Herrero Molinero P, El Jaramany D, Lozano-Bartolome J, Mejia-Ramirez E, Gonzalez J, Del Sol A, Bigas A, Florian MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056036"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","journal":"Blood","issue":"2026 January 8; 147(2):138-163. doi: 10.1182\/blood.2025029640","author":"Herrmann US, Felber M, Worth A, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll A, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans C, Bordon V, Bredius RGM, Kuhl JS, Voller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl M, Lankester A, Ikinciogullari A, Guilcher GMT, Hackenberg A, Yesilipek A, Davies G, Rao K, Hershfield MS, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, Gungor T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","journal":"N Engl J Med","issue":"2026 January 15; 394(3):253-267. doi: 10.1056\/NEJMoa2509820","author":"Li R, Pan H, Zhang L, Ma J, Li W, Gao Z, Fang L, Tian L, Shen Y, Yang F, Zhao J, Nie N, Li J, Wang W, Pan X, Lian Y, Li X, Peng G, Li L, Yu X, Xu C, Liu Y, Kuang Z, Huang J, Zhao X, Ge M, Liu L, Chen S, Feng Y, Chang AH, Deng B, Dai M, Huang L, Lv L, Zheng Y, Luo Y, Xiong H, Shi J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41534043"},{"title01":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.","title02":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 January; 27(1):103-115. doi: 10.1016\/S1470-2045(25)00401-2","author":"Hsu CH, Lu Z, Gao S, Wang J, Sun JM, Liu T, Fan Q, Cai J, Ge F, Li S, Zhang L, Cha E, Allen S, Shen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449142"},{"title01":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","title02":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e41-e48. doi: 10.1016\/S2352-3026(25)00291-1","author":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41365312"},{"title01":"Management of transfusion-dependent beta-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.","title02":"Management of transfusion-dependent beta-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e49-e54. doi: 10.1016\/S2352-3026(25)00320-5","author":"Musallam KM, Sheth S, Cappellini MD, Shah F, Rivella S, Sankaran VG, Kuo KHM, Viprakasit V, Eleftheriou A, Angastiniotis M, Locatelli F, Taher AT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482447"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage.","title02":"Uterine atony and anaemia in postpartum haemorrhage.","journal":"Lancet","issue":"2026 January 3; 407(10523):29. doi: 10.1016\/S0140-6736(25)02050-1","author":"Roberts I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483908"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage.","title02":"Uterine atony and anaemia in postpartum haemorrhage.","journal":"Lancet","issue":"2026 January 3; 407(10523):28-29. doi: 10.1016\/S0140-6736(25)02051-3","author":"Mansukhani R, Chaudhri R, Bello FA, Muganyizi P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483905"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage – Authors’ reply.","title02":"Uterine atony and anaemia in postpartum haemorrhage – Authors’ reply.","journal":"Lancet","issue":"2026 January 3; 407(10523):29-30. doi: 10.1016\/S0140-6736(25)02262-7","author":"Yunas I, Devall A, Coomarasamy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483907"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Warm autoimmune haemolytic anaemia: Clinical considerations.","title02":"Warm autoimmune haemolytic anaemia: Clinical considerations.","journal":"Br J Haematol","issue":"2026 January 13. doi: 10.1111\/bjh.70331. Online ahead of print","author":"Murakhovskaya I, Yazdanbakhsh K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41531134"},{"title01":"Short- and long-term effects of transfusion in beta-thalassemia: a longitudinal study of transfusion efficiency factors.","title02":"Short- and long-term effects of transfusion in beta-thalassemia: a longitudinal study of transfusion efficiency factors.","journal":"Blood advances","issue":"2026 January 13; 10(1):192-207. doi: 10.1182\/bloodadvances.2025017090","author":"Theocharaki K, Barla I, Delicou S, Anastasiadi AT, Tzounakas VL, Rouvela S, Tzafa G, Stylianaki EA, Koufogeorgou EI, Gousdovas T, Pavlou E, Kostopoulos IV, Simantiris N, Vassilaki N, Moraki M, Stamoulis K, Voskaridou E, Nomikou E, Tsitsilonis O, Thomaidis N, Gikas E, Politou M, Komninaka V, Antonelou MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115240"},{"title01":"Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia.","title02":"Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):124-131. doi: 10.1182\/bloodadvances.2025017722","author":"Fattizzo B, Zaninoni A, Pedone GL, Bortolotti M, Passamonti F, Barcellini W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061187"},{"title01":"Cost-Effectiveness of First-Line IV Versus Oral Iron for Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding.","title02":"Cost-Effectiveness of First-Line IV Versus Oral Iron for Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding.","journal":"Blood advances","issue":"2026 January 8. doi: 10.1182\/bloodadvances.2025018315. Online ahead of print","author":"Wang D, Sra MS, Ito S, Ng DQ, Glaeser-Khan S, Wang DY, Hirniak S, Lee AI, Cuker A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504430"},{"title01":"Pomalidomide for Hereditary Hemorrhagic Telangiectasia: After Trial Longitudinal Assessment Study (PATH-HHT ATLAS).","title02":"Pomalidomide for Hereditary Hemorrhagic Telangiectasia: After Trial Longitudinal Assessment Study (PATH-HHT ATLAS).","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018382. Online ahead of print","author":"Zhang E, Kasthuri RS, Parambil J, Prasad V, Iyer V, Whitehead K, Hodges PG, Pishko A, Conrad M, Phelan D, Rodriguez-Lopez J, McCrae KR, Al-Samkari H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512167"},{"title01":"Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice.","title02":"Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018680. Online ahead of print","author":"Lucero MJ, Setua S, Thangaraju K, Khan A, Lamb DR, Lisk C, Swindle D, Cendali FI, Dzieciatkowska M, Stephenson D, Pak DI, Tolson R, Zaeske S, Rana NK, Khan S, Westover N, Davizon-Castillio P, George G, Hassell KL, Nuss R, D'Alessandro A, Manolova V, Irwin DC, Buehler PW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538305"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","journal":"Leukemia","issue":"2026 January; 40(1):63-71. doi: 10.1038\/s41375-025-02781-6","author":"Bill M, Eckardt JN, Dohner K, Rohnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Einsele H, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Valka J, Sramek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Recher C, Pigneux A, Herold T, Ganser A, Dohner H, Bornhauser M, Thiede C, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2026 January; 40(1):178-187. doi: 10.1038\/s41375-025-02814-0","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","title02":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02831-z. Online ahead of print","author":"Santini V, Zeidan AM, Van Eygen K, Fenaux P, Germing U, Madanat YF, Raza A, Savona MR, Sekeres MA, Thepot S, Raddi MG, Boyer T, Sun L, Wan Y, Berry T, Xia Q, Huang F, Dougherty S, Navada S, Feller F, Komrokji RS, Platzbecker U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526614"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","journal":"Haematologica","issue":"2026 January 1; 111(1):329-334. doi: 10.3324\/haematol.2024.286719","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K, Of Japanese Children's Cancer Group TTACTC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","title02":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","journal":"Blood advances","issue":"2026 January 13; 10(1):168-180. doi: 10.1182\/bloodadvances.2025016624","author":"Ferreira AC, Dutta D, Rowan CM, Renbarger J, Cooke KR, Carpenter PA, Krance R, Duncan C, Cruz CRY, Jacobsohn D, Bollard CM, Hill E, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966416"},{"title01":"Hematopoietic transplantation for PNP deficiency: it’s time.","title02":"Hematopoietic transplantation for PNP deficiency: it’s time.","journal":"Blood","issue":"2026 January 8; 147(2):97-98. doi: 10.1182\/blood.2025031143","author":"Grunebaum E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505148"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025031080. Online ahead of print","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk FA, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","title02":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025028645. Online ahead of print","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","title02":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031455. Online ahead of print","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2026 January 15; 147(3):312-315. doi: 10.1182\/blood.2025031426","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","title02":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","journal":"Blood","issue":"2026 January 15; 147(3):241-253. doi: 10.1182\/blood.2025028625","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa R, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin L, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Savasan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","title02":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","journal":"Blood","issue":"2026 January 1; 147(1):35-47. doi: 10.1182\/blood.2025029121","author":"Penter L, Maurer K, Cieri N, Lu WS, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026928"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","journal":"Blood","issue":"2026 January 8; 147(2):138-163. doi: 10.1182\/blood.2025029640","author":"Herrmann US, Felber M, Worth A, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll A, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans C, Bordon V, Bredius RGM, Kuhl JS, Voller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl M, Lankester A, Ikinciogullari A, Guilcher GMT, Hackenberg A, Yesilipek A, Davies G, Rao K, Hershfield MS, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, Gungor T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","title02":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","journal":"Blood","issue":"2026 January 8; 147(2):180-196. doi: 10.1182\/blood.2025029302","author":"Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898981"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","title02":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02857-3. Online ahead of print","author":"Mehta RS, Aljawai YM, Kebriaei P, Rondon G, Fingrut W, Smallbone P, Oran B, Olson A, Champlin RE, Shpall EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526616"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","title02":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02850-w. Online ahead of print","author":"Zhou J, Hu T, Li D, Li S, Li M, Shi X, Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526615"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","journal":"Haematologica","issue":"2026 January 1; 111(1):177-183. doi: 10.3324\/haematol.2025.287457","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70327. Online ahead of print","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 January 8. doi: 10.1111\/bjh.70318. Online ahead of print","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","title02":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018032. Online ahead of print","author":"Shimony S, Wang Y, Cronin AM, Walsh TP, Charles A, Slopen N, Cho HL, Stahl MF, Bystrom RP, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538295"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017621. Online ahead of print","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner BJ, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","title02":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018031. Online ahead of print","author":"Badar T, Marando L, Latorre-Crespo E, Lasho TL, Oliva FD, Lin C, McCormick BJ, El Kettani M, Shah K, Kusne YN, Jamy O, Diebold K, Coltoff A, Finke CM, Foran JM, Kharfan-Dabaja MA, Fan YS, Jiang L, He R, Thomas M, Patel AA, Viswanatha DS, Shah MV, Saliba AN, Mangaonkar AA, Kirschner K, Al-Kali A, Gangat N, Litzow MR, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499760"},{"title01":"FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q.","title02":"FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q.","journal":"Haematologica","issue":"2026 January 1; 111(1):385-391. doi: 10.3324\/haematol.2025.287904","author":"Kikuchi J, Osada N, Matsuoka S, Ohta T, Kazama H, Shirai H, Meloni M, Chiron M, Yasui H, Nakasone H, Furukawa Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820736"},{"title01":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","title02":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70323. Online ahead of print","author":"Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482478"},{"title01":"Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.","title02":"Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.","journal":"Blood advances","issue":"2026 January 13; 10(1):95-105. doi: 10.1182\/bloodadvances.2025017721","author":"Sudha P, Pham P, Niu W, Liu E, Wang L, Truong G, Ligocki C, Al-Azzawi R, Surapenini M, Bray SM, Vetrini F, Czader M, Tayeh MK, Lee K, Abonour R, Suvannasankha A, Walker BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092482"},{"title01":"A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.","title02":"A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2024015266. Online ahead of print","author":"Salehi M, Wilkens LR, Wan JY, Cortessis VK, Stram D, Conti DV, Aparicio J, Lam E, Bernstein MP, Desai P, Bertrand KA, Rosenberg AS, Lee L, Le Marchand L, Haiman CA, Emerson J, Cozen W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529215"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2026 January 15; 147(3):312-315. doi: 10.1182\/blood.2025031426","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.","title02":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.","journal":"Blood","issue":"2026 January 15; 147(3):266-275. doi: 10.1182\/blood.2025029999","author":"Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini-Piocelle F, Mohty M, Schiano de Collela JM, Macro M, Adiko D, Dib M, Fontan J, Luttiau-Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala J, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991836"},{"title01":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.","title02":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.","journal":"Blood","issue":"2026 January 1; 147(1):48-60. doi: 10.1182\/blood.2025029950","author":"Yan Z, Han Z, Wang Y, Beus M, Zhang Y, Picado A, Wells CI, Wu J, Weidenhammer LB, Pires KM, Leibold EA, Liu L, Gooden DM, Spasojevic I, Soderblom EJ, Kang Y, Boise LH, Willson TM, Nikiforov MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40953235"},{"title01":"Targeting STK17B: unlocking ferroptosis in myeloma.","title02":"Targeting STK17B: unlocking ferroptosis in myeloma.","journal":"Blood","issue":"2026 January 1; 147(1):6-7. doi: 10.1182\/blood.2025031316","author":"Liu B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477748"},{"title01":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","title02":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2025029996. Online ahead of print","author":"Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante MA, Diamond BT, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren CO, Usmani SZ, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar SK, Maura F, Baughn LB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481388"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","title02":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288892. Online ahead of print","author":"Park-Egan B, Hough CL, Lyons PG, Newell LF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537342"},{"title01":"Hepatic response criteria in light chain amyloidosis: a multicenter validation study.","title02":"Hepatic response criteria in light chain amyloidosis: a multicenter validation study.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.289218. Online ahead of print","author":"Muchtar E, Palladini G, Schonland S, Geyer S, Dooley KE, Dispenzieri A, Wisniowski B, Merlini G, Milani P, Hegenbart U, Dittrich T, Kastritis E, Dimopoulos MA, Sanchorawala V, Szalat R, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Cibeira MT, Blade J, Kumar SK, Wechalekar A, Gertz MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537335"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288371. Online ahead of print","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","journal":"Haematologica","issue":"2026 January 1; 111(1):177-183. doi: 10.3324\/haematol.2025.287457","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","title02":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","journal":"Haematologica","issue":"2026 January 1; 111(1):230-244. doi: 10.3324\/haematol.2024.287114","author":"Gao M, Zhang K, Li S, Guo H, Sun Y, Kong J, Han T, Chang Y, Huang X, Zhao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820727"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","title02":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):135-148. doi: 10.3324\/haematol.2024.286228","author":"Zhao HG, Cruz-Rodriguez N, Johnson KC, Pomicter AD, Bates B, Bateman B, Haferlach T, Gu T, Ahmann J, Yan D, Lee GS, Zhu W, Bishop J, Odelberg SJ, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637748"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","title02":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70323. Online ahead of print","author":"Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482478"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70327. Online ahead of print","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 January 8. doi: 10.1111\/bjh.70318. Online ahead of print","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018057. Online ahead of print","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas RO, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017621. Online ahead of print","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner BJ, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","title02":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","journal":"Blood advances","issue":"2026 January 13; 10(1):111-120. doi: 10.1182\/bloodadvances.2025017540","author":"Matsui H, Arai Y, Kanda J, Kondo T, Schoettler ML, Mohty M, Perales MA, Duarte RF, Rambaldi A, Takaori-Kondo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071950"},{"title01":"Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.","title02":"Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.","journal":"Blood advances","issue":"2026 January 13; 10(1):75-82. doi: 10.1182\/bloodadvances.2025017234","author":"Aymard M, Cheminant M, Houot R, Cuozzo A, Gat E, Thieblemont C, Ricard L, Roulin L, Bouabdallah K, Safar V, Guidez S, Fayard A, Brisou G, Ysebaert L, Hermine O, Tessoulin B, Herbaux C, Le Gouill S, Sarkozy C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026973"},{"title01":"PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.","title02":"PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.","journal":"Blood","issue":"2026 January 15; 147(3):254-265. doi: 10.1182\/blood.2025028848","author":"Thompson C, Trneny M, Morschhauser F, Salles G, Reagan PM, Hertzberg M, Zhang H, Thieblemont C, Hu B, Fonseca G, Kim WS, Martelli M, Mehta A, Singh A, Yan M, Hirata J, Sugidono M, Lee C, Sharman JP, Mehta-Shah N, Flowers CR, Tilly H, Chua N, Casasnovas RO, Miall F, Kim TM, Tsai XC, Nasta S, Lee ST, Friedberg JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40997297"},{"title01":"The treatment of marginal zone lymphoma.","title02":"The treatment of marginal zone lymphoma.","journal":"Blood","issue":"2026 January 8; 147(2):115-126. doi: 10.1182\/blood.2024028269","author":"Alderuccio JP, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663786"},{"title01":"Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.","title02":"Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.","journal":"Blood","issue":"2026 January 13. doi: 10.1182\/blood.2025029535. Online ahead of print","author":"Flerlage JE, Feraco AM MD, MMSc, Zhou Y, Zheng Y MS, Liang J, Lucas JT Jr, Friedmann AM, Weinstein HJ, Yock TI, Shulkin BL, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis AE, Larsen EC, Marcus KJ, Billett A, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529162"},{"title01":"The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.","title02":"The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.","journal":"Blood","issue":"2026 January 8; 147(2):105-114. doi: 10.1182\/blood.2024028268","author":"Laurent C, Bertoni F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026919"},{"title01":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","title02":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031455. Online ahead of print","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","title02":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","journal":"Blood","issue":"2026 January 15; 147(3):276-289. doi: 10.1182\/blood.2025030558","author":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144772"},{"title01":"Drug development in MZL: caring for the forgotten child.","title02":"Drug development in MZL: caring for the forgotten child.","journal":"Blood","issue":"2026 January 8; 147(2):127-137. doi: 10.1182\/blood.2024028270","author":"Thieblemont C, Carras S, Bommier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961241"},{"title01":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.","title02":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.","journal":"Blood","issue":"2026 January 8; 147(2):209-214. doi: 10.1182\/blood.2025031086","author":"Ronceray L, Huibers MHW, Reutter K, Abla O, Andres M, Balague O, Csoka M, Gilad G, Hagleitner MM, Hori D, Hjalgrim LL, Jazbec J, Klapper W, Nakazawa A, Verdu-Amoros J, von Mersi H, Wossmann W, Xavier AC, Burkhardt B, Salaverria I, Attarbaschi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160801"},{"title01":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","title02":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","journal":"N Engl J Med","issue":"2026 January 1; 394(1):51-61. doi: 10.1056\/NEJMoa2514752","author":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358582"},{"title01":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","title02":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 January 7. doi: 10.1016\/S1470-2045(25)00653-9. Online ahead of print","author":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martinez-Lopez J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519141"},{"title01":"Measurable residual disease assessment in multiple myeloma.","title02":"Measurable residual disease assessment in multiple myeloma.","journal":"Leukemia","issue":"2026 January; 40(1):25-28. doi: 10.1038\/s41375-025-02830-0","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41350429"},{"title01":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","title02":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","journal":"Leukemia","issue":"2026 January; 40(1):235-240. doi: 10.1038\/s41375-025-02802-4","author":"Pertesi M, Demangel D, Niroula A, Perrial E, Mahecha Escobar ML, Vallee M, Liacos C, Samur MK, Sperling AS, Munshi NC, Kastritis E, Dimopoulos MA, McKay JD, Mellqvist UH, Hansson M, Dumontet C, Nilsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254116"},{"title01":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","title02":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02841-x. Online ahead of print","author":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, Shelat SG, Burgess MR, Godwin C, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501501"},{"title01":"Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.","title02":"Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e30-e40. doi: 10.1016\/S2352-3026(25)00298-4","author":"Korst CLBM, Plattel W, de Kort EA, Smits F, Croockewit AJ, Levin MD, Westerman M, de Weerdt O, Nijhof IS, Wegman J, Smit N, Verkleij CPM, Mutis T, Nasserinejad K, Kerstiens R, van der Klift M, Franssen LE, de Ruijter MEM, Groen K, van der Spek E, Roeloffzen WWH, Zweegman S, van de Donk NWCJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482445"},{"title01":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","title02":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","journal":"J Clin Oncol","issue":"2026 January 6; JCO2502587. doi: 10.1200\/JCO-25-02587. Online ahead of print","author":"Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41494138"},{"title01":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","title02":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.289162. Online ahead of print","author":"Han S, Munawar U, Truger M, Gerhard-Hartmann E, Verbruggen C, Pfeiffer L, Hainold AS, Kurian S, Nerreter S, Besant E, Vogt C, Rein N, Koppel M, Lehmann J, Schmitt F, Tamamushi Y, Zhou X, Steinbrunn T, Haferlach C, Rosenwald A, Einsele H, Rasche L, Waldschmidt JM, Kortum MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504227"},{"title01":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.","title02":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.","journal":"Haematologica","issue":"2026 January 1; 111(1):184-195. doi: 10.3324\/haematol.2025.287783","author":"Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637727"},{"title01":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis.","title02":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis.","journal":"Haematologica","issue":"2026 January 1; 111(1):271-285. doi: 10.3324\/haematol.2025.287312","author":"Dong M, He D, Zhang J, Yan H, Chen H, Zhang E, Feng Y, He J, Huang X, Chen G, Sun X, Cheng F, Gu H, Wang H, Xie A, Cai Z, Lab C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568729"},{"title01":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.","title02":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.","journal":"Haematologica","issue":"2026 January 1; 111(1):431-435. doi: 10.3324\/haematol.2025.288521","author":"Siegel A, Reci S, Grossman L, Gleason C, Crary J, Song L, Park J, Verina D, Desai S, Kappes K, Stillman I, LaBaer J, Aleman A, Jagannath S, Parekh S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063705"},{"title01":"After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections.","title02":"After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections.","journal":"Haematologica","issue":"2026 January 1; 111(1):86-88. doi: 10.3324\/haematol.2025.288539","author":"Beyar-Katz O, Stern A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836786"},{"title01":"Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.","title02":"Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.","journal":"Haematologica","issue":"2026 January 1; 111(1):379-384. doi: 10.3324\/haematol.2025.287889","author":"Lee JY, Jung S, Choi S, Park SS, Kim JS, Lee JJ, Park SK, Kim HJ, Lee GW, Park YH, Eom HS, Kim JA, Kim MK, Kim Y, Shin HJ, Lee HS, Kwon J, Min CK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820811"},{"title01":"Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.","title02":"Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):361-367. doi: 10.3324\/haematol.2025.287510","author":"Bringhen S, Cani L, Giuliani N, Mangiacavalli S, Benevolo G, Antonioli E, Zambello R, Ria R, Vincelli ID, Ronconi S, More S, Falcone AP, Allegra A, D'Agostino M, Evangelista A, Capra A, Sciorsci E, Curci P, Tosi P, Liberati AM, Cafro AM, Belotti A, Patriarca F, Mannina D, Mancuso K, Cattel F, Ciccone G, Bruno B, Boccadoro M, Larocca A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820797"},{"title01":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","title02":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2026 January 1; 111(1):286-299. doi: 10.3324\/haematol.2025.288041","author":"Mizuno S, Gras L, Baaij LGA, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Kawamura K, Kodera Y, Hamad N, Ko BS, Liam C, Ho KW, Goh AS, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry BQUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Verburgh E, Galeano S, Bass F, Mian H, McCurdy A, Wang FR, Neumann D, Koh MBC, Snowden JA, Schonland S, McLornan DP, Hayden PJ, Balari AMS, Greinix HT, Aljurf M, Atsuta Y, Rondelli D, Niederwieser DW, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820767"},{"title01":"Time to say adieu to FISH in myeloma diagnostics.","title02":"Time to say adieu to FISH in myeloma diagnostics.","journal":"Blood","issue":"2026 January 15; 147(3):221-222. doi: 10.1182\/blood.2025031255","author":"Garces JJ, Maura F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538211"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","title02":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):130-137. doi: 10.1038\/s41375-025-02764-7","author":"Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145674"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","title02":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","journal":"Haematologica","issue":"2026 January 1; 111(1):314-328. doi: 10.3324\/haematol.2025.287720","author":"Bernaudin F, Arnaud C, Kamdem A, Youn J, Vasile M, Hau I, Madhi F, Malterre A, Delestrain C, Epaud R, Jung C, Verlhac S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568713"},{"title01":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","title02":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","journal":"J Clin Oncol","issue":"2026 January 5; JCO2502779. doi: 10.1200\/JCO-25-02779. Online ahead of print","author":"Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490480"},{"title01":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","title02":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","journal":"J Clin Oncol","issue":"2026 January 9; JCO2500203. doi: 10.1200\/JCO-25-00203. Online ahead of print","author":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512237"},{"title01":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","title02":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):86-91. doi: 10.1200\/JCO-25-00507","author":"Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41252666"},{"title01":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 January; 44(1):71. doi: 10.1200\/JCO-25-02667","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264903"},{"title01":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","title02":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):117-128. doi: 10.1200\/JCO-25-00892","author":"Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquieres H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janikova A, Mocikova H, Furst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329901"},{"title01":"Improving the predictive value of end-of-treatment PET\/CT in diffuse large B-cell lymphoma.","title02":"Improving the predictive value of end-of-treatment PET\/CT in diffuse large B-cell lymphoma.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288821. Online ahead of print","author":"Bes AL, Zwezerijnen GJC, Heymans MW, Duhrsen U, Eertink JJ, Wiegers SE, Lugtenburg PJ, Huttmann A, Kurch L, Hanoun C, Mikhaeel GN, Ceriani L, Zucca E, Czibor S, Gyorke T, Chamuleau MED, Fanti S, Lee ST, Hoekstra OS, Zijlstra JM, Barrington SF, Boellaard R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504226"},{"title01":"Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.","title02":"Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288700. Online ahead of print","author":"Simonsen MR, Eyre TA, Hawkes EA, El-Galaly TC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537332"},{"title01":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.","title02":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):259-270. doi: 10.3324\/haematol.2024.286945","author":"Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605718"},{"title01":"Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin lymphoma.","title02":"Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 January 1; 111(1):368-372. doi: 10.3324\/haematol.2025.287524","author":"Iaccarino I, Beder T, Reinke S, Borchmann P, Von Tresckow B, Altenbuchinger M, Klapper W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671505"},{"title01":"Two decades of single-institution data reveal rare longterm survivors of relapsed\/refractory Burkitt lymphoma.","title02":"Two decades of single-institution data reveal rare longterm survivors of relapsed\/refractory Burkitt lymphoma.","journal":"Haematologica","issue":"2026 January 1; 111(1):345-349. doi: 10.3324\/haematol.2024.287165","author":"Molla R, Bantilan K, Berman E, Caron P, Falchi L, Hamlin P, Horwitz S, Intlekofer A, Kumar A, Lue J, Moskowitz A, Owens C, Palomba ML, Dahi PB, Salles G, Vardhana S, Shah G, Zelenetz A, Johnson W, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820818"},{"title01":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","title02":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","journal":"Br J Haematol","issue":"2026 January 5. doi: 10.1111\/bjh.70301. Online ahead of print","author":"Ueno T, Yoshimitsu M, Sameshima M, Nagano T, Akahoshi R, Takeshita Y, Shodai A, Shima K, Arima N, Kamada Y, Nakamura D, Ishitsuka K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41491883"},{"title01":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","title02":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70329. Online ahead of print","author":"Gowdy SC, Flerlage JE, Seelisch J, Palese M, Bradshaw T, Castellino SM, Cho S, Dieckmann K, Hoppe BS, Howard S, Kelly KM, Kurch L, Lai HA, Lopci E, Lucas JT Jr, Mauz-Korholz C, McCarten KM, Pandit-Taskar N, Schoder H, Steglich J, Stoevesandt D, Voss SD, Milgrom SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535222"},{"title01":"Clinical trial access after CAR T-cell therapy failure in relapsed\/refractory large B-cell lymphoma.","title02":"Clinical trial access after CAR T-cell therapy failure in relapsed\/refractory large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70325. Online ahead of print","author":"Kim K, Shah R, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil LJ, Westin JR, Flowers CR, Neelapu SS, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521615"},{"title01":"Lymph node biopsy indications: Challenges in determining the ‘when’.","title02":"Lymph node biopsy indications: Challenges in determining the ‘when’.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70322. Online ahead of print","author":"Matos DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521584"},{"title01":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenstrom Macroglobulinemia.","title02":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenstrom Macroglobulinemia.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025017751. Online ahead of print","author":"Zanwar S, Abeykoon JP, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar SK, Dimopoulos MA, Ansell SM, Treon SP, Castillo JJ, Kapoor P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499755"},{"title01":"Infections Following Bispecific Antibodies in B-cell Lymphomas.","title02":"Infections Following Bispecific Antibodies in B-cell Lymphomas.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017366. Online ahead of print","author":"Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538299"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.","title02":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 13; 10(1):217-227. doi: 10.1182\/bloodadvances.2024015599","author":"Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumari PR, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811818"},{"title01":"Zamtocabtagene Autoleucel in Relapsed\/refractory B-NHL: 5-year Follow Up of a CD20\/19 tandem CAR T Cell Phase 1 Trial.","title02":"Zamtocabtagene Autoleucel in Relapsed\/refractory B-NHL: 5-year Follow Up of a CD20\/19 tandem CAR T Cell Phase 1 Trial.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018073. Online ahead of print","author":"Balke-Want H, Godel P, Schmid C, Ayuk FA, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wohle C, Biedermann S, Burger I, Orentas RJ, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek MJ, Borchmann P, Kutsch N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512222"},{"title01":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018057. Online ahead of print","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas RO, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.","title02":"Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.","journal":"Blood advances","issue":"2026 January 13; 10(1):29-38. doi: 10.1182\/bloodadvances.2025017107","author":"Yin Y, Rai S, Jiang A, Xu A, O'Brien L, Telenius A, Delabie J, Chong L, Hung S, Merchant A, Scott DW, Savage KJ, Aoki T, Steidl C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924921"},{"title01":"Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed\/Refractory Follicular Lymphoma.","title02":"Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed\/Refractory Follicular Lymphoma.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018546. Online ahead of print","author":"Iacoboni G, Kyvsgaard E, Navarro V, Russler-Germain DA, Lewis KL, Martin Garcia-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela Vilchez D, Ku M, Gomez-Prieto P, Valencia-Espinoza E, Vega G, Jimenez-Ubieto A, Bastos Oreiro MB, Serna A, Husby S, de la Cruz Benito B, Luan J, Camarillas S, Medina L, Cabero Martinez A, Cordoba R, Canales MA, Sancho JM, Bosch F, Sureda A, Schuster SJ, Cheah CY, Hutchings M, Barba P, Abrisqueta P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499758"},{"title01":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","title02":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025016953. Online ahead of print","author":"Agrusa JE, Abdel Fattah E, Lin H, Velazquez J, Salinas SA, Abhyankar HA, Scull BP, Fleischmann R, Elghetany MT, Marcogliese AN, Curry CV, Punia JN, Ozuah NW, Eckstein OS, El-Mallawany NK, Gulati N, Lubega J, Horton TM, Kamdar KY, McClain KL, Man TK, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538304"},{"title01":"Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.","title02":"Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 January 13; 10(1):183-191. doi: 10.1182\/bloodadvances.2025016797","author":"Toner K, Renfro LA, Dave H, Pezzella G, Pei Q, Giulino-Roth L, Horton T, Keller FG, Kelly KM, Castellino SM, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40990939"},{"title01":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.","title02":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.","journal":"Blood advances","issue":"2026 January 13; 10(1):228-232. doi: 10.1182\/bloodadvances.2025016968","author":"Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124653"},{"title01":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","title02":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):276-288. doi: 10.1182\/bloodadvances.2025017526","author":"Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052404"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031409. Online ahead of print","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee AE, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang AG, Barsouk A, Cho JH, Shaw CE, Singh EB, Ugwuanyi O, Paruzzo L, Stella F MD, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey AD Jr, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.","title02":"Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.","journal":"Blood","issue":"2026 January 8; 147(2):95. doi: 10.1182\/blood.2025031752","author":"Armand P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505146"},{"title01":"Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.","title02":"Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030489. Online ahead of print","author":"Wiegand L, Silva P, Noerenberg D, Christen F, Kopp K, Locher BN, Lowe P, Tilgner M, Altwasser R, Storzer V, Stein CM, Briest F, Arends CM, Frick M, Ihlow J, Dolnik A, Ishaque N, Keller U, Na IK, Penter L, Bullinger L, Hablesreiter R, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490454"},{"title01":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","title02":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","journal":"Blood","issue":"2026 January 15. doi: 10.1182\/blood.2025030760. Online ahead of print","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N Jr, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti SML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia.","title02":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood","issue":"2026 January 1; 147(1):24-34. doi: 10.1182\/blood.2024027009","author":"Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41055698"},{"title01":"Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.","title02":"Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.","journal":"Blood","issue":"2026 January 8; 147(2):215. doi: 10.1182\/blood.2025031138","author":"Sharpe-Davidson WF, Wan YO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505145"},{"title01":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.","title02":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.","journal":"Blood","issue":"2026 January 1; 147(1):61-72. doi: 10.1182\/blood.2025029686","author":"Mendoza-Castrejon J, Yang W, Denby E, Wang HC, Casey EB, Muthukumar R, Patel RM, Yoon J, Li Y, White JM, Chen R, Batista LFZ, Magee JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032751"},{"title01":"Measurable residual disease intervention in AML: a new therapeutic horizon.","title02":"Measurable residual disease intervention in AML: a new therapeutic horizon.","journal":"Blood","issue":"2026 January 1; 147(1):13-23. doi: 10.1182\/blood.2025029010","author":"Wei AH, Iland HJ, DiNardo CD, Reynolds J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105915"},{"title01":"CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.","title02":"CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.","journal":"Blood","issue":"2026 January 15; 147(3):229-240. doi: 10.1182\/blood.2025030775","author":"Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, Goncalves-Dias J, Issa H, Miladinovic M, Rettinger E, Wehner S, Kreyenberg H, Bremm M, Hunecke S, Kerp H, Waack-Buchholz K, Thol F, Goemans BF, De Moerloose B, Boztug H, Scheidegger N, Pawinska-Wasikowska K, Reinhardt D, Klusmann JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118594"},{"title01":"Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","title02":"Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030722. Online ahead of print","author":"Dohner H, Spath D, Saadati M, Fiedler W, Gotze KS, Koller E, Westermann J, Vogel W, Heuser M, Lubbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wolfler A, Nachbaur D, Hertenstein B, Schroers R, Martens UM, von Harsdorf S, Radsak MP, Aschauer G, Weisshaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol FR, Paschka P, Bullinger L, Benner A, Dohner K, Ganser A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490515"},{"title01":"Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.","title02":"Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.","journal":"N Engl J Med","issue":"2026 January 1; 394(1):93-96. doi: 10.1056\/NEJMc2513023","author":"Merli M, Genuardi E, Zibellini S, Rattotti S, Spina M, Roti G, Motta M, Piazza F, Boccomini C, Ferreri AJM, Perbellini O, Brociner M, Dodero A, Vallisa D, Pulsoni A, Santoro A, Del Giudice I, Zuccaro V, Chimienti E, Russo S, Varraso C, Rizzo E, Bosi A, Cappello E, Favrin G, Marcheselli L, Visco C, Luminari S, Passamonti F, Ferrero S, Arcaini L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41467657"},{"title01":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):106-119. doi: 10.1038\/s41375-025-02777-2","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057685"},{"title01":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","title02":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","journal":"Leukemia","issue":"2026 January; 40(1):199-210. doi: 10.1038\/s41375-025-02815-z","author":"Liu X, Shi Y, Zhang J, Shetty K, Chew K, Kucuk C, Gong Q, Esmeray E, Li H, Chen R, Pan S, Dabrowska K, Moore RE, Garcia-Mansfield K, Pirrotte P, Wang J, Li Y, Dong G, Lee L, McKeithan TW, Iqbal J, Chan WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366532"},{"title01":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):252-259. doi: 10.1038\/s41375-025-02808-y","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41266881"},{"title01":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","title02":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):152-165. doi: 10.1038\/s41375-025-02809-x","author":"Wei W, Song Z, Wang Y, Li S, Tan L, Lee J, Cai KQ, Nejati R, Kadin ME, Campbell KS, Nakagawa M, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225182"},{"title01":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","title02":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","journal":"Leukemia","issue":"2026 January; 40(1):219-223. doi: 10.1038\/s41375-025-02795-0","author":"Moia R, Ragaini S, Cascione L, Rinaldi A, Genuardi E, Talotta D, Almasri M, Bruscaggin A, Zaccaria GM, Evangelista A, Civita AM, Di Rocco A, Petrucci L, Cavallo F, Celli M, Luppi M, Stelitano C, Stefani PM, Visco C, Billio A, Casaroli I, Castellino C, Pavone E, Galimberti S, Plenteda C, Merli F, Mahmoud AM, Rossi D, Gaidano G, Ladetto M, Bertoni F, Ferrero S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204002"},{"title01":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","title02":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","journal":"Leukemia","issue":"2026 January; 40(1):95-105. doi: 10.1038\/s41375-025-02787-0","author":"Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Gine E, Visco C, Bruggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184633"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.","title02":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.","journal":"Leukemia","issue":"2026 January; 40(1):87-94. doi: 10.1038\/s41375-025-02759-4","author":"Khouja M, Kehden B, Blair D, Kuffer C, Wagner S, Versteegen T, Nakov P, Bruggemann M, Baldus C, Belada D, Nowakowski GS, Schilhabel A, Darzentas N, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145670"},{"title01":"Lymphoma in the BiTE era.","title02":"Lymphoma in the BiTE era.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e1. doi: 10.1016\/S2352-3026(25)00344-8","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482441"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e8-e21. doi: 10.1016\/S2352-3026(25)00327-8","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","title02":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","journal":"Lancet","issue":"2026 January 10; 407(10524):133-146. doi: 10.1016\/S0140-6736(25)01778-7","author":"Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360064"},{"title01":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","title02":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):110-112. doi: 10.1016\/S0140-6736(25)02436-5","author":"Magnano L, Rivero A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371239"},{"title01":"A new standard for relapsed or refractory follicular lymphoma.","title02":"A new standard for relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):108-109. doi: 10.1016\/S0140-6736(25)01965-8","author":"Harel R, Cohen JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360063"},{"title01":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","title02":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","journal":"Lancet","issue":"2026 January 10; 407(10524):161-173. doi: 10.1016\/S0140-6736(25)02360-8","author":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371238"},{"title01":"Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.","title02":"Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):126-127. doi: 10.1016\/S0140-6736(25)02386-4","author":"Ceppi F, Veening M, Mascarin M, Balwierz W, Mauz-Koerholz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519588"},{"title01":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","title02":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):76-80. doi: 10.1200\/JCO-25-02323","author":"Pophali PA, Kenkre VP, Hayes CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370745"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","title02":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018724. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"MRD assessment by flow cytometry in B-ALL made easier.","title02":"MRD assessment by flow cytometry in B-ALL made easier.","journal":"Blood advances","issue":"2026 January 13; 10(1):121-123. doi: 10.1182\/bloodadvances.2025018222","author":"DiGiuseppe J, Cherian S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41474522"},{"title01":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","title02":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","journal":"Blood advances","issue":"2026 January 13; 10(1):262-272. doi: 10.1182\/bloodadvances.2025017601","author":"Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda R, Miyake H, Yamamoto N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056522"},{"title01":"Liberalizing hospital proximity requirements for children\/young adults with low-burden B-ALL receiving tisagenlecleucel.","title02":"Liberalizing hospital proximity requirements for children\/young adults with low-burden B-ALL receiving tisagenlecleucel.","journal":"Blood advances","issue":"2026 January 13; 10(1):106-110. doi: 10.1182\/bloodadvances.2025017012","author":"Appell LE, Baggott C, Nguyen K, Prabhu S, Pacenta H, John S, Fabrizio VA, Phillips CL, Rossoff J, Talano JA, Moskop A, Phelan R, Baumeister SHC, Verneris MR, Hall EM, Myers GD, Karras NA, Cooper SL, Qayed M, Raikar SS, Winestone L, Hermiston M, Satwani P, Krupski C, Keating AK, Friedman DN, Curran KJ, Hoover A, MacMillan ML, Ebens CL, Ramgopal A, Rahrig AL, Mackall CL, Laetsch TW, McNerney K, Schultz LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026960"},{"title01":"Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.","title02":"Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.","journal":"Blood advances","issue":"2026 January 13; 10(1):70-74. doi: 10.1182\/bloodadvances.2025017013","author":"Faulk KE, Kairalla JA, Hibbitts E, Long-Boyle J, Devidas M, August A, Gore L, Raetz E, Hunger SP, Loh ML, Teachey DT, Brown P, Breese EH, Kotecha RS, Guest E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991382"},{"title01":"Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia.","title02":"Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):25-28. doi: 10.1182\/bloodadvances.2025016565","author":"Short NJ, Kantarjian H, Jain N, Kadia TM, Senapati J, Haddad FG, Maroun MM, Sasaki K, Xiao L, Huang X, Karrar O, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Jabbour E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763277"},{"title01":"Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.","title02":"Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.","journal":"Blood advances","issue":"2026 January 13; 10(1):58-69. doi: 10.1182\/bloodadvances.2025016126","author":"Seheult JN, Otteson GE, Timm MM, Weybright MJ, Shi M, Olteanu H, Jevremovic D, Chen C, Chiu A, Horna P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966417"},{"title01":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","title02":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):276-288. doi: 10.1182\/bloodadvances.2025017526","author":"Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052404"},{"title01":"Shifting clones: CLL evolution under pirtobrutinib treatment.","title02":"Shifting clones: CLL evolution under pirtobrutinib treatment.","journal":"Blood","issue":"2026 January 1; 147(1):3-4. doi: 10.1182\/blood.2025031598","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477751"},{"title01":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","title02":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","journal":"Blood","issue":"2026 January 15; 147(3):276-289. doi: 10.1182\/blood.2025030558","author":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144772"},{"title01":"Resistance is not futile: RAS inhibition resensitizes AML.","title02":"Resistance is not futile: RAS inhibition resensitizes AML.","journal":"Blood","issue":"2026 January 15; 147(3):222-224. doi: 10.1182\/blood.2025031932","author":"Collins C, Majeti R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538212"},{"title01":"Fetal defense against leukemia: a developmental shield.","title02":"Fetal defense against leukemia: a developmental shield.","journal":"Blood","issue":"2026 January 1; 147(1):7-8. doi: 10.1182\/blood.2025031544","author":"Keeshan K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477746"},{"title01":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","title02":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","journal":"Blood","issue":"2026 January 1; 147(1):35-47. doi: 10.1182\/blood.2025029121","author":"Penter L, Maurer K, Cieri N, Lu WS, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026928"},{"title01":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","title02":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","journal":"Blood","issue":"2026 January 8; 147(2):197-208. doi: 10.1182\/blood.2025028644","author":"Guarnera L, Wahida A, Gurnari C, Hutter S, Stainczyk SA, Williams ND, Durmaz A, Kubota Y, Bravo-Perez C, Kawashima N, Orland M, Pagliuca S, Huang Y, LaFramboise T, Visconte V, Walter W, Meggendorfer M, Kern W, Westermann F, Feuerbach L, Haferlach T, Maciejewski JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983034"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","title02":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","journal":"Blood","issue":"2026 January 8; 147(2):180-196. doi: 10.1182\/blood.2025029302","author":"Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898981"},{"title01":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","title02":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 January 12. doi: 10.1182\/blood.2024028031. Online ahead of print","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031409. Online ahead of print","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee AE, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang AG, Barsouk A, Cho JH, Shaw CE, Singh EB, Ugwuanyi O, Paruzzo L, Stella F MD, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey AD Jr, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.","title02":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030230. Online ahead of print","author":"Schimmer R, Klemm N, Fullin J, Topcu E, Treacy M, Zielinska K, Doerdelmann C, Devesa-Serrano D, Lock M, Caiado F, Koch C, Dietliker N, Schwotzer R, Buehler MM, Myllymaki M, Kurppa KJ, Manz MG, Lopes M, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490322"},{"title01":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","title02":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288587. Online ahead of print","author":"Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504229"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"Metallothionein 1 mediates growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia.","title02":"Metallothionein 1 mediates growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):373-378. doi: 10.3324\/haematol.2025.287662","author":"Colom Diaz PA, Mistry JJ, Young KA, Chou CH, Boyer N, Levine RL, Salomonis N, Grimes HL, Trowbridge JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820834"},{"title01":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the CON.","title02":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the CON.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288786. Online ahead of print","author":"Russell NH, Lewis KD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537333"},{"title01":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","title02":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.287809. Online ahead of print","author":"Palhais B, Sharma ND, Fijalkowski I, Pieters T, Deforce D, Nieuwerburgh FV, Mestdagh P, Ntziachristos P, Matlawska-Wasowska K, Vlierberghe PV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537349"},{"title01":"Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.","title02":"Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288461. Online ahead of print","author":"Yeung CCS, Eacker SM, Sala-Torra O, Wood M, Beppu L, Woolston DW, Liachko I, Malig M, Stirewalt D, Muratov A, Fang M, Radich J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537347"},{"title01":"Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD19-directed immunotherapy.","title02":"Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD19-directed immunotherapy.","journal":"Haematologica","issue":"2026 January 1; 111(1):93-95. doi: 10.3324\/haematol.2025.288192","author":"Zeckanovic A, Baruchel A, Bourquin JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836779"},{"title01":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO.","title02":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288785. Online ahead of print","author":"Kayser S, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537334"},{"title01":"Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study.","title02":"Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288555. Online ahead of print","author":"Cerrano M, Lazzarotto D, Boscaro E, Borlenghi E, Tanasi I, Chiusolo P, Minetto P, Grimaldi F, Giglio F, Dargenio M, Leoncin M, Trappolini S, Papayannidis C, Forghieri F, Gurrieri C, Zappasodi P, La Starza R, Fracchiolla N, Di Biase F, Del Principe MI, Defina M, Pasciolla C, Cambo B, Mosna F, Pietrasanta D, Mariani S, Mancini V, Guolo F, Lussana F, Todisco E, Annunziata M, Calafiore V, Ciccone M, Pasquini A, Dragani ME, Sani B, Mauro E, Basilico C, De Marco B, Antonacci M, Forlani L, Fumagalli M, Trastulli F, Lunghi M, Salutari P, Mastaglio S, Chiaretti S, Candoni A, Ferrara F, Pizzolo G, Foa R, Bonifacio M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537316"},{"title01":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia.","title02":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):423-426. doi: 10.3324\/haematol.2025.288275","author":"Breimer GE, Rozeman EA, Braunius WW, Daenen LGM, Kester LA, Leguit RJ, Mahieu R, Solleveld-Westerink N, Straatman L, Schutgens F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931869"},{"title01":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia.","title02":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):89-90. doi: 10.3324\/haematol.2025.288379","author":"Owen C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874327"},{"title01":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","title02":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288974. Online ahead of print","author":"Sato A, Yusa N, Takamori H, Shimizu E, Jimbo K, Kato S, Konuma T, Yokoyama K, Imoto S, Takahashi S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537315"},{"title01":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel.","title02":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel.","journal":"Haematologica","issue":"2026 January 1; 111(1):98-107. doi: 10.3324\/haematol.2025.288228","author":"Wang SA, Arenillas L, Buccisano F, Bruggemann M, Kern W, Menes M, Plesa A, Stone L, Wellnitz D, Westerman DA, Wood BL, Freeman SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905082"},{"title01":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","title02":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288277. Online ahead of print","author":"Chalise S, Roshal M, Roshal S, Baik J, Gao Q, Li A, Dogan A, Veeraraghavan H, Zhu ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504225"},{"title01":"Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia.","title02":"Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):96-97. doi: 10.3324\/haematol.2025.288820","author":"Yan B, Guryanova OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963388"},{"title01":"Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.","title02":"Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70332. Online ahead of print","author":"Breccia M, Giai V, Rosso T, Pregno P, Castagnetti F, Bonifacio M, Capodanno I, Tiribelli M, Stagno F, Mulas O, Gozzini A, Patriarca A, Sora F, Loglisci G, Rossi AR, Coppi MR, Miggiano MC, Di Raimondo F, Rosti G, Pane F, Saglio G, Ciccone G, Specchia G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521026"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","title02":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","journal":"Br J Haematol","issue":"2026 January 5. doi: 10.1111\/bjh.70301. Online ahead of print","author":"Ueno T, Yoshimitsu M, Sameshima M, Nagano T, Akahoshi R, Takeshita Y, Shodai A, Shima K, Arima N, Kamada Y, Nakamura D, Ishitsuka K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41491883"},{"title01":"More than CLK bait? Rogocekib for MDS and AML.","title02":"More than CLK bait? Rogocekib for MDS and AML.","journal":"Blood advances","issue":"2026 January 13; 10(1):260-261. doi: 10.1182\/bloodadvances.2025018552","author":"Chen EC, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528737"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018408. Online ahead of print","author":"Boertjes EL, Grob T, Al Hinai ASA, Beverloo BH, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck-Verschueren CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska P, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysis.","title02":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysis.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025016879. Online ahead of print","author":"Oliveros MJ, Chowdhury SR, Roldan Y, Ibrahim S, Bravo-Soto G, Foucar CE, Bhogal G, Burgos-Mansilla B, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Taj TK, Chang Y, Hadeiy SK, Demichelis-Gomez R, Malcovati L, Loh KP, Platzbecker U, Gilberto L, Treitz J, Baer MR, Marini BL, Mattison RJ, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538293"},{"title01":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","title02":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018032. Online ahead of print","author":"Shimony S, Wang Y, Cronin AM, Walsh TP, Charles A, Slopen N, Cho HL, Stahl MF, Bystrom RP, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538295"},{"title01":"Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia.","title02":"Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018345. Online ahead of print","author":"Batatinha H, Valenzuela AM, Filioglou D, Wilde P, Leite G, Kistner TM, Baker FL, Katsanis E, Simpson RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538301"},{"title01":"Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.","title02":"Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018757. Online ahead of print","author":"Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A, Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M, Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F, Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis RM, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V Sr, Vitale C, Romeo A, Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499776"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","title02":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January 8. doi: 10.1038\/s41375-025-02845-7. Online ahead of print","author":"Gonzales F, Schneider C, Alexe G, Lin S, Khalid D, Alvarez M, Basanthakumar A, Ellegast JM, Merickel L, Salhotra S, Taillon A, Giaimo M, Wunderlich M, Ansari M, Perry JA, Degar B, Pikman Y, Stegmaier K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41507381"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","journal":"Leukemia","issue":"2026 January; 40(1):63-71. doi: 10.1038\/s41375-025-02781-6","author":"Bill M, Eckardt JN, Dohner K, Rohnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Einsele H, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Valka J, Sramek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Recher C, Pigneux A, Herold T, Ganser A, Dohner H, Bornhauser M, Thiede C, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e8-e21. doi: 10.1016\/S2352-3026(25)00327-8","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","title02":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","journal":"Lancet Haematol","issue":"2026 January 14. doi: 10.1016\/S2352-3026(25)00323-0. Online ahead of print","author":"Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Lehmann A, Krolla C, Andrieux G, Kohler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Bruggemann M, Rammensee HG, Salih HR, Walz JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41547362"},{"title01":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):134. doi: 10.1200\/JCO-25-02762","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41325561"},{"title01":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2026 January; 44(1):68-70. doi: 10.1200\/JCO-25-02252","author":"Marvin-Peek J, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264889"},{"title01":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.","title02":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.","journal":"Haematologica","issue":"2026 January 1; 111(1):412-417. doi: 10.3324\/haematol.2025.288323","author":"Molica S, Shanafelt TD, Giannarelli D, Allsup D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605690"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).","title02":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).","journal":"Haematologica","issue":"2026 January 1; 111(1):158-167. doi: 10.3324\/haematol.2025.288085","author":"Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702896"},{"title01":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.","title02":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.","journal":"Haematologica","issue":"2026 January 1; 111(1):401-404. doi: 10.3324\/haematol.2025.288105","author":"Alkabbani O, Jabban Y, He R, Viswanatha D, Bessonen K, Greipp P, Jevremovic D, Foran JM, Badar T, Yi CA, Kusne Y, Saliba AN, Hefazi M, Matin A, Hogan WJ, Mangaonkar A, Alkhateeb H, Patnaik M, Shah M, Begna K, Litzow MR, Al-Kali A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671498"},{"title01":"CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.","title02":"CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):196-205. doi: 10.3324\/haematol.2025.287564","author":"Carrillo-Serradell L, Pineyroa JA, Bousquets-Munoz P, Planells-Romeo V, Aragon-Serrano L, Casado-Llombart S, Colomer D, Andres MV, Puente XS, Delgado J, Mozas P, Lozano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605694"},{"title01":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.","title02":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):108-121. doi: 10.3324\/haematol.2024.287124","author":"Stanulovic VS, Binhassan S, Jaber BA, Alazmi S, Saleman FMB, Potluri S, Pratt G, Ludwig C, Ward DG, Hoogenkamp M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637766"},{"title01":"Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.","title02":"Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.","journal":"Haematologica","issue":"2026 January 1; 111(1):206-218. doi: 10.3324\/haematol.2025.287799","author":"Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Barate C, Pane F, Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C, Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M, Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M, Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M, Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G, Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A, Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568727"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"IDH1-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism.","title02":"IDH1-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288472. Online ahead of print","author":"Qian Y, Shen D, Ling Q, Zhao S, Zhou Y, Zhao Y, Li X, Wang Y, Huang J, Wang J, Yu W, Tong H, Sun J, Zhang X, Jin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504243"},{"title01":"NKX2-1 regulates cell survival, maturation, and DNA-damage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","title02":"NKX2-1 regulates cell survival, maturation, and DNA-damage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.287966. Online ahead of print","author":"Van Aerschot L, Demeyer S, Timcheva K, Heylen E, Verstraete P, De Groote D, Caruso M, Lauwereins L, Veloso A, Kampen KR, Pepe D, Boeckx N, Royaert J, Verbeeck J, Segers H, Cools J, De Keersmaecker K, Granados DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504233"},{"title01":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","title02":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):135-148. doi: 10.3324\/haematol.2024.286228","author":"Zhao HG, Cruz-Rodriguez N, Johnson KC, Pomicter AD, Bates B, Bateman B, Haferlach T, Gu T, Ahmann J, Yan D, Lee GS, Zhu W, Bishop J, Odelberg SJ, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637748"},{"title01":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia.","title02":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):355-360. doi: 10.3324\/haematol.2025.287392","author":"Thastrup M, Marquart HV, Levinsen M, Ulvmoen A, Albertsen BK, Pronk CJ, Olsen M, Wehner P, Taskinen M, Als-Nielsen B, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637739"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","journal":"Haematologica","issue":"2026 January 1; 111(1):329-334. doi: 10.3324\/haematol.2024.286719","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K, Of Japanese Children's Cancer Group TTACTC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Mechanisms sensitive to different drugs mediate a proadhesive and pro-thrombotic platelet phenotype in antiphospholipid syndrome.","title02":"Mechanisms sensitive to different drugs mediate a proadhesive and pro-thrombotic platelet phenotype in antiphospholipid syndrome.","journal":"Haematologica","issue":"2026 January 1; 111(1):219-229. doi: 10.3324\/haematol.2024.287133","author":"Camera M, Brambilla M, Lonati PA, Becchetti A, Grossi C, Nallio K, Da Via A, Trespidi L, Borghi MO, Tedesco F, Meroni PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605716"},{"title01":"Don’t forget about thrombosis in acute promyelocytic leukemia.","title02":"Don’t forget about thrombosis in acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.300189. Online ahead of print","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537346"},{"title01":"Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.","title02":"Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288876. Online ahead of print","author":"Abraham IE, Rauscher GH, Luo J, Monick S, Burkart M, Doukas P, Aleem A, Raptis N, Dave A, Wilmington A, Debettencourt M, Nwachukwu M, Fatima J, Erra A, Shankar G, Tsai SB, Larson M, Zia M, Quigley J, Altman JK, Stock W, Patel A, Khan I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537345"},{"title01":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","title02":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","journal":"Lancet Oncol","issue":"2026 January; 27(1):125-136. doi: 10.1016\/S1470-2045(25)00526-1","author":"Cheville AL, Herrin J, Pachman DR, Grzegorczyk V, Kroenke K, Ridgeway JL, Minteer SA, Austin JD, Griffin JM, Chlan L, Tofthagen C, Mitchell SA, Smith A, Ruddy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344348"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","title02":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):3-24. doi: 10.1038\/s41375-025-02804-2","author":"Mikkelsen T, Helenius M, Ampatzidou M, Attarbaschi A, Andres-Jensen L, Borkhardt A, Conde Cuevas N, Escherich G, Hagleitner MM, Halsey C, Josephs-Spaulding J, Lundgren L, Pehn S, Polychronopoulou S, Stoltze U, Toksvang LN, Wahlberg A, Junk SV, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361660"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2026 January; 40(1):261. doi: 10.1038\/s41375-025-02824-y","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41331358"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2026 January; 40(1):178-187. doi: 10.1038\/s41375-025-02814-0","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"40 years of LEUKEMIA.","title02":"40 years of LEUKEMIA.","journal":"Leukemia","issue":"2026 January; 40(1):1-2. doi: 10.1038\/s41375-025-02840-y","author":"Hochhaus A, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361661"},{"title01":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","title02":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02859-1. Online ahead of print","author":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Mohle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuss A, Gothert JR, Ernst T, Abu-Samra M, Hoffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526617"},{"title01":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.","title02":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.","journal":"Leukemia","issue":"2026 January; 40(1):120-129. doi: 10.1038\/s41375-025-02753-w","author":"Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41073560"},{"title01":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","title02":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):188-198. doi: 10.1038\/s41375-025-02818-w","author":"Dehgane L, Mallet E, Brasseur C, Krzisch D, Zeitouni W, Hitier C, Ayoub M, Dubois K, Perez Carretero C, Roos-Weil D, Choquet S, Maloum K, Bravetti C, Armand M, Garnier D, Hernandez-Rivas JM, Susin SA, Nguyen-Khac F, Chapiro E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366531"},{"title01":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","title02":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):262. doi: 10.1038\/s41375-025-02827-9","author":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372600"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","title02":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","journal":"Leukemia","issue":"2026 January; 40(1):29-36. doi: 10.1038\/s41375-025-02826-w","author":"Ernst P, Lohse C, Lauseker M, Geissler J, le Coutre P, Brummendorf TH, Saussele S, Burchert A, Franke GN, La Rosee P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419606"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","title02":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02846-6. Online ahead of print","author":"Ayoub M, Hitier C, Dehgane L, Mallet E, Tannoury M, Nemazanyy I, Roos-Weil D, Maloum K, Ringshausen I, Chapiro E, Nguyen-Khac F, Garnier D, Lagouge M, Lerner LK, Susin SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501504"},{"title01":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","title02":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02797-y. Online ahead of print","author":"Agathangelidis A, Iatrou A, Pechlivanis N, Karakatsoulis G, Zaragoza-Infante L, Galigalidou C, Maity PC, Ranghetti P, Almeida J, Fuentes-Herrero B, Navarro A, Alcoceba M, Rabbani L, Thorvaldsdottir B, Scarfo L, Orfao A, Psomopoulos F, Jumaa H, Rosenquist R, Chatzidimitriou A, Ghia P, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501505"},{"title01":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"J Clin Oncol","issue":"2026 January; 44(1):42-53. doi: 10.1200\/JCO-25-01841","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Garcia Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret-Madrid P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Sole Rodriguez M, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41082703"},{"title01":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2026 January; 44(1):68. doi: 10.1200\/JCO-25-01666","author":"Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264888"},{"title01":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","title02":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","journal":"J Clin Oncol","issue":"2026 January 8; JCO2501806. doi: 10.1200\/JCO-25-01806. Online ahead of print","author":"Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Huitema ADR, Pieters R, van der Sluis IM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505662"},{"title01":"Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed\/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.","title02":"Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed\/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.","journal":"Haematologica","issue":"2026 January 1; 111(1):340-344. doi: 10.3324\/haematol.2024.287023","author":"Wan X, Wang T, Yang J, Yang X, Li W, Ding L, Yang L, Zhang J, Su M, An K, Zhou Z, Li Y, Wang X, Zhu H, Luo C, Gu L, Chen J, Song L, Tang Y, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400462"},{"title01":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.","title02":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):350-354. doi: 10.3324\/haematol.2024.287253","author":"Rockwell B, Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica AR, Kornblum N, Shah N, Levitz D, Shapiro LC, Gupta R, Munoz A, Dhawan A, Fehn K, Comas M, Verceles J, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671491"},{"title01":"Asparaginase-associated pancreatitis during therapy for pediatric acute lymphoblastic leukemia.","title02":"Asparaginase-associated pancreatitis during therapy for pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):335-339. doi: 10.3324\/haematol.2024.286803","author":"McCarville MB, Ashcraft E, Ribeiro RC, Rees M, Swanson HD, Inaba H, Jeha S, Cheng C, Pui CH, Karol SE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820809"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.","title02":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.","journal":"Leukemia","issue":"2026 January; 40(1):215-218. doi: 10.1038\/s41375-025-02789-y","author":"Nikkila A, Lohi O, Abrahamsson J, Griskevicius L, Hallbook H, Jonsson OG, Lund B, Marquart HV, Overgaard U, Palk K, Pruunsild K, Quist-Paulsen P, Toft N, Vaitkeviciene GE, Wartiovaara-Kautto U, Heyman M, Vettenranta K, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145672"},{"title01":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage.","title02":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage.","journal":"Leukemia","issue":"2026 January; 40(1):72-86. doi: 10.1038\/s41375-025-02791-4","author":"Benz T, Larghero P, Meyer C, Hanewald T, Bruggmann D, Hentrich AE, Louwen F, Marschalek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145673"},{"title01":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","title02":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):130-137. doi: 10.1038\/s41375-025-02764-7","author":"Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145674"},{"title01":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","title02":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","journal":"Leukemia","issue":"2026 January; 40(1):138-151. doi: 10.1038\/s41375-025-02799-w","author":"Dhir A, Ethell A, Watkins R, Lam C, Tur-Rodriguez K, Persinger J, Dobish KK, Panda S, Buckley SM, Swenson SA, Brahma S, Rowley MJ, Hyde RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214140"},{"title01":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","title02":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","journal":"Leukemia","issue":"2026 January; 40(1):230-234. doi: 10.1038\/s41375-025-02800-6","author":"Locatelli F, Rizzari C, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, Desai R, Henry M, Zugmaier G, von Stackelberg A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41233549"},{"title01":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","title02":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):166-177. doi: 10.1038\/s41375-025-02803-3","author":"Sui P, Li Y, Hong J, Delma CR, Chen S, Wang J, Zhang P, Han S, Noor A, Yang H, Pang Y, Luan Y, Xu M, Lee J, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41249566"},{"title01":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","title02":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","journal":"Leukemia","issue":"2026 January; 40(1):47-54. doi: 10.1038\/s41375-025-02796-z","author":"Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254114"},{"title01":"Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.","title02":"Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.","journal":"Blood","issue":"2025 December 25; 146(26):3201-3212. doi: 10.1182\/blood.2025029836","author":"Newton NM, Agrawal K, Odell AV, Tracy T, Hackett C, Eldrup A, Whitfield M, Martyanov V, Girardi M, Sefik E, Flavell RA, Odell ID","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961242"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","title02":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","journal":"Blood advances","issue":"2025 December 23; 9(24):6370-6379. doi: 10.1182\/bloodadvances.2025017197","author":"Khandelwal P, Ibrahimova A, Lane A, Grimley M, Davies SM, Jodele S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938738"},{"title01":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","title02":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","journal":"Blood advances","issue":"2025 December 23; 9(24):6394-6401. doi: 10.1182\/bloodadvances.2025016655","author":"Bhasin-Chhabra B, Wang T, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991367"},{"title01":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs.","title02":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs.","journal":"Blood advances","issue":"2025 December 23; 9(24):6563-6574. doi: 10.1182\/bloodadvances.2025016775","author":"Karimzadeh A, Kim R, Garcia V, Florea M, Peacker BL, Kobayashi S, Watkins D, Messemer K, Zeng J, Bauer DE, Serwold T, Wagers AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991373"},{"title01":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","title02":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","journal":"Blood advances","issue":"2025 December 23; 9(24):6305-6313. doi: 10.1182\/bloodadvances.2025017097","author":"Rubinstein JD, Pham G, Sridharan A, Khoury R, Wang YM, Hudda Z, Wilhelm J, Lichtenstein DA, Heyenbruch D, Cancelas JA, Davies SM, Lutzko C, Grimley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991376"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.","title02":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.","journal":"Blood","issue":"2025 December 25; 146(26):3188-3200. doi: 10.1182\/blood.2025029115","author":"Meaker GA, Nicholls M, Chahrour C, Hsu I, Smith A, Bozhilov Y, Leung M, Vassort H, Olender L, Beaven O, Huang X, Brown EJ, Vanden Bempt M, Khoo HM, Bhadury J, Milne TA, Wilkinson AC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961240"},{"title01":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","title02":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3098-3105. doi: 10.1182\/blood.2025028914","author":"Pastoors D, Havermans M, Mulet-Lazaro R, Smeenk L, Ottema S, Erpelinck-Verschueren C, van Herk S, Anthonissen M, Grob T, Subramanian S, Thoms JAI, Pimanda JE, Wouters BJ, Beverloo B, Haferlach T, Haferlach C, Zuber J, Bindels E, Delwel R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060369"},{"title01":"Runx2 takes center stage in regulating HSC expansion.","title02":"Runx2 takes center stage in regulating HSC expansion.","journal":"Blood","issue":"2025 December 25; 146(26):3135-3136. doi: 10.1182\/blood.2025031276","author":"Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447456"},{"title01":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024028248. Online ahead of print","author":"Nguyen C, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo GK, Huang AS, Martinez M, Chen Y, Ghazarian DM, Docampo MD, Pathak KV, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.","title02":"Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.","journal":"Lancet","issue":"2025 December 21; 404(10471):2543-2583. doi: 10.1016\/S0140-6736(24)01821-X","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39667386"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"Platelet Dysfunction in Chronic Kidney Disease Arises from Bone Marrow Remodeling and Megakaryocyte Reprogramming.","title02":"Platelet Dysfunction in Chronic Kidney Disease Arises from Bone Marrow Remodeling and Megakaryocyte Reprogramming.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025017625. Online ahead of print","author":"Carminita E, Camacho V, Branfield S, Walsey E, Barrachina MN, Tabang DN, Lee DH, Becker IC, Brodsky S, Issa SM, Gendron N, Machado S, Wolberg AS, Steen H, Kerlin BA, Machlus KR, Zarjou A, Italiano JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411491"},{"title01":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","title02":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017907. Online ahead of print","author":"Winward A, Lalonde L, Nair D, Socolovsky M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441873"},{"title01":"Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression.","title02":"Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression.","journal":"Blood","issue":"2025 December 18; 146(25):3106-3123. doi: 10.1182\/blood.2025028783","author":"Xie X, Zou A, Zhang L, Ma X, He Y, Liu H, Lu Y, Yang Y, Ouyang J, Liu K, Zhong P, Li J, Xu S, Zhou L, Han B, Chen M, Lv K, Zhang D, Liu L, Mei Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961234"},{"title01":"NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis.","title02":"NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis.","journal":"Blood","issue":"2025 December 25; 146(26):3246-3249. doi: 10.1182\/blood.2025030958","author":"Ruiter TJJ, van Oirschot BA, Waanders E, Koop K, van Solinge WW, van Wijk R, Jans JJM, Bartels M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100733"},{"title01":"Rbm38 binds Fech pre-mRNA to prevent anemia and porphyria.","title02":"Rbm38 binds Fech pre-mRNA to prevent anemia and porphyria.","journal":"Blood","issue":"2025 December 18; 146(25):3016-3017. doi: 10.1182\/blood.2025031227","author":"An X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410917"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2025 December 17. doi: 10.1038\/s41375-025-02839-5. Online ahead of print","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","title02":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289133. Online ahead of print","author":"Revilla N, Atance M, Grasa JM, Garcia-Ortego A, Soto C, Rodriguez-Pinilla SM, Arquero T, Perlado S, Ledesma S, Esquinas-Tarifa E, Serrano-Lopez J, Lopez-Lorenzo JL, Velasco-Rodriguez D, Alonso-Dominguez JM, Mata R, Llamas-Sillero P, Salgado RN, Rio-Machin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437813"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288906. Online ahead of print","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437825"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: a systematic review and meta-analysis.","title02":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2025 December 23; 9(24):6511-6523. doi: 10.1182\/bloodadvances.2025017611","author":"Alhajahjeh A, Woite NL, Rolles B, Stempel JM, Mina A, Mendez L, Kewan T, Podoltsev NA, Stahl M, Grimshaw AA, Zeidan AM, Bewersdorf JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966428"},{"title01":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","title02":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 December 23. doi: 10.1038\/s41375-025-02836-8. Online ahead of print","author":"Guy A, Mansier O, Decilap M, Catherineau A, Garcia G, Labrouche-Colomer S, Bats ML, Boyer F, Ianotto JC, Lippert E, Roy L, Tavitian S, Slama B, Girault S, Etienne G, Parry A, Saint-Lezer A, Denis G, Mediavilla C, Viallard JF, Legros L, Ranta D, Wemeau M, Nicolini FE, Lifermann F, Cambier N, Darnige L, Girodon F, Soret-Dulphy J, Cayssials E, Vacheret F, Sureau L, Paz DL, Ugo V, Kiladjian JJ, Thiebaut R, James C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436639"},{"title01":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","title02":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","journal":"Blood","issue":"2025 December 25; 146(26):3228-3233. doi: 10.1182\/blood.2025028489","author":"Tapper WJ, Dawoud AAZ, Score J, Chase AJ, Baxter EJ, Ewing J, Wallis L, Guglielmelli P, Colomer D, Bellosillo B, Gomez M, Hernandez-Boluda JC, Besses C, Cervantes F, Koschmieder S, Green AR, Reiter A, Vannucchi A, Harrison C, Cross NCP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026930"},{"title01":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","title02":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025028703. Online ahead of print","author":"Yan Y, Liu J, Zhao S, Li F, Yang L, Xu Z, Qin T, Zhu X, An W, Shi Z, Shen W, Zhang P, Huang G, Rampal RK, Xiao Z, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405487"},{"title01":"MPN predisposition: shared roots, split branches.","title02":"MPN predisposition: shared roots, split branches.","journal":"Blood","issue":"2025 December 25; 146(26):3140-3141. doi: 10.1182\/blood.2025031510","author":"Agarwal G, Sankaran VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447454"},{"title01":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","title02":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.288511. Online ahead of print","author":"Han H, Zhou M, Qi J, Song X, Li X, Zhang Z, Pan T, Xu X, Guo M, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414965"},{"title01":"Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study.","title02":"Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study.","journal":"Br J Haematol","issue":"2025 December 22. doi: 10.1111\/bjh.70299. Online ahead of print","author":"Rasmussen M, Mannering N, Frederiksen H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431208"},{"title01":"Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients.","title02":"Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018655. Online ahead of print","author":"Mian H, Arribas M, Fonseca R, Mutterback E, Shahid O, Gouda R, Pond GR, Visram A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411522"},{"title01":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","title02":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018342. Online ahead of print","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan SV, Dhakal B, D'Souza A, Lin DI, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","title02":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6340-6344. doi: 10.1182\/bloodadvances.2025017770","author":"Roerden M, Hensen L, Besemer B, Schwartz F, Reuss K, Weiss-Haug A, Harland L, Ginsberg F, Faul C, Bethge W, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026972"},{"title01":"Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.","title02":"Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6246-6251. doi: 10.1182\/bloodadvances.2025016659","author":"Bilotta MT, Solimando AG, Desantis V, Di Marzo L, Sabatini A, Forcelloni S, Andriano A, Morizio A, Argentiero A, Ria R, Quatrini L, Moretta L, Vacca P, Tumino N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924928"},{"title01":"Clinical applications of mass spectrometry in multiple myeloma.","title02":"Clinical applications of mass spectrometry in multiple myeloma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6593-6603. doi: 10.1182\/bloodadvances.2024015685","author":"Derman BA, Yee AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921003"},{"title01":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","title02":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","journal":"Blood","issue":"2025 December 18. doi: 10.1182\/blood.2025030083. Online ahead of print","author":"Fokkema C, Bertamini L, de Jong MME, Tahri S, Hofste Op Bruinink D, Kellermayer Z, Papazian N, den Hollander C, Vermeulen M, Stoetman ECG, van Beek G, Hoogenboezem R, van der Velden VHJ, Hulin C, Perrot A, Moreau P, Rowe M, Vieyra D, Carson R, van Duin M, Sanders MA, Broijl A, Sonneveld P, Cupedo T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411148"},{"title01":"Premaintenance PET in patients with myeloma.","title02":"Premaintenance PET in patients with myeloma.","journal":"Blood","issue":"2025 December 18; 146(25):3130. doi: 10.1182\/blood.2025032271","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410915"},{"title01":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.","title02":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025029572. Online ahead of print","author":"Jelinek T, Zihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O, Moreno C, Fotiou D, Radova E, Tamariz-Amador LE, Theodorakakou F, Muronova L, Manubens A, Tsitsilonis O, Popkova T, Gonzalez C, Anilkumar Sithara A, Corrado F, Bidikian N, Guerrero C, Kapustova V, Bilek D, Hagner PR, Larrayoz M, Martinez-Climent JA, Broskevicova L, Mihalyova J, Merz M, Sevcikova T, Ghobrial IM, San-Miguel JF, Dimopoulos MA, Rodriguez-Otero P, Radocha J, Kastritis E, Paiva B, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405507"},{"title01":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.","title02":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.","journal":"Blood","issue":"2025 December 18; 146(25):3050-3058. doi: 10.1182\/blood.2025030084","author":"Kraeber-Bodere F, Jamet B, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Moreau P, Carlier T, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991848"},{"title01":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","title02":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","journal":"Blood advances","issue":"2025 December 23; 9(24):6305-6313. doi: 10.1182\/bloodadvances.2025017097","author":"Rubinstein JD, Pham G, Sridharan A, Khoury R, Wang YM, Hudda Z, Wilhelm J, Lichtenstein DA, Heyenbruch D, Cancelas JA, Davies SM, Lutzko C, Grimley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991376"},{"title01":"Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.","title02":"Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.","journal":"Blood advances","issue":"2025 December 23; 9(24):6481-6490. doi: 10.1182\/bloodadvances.2025016701","author":"Sharma A, Locatelli F, Bhatia M, Molinari L, Mapara MY, Liem RI, Dedeken L, Wall D, Eckrich MJ, Kuo KHM, Smith W, Imren S, Kohli P, Li N, Liu T, Rubin J, Hobbs W, Grupp SA, Frangoul H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857358"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel.","title02":"Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel.","journal":"Blood advances","issue":"2025 December 23; 9(24):6502-6510. doi: 10.1182\/bloodadvances.2025016702","author":"Fuente J, Frangoul H, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara MY, Liem RI, Rupprecht J, Kuo KHM, Merkeley H, Algeri M, Smith W, Kohli P, Li N, Rubin J, Zhang S, Hobbs W, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40862696"},{"title01":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","title02":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017795. Online ahead of print","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","title02":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3163-3174. doi: 10.1182\/blood.2025029532","author":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864984"},{"title01":"Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What’s next?","title02":"Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What’s next?","journal":"Blood","issue":"2025 December 18. doi: 10.1182\/blood.2025030416. Online ahead of print","author":"Curtis DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411147"},{"title01":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024028248. Online ahead of print","author":"Nguyen C, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo GK, Huang AS, Martinez M, Chen Y, Ghazarian DM, Docampo MD, Pathak KV, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288933. Online ahead of print","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","title02":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6575-6589. doi: 10.1182\/bloodadvances.2024015762","author":"Liu X, Wu J, Li X, Pan R, Liu L, Huang T, Ma L, Chen G, Wang Q, Zhang N, Tong X, Tan Y, Jiang H, Liang Y, Shen M, Li R, Yin W, Zhang X, Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920990"},{"title01":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial.","title02":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3788-3798. doi: 10.1200\/JCO-25-00992","author":"Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jorgensen JM, Zinzani PL, Leung W, Bottos A, Li D, Relf J, Tandon M, Sellam G, Gritti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115257"},{"title01":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","title02":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3799-3811. doi: 10.1200\/JCO-25-01957","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","title02":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","journal":"J Clin Oncol","issue":"2025 December 22; JCO2501587. doi: 10.1200\/JCO-25-01587. Online ahead of print","author":"Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, Kaji F, Raso-Barnett L, Cheow H, Elzubeir L, Smith J, Kamil A, Barbara RR, Price J, Elston K, Kolodziejczyk A, Tarantino S, Mariscotti F, Barry P, Frost S, Demiris N, Thomas MG, Hassane D, Munugalavadla V, Nagumantry SK, Karanth MJ, Ahearne M, Shah N, Fox CP, Anand S, Hodson DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428995"},{"title01":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis.","title02":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288419. Online ahead of print","author":"Marcus R, Avigdor A, Greenbaum U, Brown S, Fried S, Golan-Accav N, Shem-Tov N, Yerushalmi R, Danylesko I, Jacoby E, Nagler A, Shimoni A, Itzhaki O, Esensten J, Valid OB, Ballweg A, Deschenes-Simard X, Luttwak E, Shah G, Scordo M, Dahi P, Perales MA, Zuckerman T, Devlin SM, Yehudai-Ofir D, Khatib H, Shibly N, Shouval R, Beyar-Katz O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437832"},{"title01":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","title02":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289294. Online ahead of print","author":"Lee D, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437826"},{"title01":"Secondary T-cell lymphoma arising from pre-existing clones in a patient with diffuse large B-cell lymphoma during epcoritamab treatment following CAR-T therapy.","title02":"Secondary T-cell lymphoma arising from pre-existing clones in a patient with diffuse large B-cell lymphoma during epcoritamab treatment following CAR-T therapy.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289269. Online ahead of print","author":"Terakawa T, Fuji S, Shi H, Amemiya Y, Nakahara W, Matsuoka Y, Tada Y, Shingai Y, Yuda S, Ishikawa J, Satomi H, Murakami H, Suga M, Hosen N, Nannya Y, Ogawa S, Yokota T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437820"},{"title01":"The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.","title02":"The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70290. Online ahead of print","author":"Zilioli VR, Tucci A, Spina M, Merli F, Arcari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449752"},{"title01":"T-cell\/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review.","title02":"T-cell\/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review.","journal":"Br J Haematol","issue":"2025 December 23. doi: 10.1111\/bjh.70294. Online ahead of print","author":"Choy JP, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436860"},{"title01":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","title02":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70286. Online ahead of print","author":"Kirk A, James B, Feltbower RG, Mushtaq T, Whitehead E, Kraft J, Motwani J, Parkin H, Guest J, Gray J, Palmer J, Pelling J, Appleby J, Ledwich N, Dondo TB, Amin N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410159"},{"title01":"Dynamics of circulating tumour DNA in relapsed\/refractory diffuse large B-cell lymphoma patients.","title02":"Dynamics of circulating tumour DNA in relapsed\/refractory diffuse large B-cell lymphoma patients.","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70296. Online ahead of print","author":"Zhong Y, Bult J, Veltmaat N, de Jesus FM, Sillje L, Kluiver J, van den Berg A, Plattel W, Diepstra A, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410192"},{"title01":"Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.","title02":"Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6425-6431. doi: 10.1182\/bloodadvances.2025017181","author":"Gao L, Kallam A, Shouse G, Baird JH, Pak S, Qin Y, Song JY, Marcucci G, Ghoda LY, Guillen C, Hyung SJ, Saad OM, Davis H, Dere R, Batlevi CL, Meinert J, Budde LE, Danilov AV, Herrera AF, Kwak LW, Forman SJ, Godfrey JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061156"},{"title01":"Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL.","title02":"Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6549-6562. doi: 10.1182\/bloodadvances.2025017118","author":"Xia Z, Cao J, Li Y, Wu J, Ren J, Sheng W, Li C, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026974"},{"title01":"Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.","title02":"Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6443-6454. doi: 10.1182\/bloodadvances.2025016827","author":"Ramsower CA, Wright G, Li H, Cerhan JR, Maurer MJ, Mwangi R, Rosenthal AC, Novak AJ, Link BK, Witzig TE, Habermann TM, Kridel R, LeBlanc ML, Shadman M, Smith SM, Friedberg JW, Scott DW, Steidl C, Staudt LM, Rimsza LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966421"},{"title01":"SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.","title02":"SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6267-6278. doi: 10.1182\/bloodadvances.2025016801","author":"Dutta RP, Lee HH, Leshchenko VV, Shukla RP, Yan F, Liu Y, Kaniskan HU, Qiu X, Jin J, Alinari L, Wang M, Parekh S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845256"},{"title01":"Leukemic phase of hepatosplenic T-cell lymphoma.","title02":"Leukemic phase of hepatosplenic T-cell lymphoma.","journal":"Blood","issue":"2025 December 18; 146(25):3129. doi: 10.1182\/blood.2025031068","author":"Stalls JS, Park DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410916"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025030151. Online ahead of print","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah HR, Pederson LD, Geyer S, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef IN, Stuver RN, Herrera AF, Mei MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?","title02":"Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?","journal":"Blood","issue":"2025 December 25; 146(26):3145-3152. doi: 10.1182\/blood.2025029935","author":"Jaworek CP, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175363"},{"title01":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","title02":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","journal":"Blood","issue":"2025 December 18; 146(25):3059-3071. doi: 10.1182\/blood.2024027763","author":"Myers JA, Huang RS, Phung SK, Chacon JM, Bendzick L, Weis A, Shetty M, DePauw TA, Khaw MJ, Abrahante JE, O'Flanagan SD, Ashby KM, Lozada JR, Jameson SC, Hwang JH, Cichocki F, Felices M, Miller JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857665"},{"title01":"Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.","title02":"Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2025030190. Online ahead of print","author":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo-Domenech E, Hess BT, Schuster SR, Linhares Y, Gandhi MD, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460964"},{"title01":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.","title02":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.","journal":"Blood","issue":"2025 December 23. doi: 10.1182\/blood.2025031476. Online ahead of print","author":"Luan D, Valid OB, Beyar-Katz O, Tix T, Golan-Accav N, Alhomoud M, Avigdor A, Bucklein VL, Cohen L, Dahi PB, Einarsdottir S, Elimelech J, Escribano Serrat S, Falchi L, Fei T, Giralt SA, Gomez-Llobell M, Goy A, Horesh N, Israeli S, Kruk L, Leslie LA, Lue JK, Marcus R, Nagler A, Palomba ML, Park JH, Raj SS, Reddy ST, Romancik JT, Rosenbaum E, Salles GA, Scordo M, Shah GL, Shimoni A, von Bergwelt-Baildon M, Perales MA, Subklewe M, Greenbaum U, Ip A, Ram R, Rejeski K, Shouval R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41489404"},{"title01":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","title02":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","journal":"Leukemia","issue":"2025 December 22. doi: 10.1038\/s41375-025-02834-w. Online ahead of print","author":"Grozinger M, Schlanke M, Grone J, Erdmann S, Hajiyianni M, Poos AM, Thierjung H, Mai EK, Sauer S, Kaudewitz D, Veelken K, Michel CS, Frenking JH, Sester LS, Weber TF, Sedaghat S, Wennmann M, Muller-Tidow C, Schlemmer HP, Delorme S, Raab MS, Goldschmidt H, Weinhold N, John L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430398"},{"title01":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","title02":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02819-9. Online ahead of print","author":"Gustine JN, Scaringi JA, Bauer F, Cirstea DD, Branagan AR, Puliafito BR, Maus MV, Frigault MJ, Yee AJ, Mahmood U, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419604"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up – a case report.","title02":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up – a case report.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288950. Online ahead of print","author":"Decheiver S, Schavgoulidze A, Maheo S, Vion PA, Lucidarme O, Corre J, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437828"},{"title01":"Translocation t(11;14) and BCL2-inhibition in multiple myeloma.","title02":"Translocation t(11;14) and BCL2-inhibition in multiple myeloma.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289147. Online ahead of print","author":"Sim S, Dhakal B, Quach H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437818"},{"title01":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","title02":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.289176. Online ahead of print","author":"Uehara A, Sakuma H, Fujii F, Toho M, Tabata R, Narita K, Takeuchi M, Matsuda R, Isuge D, Ikeda D, Miyamoto T, Takamatsu H, Matsue K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414966"},{"title01":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","title02":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.289258. Online ahead of print","author":"Benini G, Taranto S, Sciume M, Rigali F, Marcheselli R, Abate A, Mitola S, Sigala S, Sacco A, Roccaro AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414960"},{"title01":"Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.","title02":"Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.","journal":"Blood advances","issue":"2025 December 23; 9(24):6252-6266. doi: 10.1182\/bloodadvances.2024015686","author":"Zamagni E, Talarico M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875592"},{"title01":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden.","title02":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden.","journal":"Blood","issue":"2025 December 18; 146(25):3072-3085. doi: 10.1182\/blood.2025029215","author":"Meermeier EW, Pfeffer K, Stein CK, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Bergsagel PL, Chesi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864972"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","title02":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3799-3811. doi: 10.1200\/JCO-25-01957","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288933. Online ahead of print","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","title02":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","journal":"Blood advances","issue":"2025 December 23; 9(24):6370-6379. doi: 10.1182\/bloodadvances.2025017197","author":"Khandelwal P, Ibrahimova A, Lane A, Grimley M, Davies SM, Jodele S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938738"},{"title01":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","title02":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","journal":"Blood advances","issue":"2025 December 23; 9(24):6394-6401. doi: 10.1182\/bloodadvances.2025016655","author":"Bhasin-Chhabra B, Wang T, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991367"},{"title01":"Androgen receptor signaling as a new target for intervention in acute myeloid leukemia.","title02":"Androgen receptor signaling as a new target for intervention in acute myeloid leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6326-6339. doi: 10.1182\/bloodadvances.2024012639","author":"Qian F, Sarkar D, Arner BE, Peduzzi VM, Bai Y, Ruan B, Jia B, Zheng H, Paulson RF, Prabhu KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991369"},{"title01":"A new sUSPect in T-ALL risk stratification.","title02":"A new sUSPect in T-ALL risk stratification.","journal":"Blood advances","issue":"2025 December 23; 9(24):6467-6468. doi: 10.1182\/bloodadvances.2025017870","author":"Si Lim SJ, Teachey DT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385206"},{"title01":"Combining drugs that bypass p53 to treat TP53-mutated leukemias.","title02":"Combining drugs that bypass p53 to treat TP53-mutated leukemias.","journal":"Blood advances","issue":"2025 December 23; 9(24):6410-6424. doi: 10.1182\/bloodadvances.2025016683","author":"Biswas S, Zahran ZAM, Gu X, Cardone L, Marti R, Mouannes N, Stich M, Jain A, Fedorov K, Tomlinson B, Goldfinger M, Verma A, Saunthararajah Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061202"},{"title01":"Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.","title02":"Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6345-6353. doi: 10.1182\/bloodadvances.2025017584","author":"Cassaday RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056518"},{"title01":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","title02":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6340-6344. doi: 10.1182\/bloodadvances.2025017770","author":"Roerden M, Hensen L, Besemer B, Schwartz F, Reuss K, Weiss-Haug A, Harland L, Ginsberg F, Faul C, Bethge W, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026972"},{"title01":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.","title02":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.","journal":"Blood advances","issue":"2025 December 23; 9(24):6455-6466. doi: 10.1182\/bloodadvances.2025017244","author":"Russell N, Othman J, Cumming O, Thomas A, Tedjaseputra A, Potter N, Jovanovic J, Gilkes A, Batten L, Canham J, Hinson E, Runglall M, Aucken P, Kottaridis P, Cavenagh J, Arnold C, Freeman S, Dennis M, Knapper S, Dillon R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026969"},{"title01":"Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.","title02":"Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.","journal":"Blood advances","issue":"2025 December 23; 9(24):6279-6291. doi: 10.1182\/bloodadvances.2025017057","author":"Yan Y, Yuan B, Qiu T, Liu G, Chen W, Wang T, Yu Y, Xiong W, An G, Zou D, Li J, Wang L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902084"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","title02":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3163-3174. doi: 10.1182\/blood.2025029532","author":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864984"},{"title01":"LEF1 and CLL: a matter of quantity and quality.","title02":"LEF1 and CLL: a matter of quantity and quality.","journal":"Blood","issue":"2025 December 25; 146(26):3138-3140. doi: 10.1182\/blood.2025031187","author":"Deaglio S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447459"},{"title01":"Armed and SAVVY: CAR T cells combat AML.","title02":"Armed and SAVVY: CAR T cells combat AML.","journal":"Blood","issue":"2025 December 25; 146(26):3133-3134. doi: 10.1182\/blood.2025031004","author":"Zinsky MT, Bonifant CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447455"},{"title01":"Acalabrutinib to assail CLL in the frail.","title02":"Acalabrutinib to assail CLL in the frail.","journal":"Blood","issue":"2025 December 25; 146(26):3131-3132. doi: 10.1182\/blood.2025030747","author":"Ryan CE, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447452"},{"title01":"LEF1 intragenic deletions: is Wnt’er coming for T-ALL?","title02":"LEF1 intragenic deletions: is Wnt’er coming for T-ALL?","journal":"Blood","issue":"2025 December 18; 146(25):3005-3006. doi: 10.1182\/blood.2025030884","author":"Fragoso AR, Barata JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410923"},{"title01":"Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.","title02":"Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3213-3227. doi: 10.1182\/blood.2025030129","author":"Mateos-Jaimez J, Vidal-Crespo A, Charalampopoulou S, Perez RF, Chapaprieta V, Jimenez-Martinez V, Caviedes-Cardenas L, Duran-Ferrer M, Espadas G, Sabido E, Largeot A, Herbst SA, Dietrich S, Boente MB, Alcoceba M, Nadeu F, Ringshausen I, Paggetti J, Moussay E, Colomer D, Campo E, Maiques-Diaz A, Martin-Subero JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983031"},{"title01":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","title02":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","journal":"Blood","issue":"2025 December 18; 146(25):3059-3071. doi: 10.1182\/blood.2024027763","author":"Myers JA, Huang RS, Phung SK, Chacon JM, Bendzick L, Weis A, Shetty M, DePauw TA, Khaw MJ, Abrahante JE, O'Flanagan SD, Ashby KM, Lozada JR, Jameson SC, Hwang JH, Cichocki F, Felices M, Miller JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857665"},{"title01":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.","title02":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.","journal":"Blood","issue":"2025 December 18; 146(25):3019-3035. doi: 10.1182\/blood.2025028954","author":"Fleming TJ, Antoszewski M, Lambo S, Gundry MC, Piussi R, Wahlster L, Shah S, Reed FE, Dong KD, Paulo JA, Gygi SP, Mimoso C, Goldman SR, Adelman K, Perry JA, Pikman Y, Stegmaier K, Barrachina MN, Machlus KR, Hovestadt V, Arruda A, Minden MD, Voit RA, Sankaran VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991835"},{"title01":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","title02":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3098-3105. doi: 10.1182\/blood.2025028914","author":"Pastoors D, Havermans M, Mulet-Lazaro R, Smeenk L, Ottema S, Erpelinck-Verschueren C, van Herk S, Anthonissen M, Grob T, Subramanian S, Thoms JAI, Pimanda JE, Wouters BJ, Beverloo B, Haferlach T, Haferlach C, Zuber J, Bindels E, Delwel R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060369"},{"title01":"A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.","title02":"A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025029971. Online ahead of print","author":"Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman PK, Wiestner A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405491"},{"title01":"The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.","title02":"The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2024028147. Online ahead of print","author":"Mujollari J, Estruch Alrich M, Khadgawat P, Choudhary S, Gustavsson T, Dagil R, Redlinger N, Loppke C, Vidal Calvo E, Anemone Nordmaj M, Theander TG, Heidenreich O, Nguyen Y, Qin S, Tolboll Sorensen AL, Gronbaek K, Porse BT, Kircher B, Mueller J, Agerbaek M, Salanti A, Theilgaard-Monch K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405498"},{"title01":"Breaking the silence: restoring CEBPA to fight leukemia.","title02":"Breaking the silence: restoring CEBPA to fight leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3014-3015. doi: 10.1182\/blood.2025031363","author":"Wilson NK, Gottgens B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410921"},{"title01":"The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.","title02":"The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.","journal":"Blood","issue":"2025 December 23. doi: 10.1182\/blood.2025029905. Online ahead of print","author":"Al-Sawaf O, Locher BN, Christen F, Hablesreiter R, Rajamani A, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Kopp K, Mertz ME, Fustero-Torre C, Kleo K, Seymour JF, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Hallek MJ, Eichhorst BF, Langerbeins P, Fischer K, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528026"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","title02":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","journal":"Lancet Haematol","issue":"2025 December 22. doi: 10.1016\/S2352-3026(25)00342-4. Online ahead of print","author":"Karmali R, Gordon LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448214"},{"title01":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","title02":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","journal":"Lancet Haematol","issue":"2025 December 22. doi: 10.1016\/S2352-3026(25)00318-7. Online ahead of print","author":"Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, Brailovski E, Assouline S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448213"},{"title01":"Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.","title02":"Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3833-3843. doi: 10.1200\/JCO-25-01114","author":"Oak N, Chen W, Blake A, Harrison L, O'Brien M, Previti C, Balasubramanian G, Maass K, Hirsch S, Penkert J, Jones BC, Schramm K, Nathrath M, Pajtler KW, Jones DTW, Witt O, Dirksen U, Li J, Sapkota Y, Ness KK, Guenther LM, Pfister SM, Kratz C, Wang Z, Armstrong GT, Hudson MM, Wu G, Autry RJ, Nichols KE, Sharma R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066719"},{"title01":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","title02":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3775-3777. doi: 10.1200\/JCO-25-02200","author":"Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202195"},{"title01":"Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.","title02":"Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.","journal":"Br J Haematol","issue":"2025 December 23. doi: 10.1111\/bjh.70287. Online ahead of print","author":"Huguet M, Morgades M, Rivas-Delgado A, Bastos-Oreiro M, Cordoba R, Salar A, de la Cruz-Vicente F, Alcoceba M, Ferrer-Lores B, Jimenez-Ubieto A, Gutierrez A, Infante M, Huerga S, Abrisqueta P, Cruz D, Montalban C, Muntanola A, Villambrosia SG, Ribera JM, Navarro JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431425"},{"title01":"Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.","title02":"Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.","journal":"Br J Haematol","issue":"2025 December 26. doi: 10.1111\/bjh.70280. Online ahead of print","author":"Terao T, Yoshida I, Kobayashi H, Urata T, Fujii F, Meguri Y, Sugiura H, Yoshioka T, Saeki K, Niiya D, Asakura S, Nishimori H, Ikeda D, Fujiwara H, Ennishi D, Maeda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41451861"},{"title01":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","title02":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025018059. Online ahead of print","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.","title02":"Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.","journal":"Blood advances","issue":"2025 December 23; 9(24):6292-6304. doi: 10.1182\/bloodadvances.2024015787","author":"Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, Andre M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758949"},{"title01":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","title02":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025016765. Online ahead of print","author":"Li N, Liu Y, Zhang L, Guo S, Wu Z, Xu Y, Yang M, Kong J, Che Y, Shao K, Yang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428986"},{"title01":"Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.","title02":"Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.","journal":"Blood advances","issue":"2025 December 23; 9(24):6491-6501. doi: 10.1182\/bloodadvances.2025016117","author":"Dodero A, Ceparano G, Casadei B, Angelillo P, Bramanti S, Tisi MC, Ljevar S, Stella F, Chiappella A, Botto B, Cutini I, Zanirato G, Chiusolo P, Barbui AM, Farina M, Di Rocco A, Grillo G, Olivieri J, Krampera M, Ladetto M, Guidetti A, Zinzani PL, Carniti C, Corradini P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763273"},{"title01":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","title02":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018353. Online ahead of print","author":"Zeremski V, Aydilek E, Behringer A, Brunner F, Haage TR, Haenel M, Kos IA, Krueger WH, Lenz G, Lesan V, Schneider J, Schultze-Florey CR, Shumilov E, Weber T, Wulf GG, Vucinic V, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411524"},{"title01":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","title02":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 22. doi: 10.1038\/s41375-025-02829-7. Online ahead of print","author":"Dinh TTT, Lordo MR, Zhang AY, Goda C, Shilo N, Altynova E, Ruesch M, Kronen P, Broughton M, Jeremy E, Sellers VL, Zhang X, Larkin KT, Collins PL, Dorrance AM, Freud AG, Oakes CC, Mundy-Bosse BL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430399"},{"title01":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02842-w. Online ahead of print","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419608"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2025 December 17. doi: 10.1038\/s41375-025-02839-5. Online ahead of print","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","title02":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02835-9. Online ahead of print","author":"Fedenko A, Czapinska H, Kramer A, Stolzel F, Bochtler T, Bochtler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419603"},{"title01":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","title02":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","journal":"Leukemia","issue":"2025 December 23. doi: 10.1038\/s41375-025-02832-y. Online ahead of print","author":"Yang Y, Liu X, Wei J, Qin J, Tan Q, Ji J, Guo F, Zheng Y, Bi F, Liu M, Wang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436638"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","title02":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","journal":"Leukemia","issue":"2026 January; 40(1):29-36. doi: 10.1038\/s41375-025-02826-w","author":"Ernst P, Lohse C, Lauseker M, Geissler J, le Coutre P, Brummendorf TH, Saussele S, Burchert A, Franke GN, La Rosee P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419606"},{"title01":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","title02":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02816-y. Online ahead of print","author":"Ho TC, LaMere MW, Kawano H, Byun DK, LaMere EA, Chiu YC, Chen C, Wang LJ, Wang J, Ramdas B, Dokholyan NV, Calvi LM, Liesveld JL, Jordan CT, Singh RK, Kapur R, Becker MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419607"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","title02":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289048. Online ahead of print","author":"Naik A, Kataria B, Sharma V, Sharma A, Batra A, Bhatia K, Singh B, Chopra A, Rout D, Sagiraju H, Talukdar R, Tiwari S, Kumar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437831"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288906. Online ahead of print","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437825"},{"title01":"Two episodes of Ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","title02":"Two episodes of Ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288671. Online ahead of print","author":"Rubio-San-Simon A, Salzer E, Luesink M, Sonneveld E, Van der Sluis I, Pieters R, Hoogerbrugge PM, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437812"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","title02":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70286. Online ahead of print","author":"Kirk A, James B, Feltbower RG, Mushtaq T, Whitehead E, Kraft J, Motwani J, Parkin H, Guest J, Gray J, Palmer J, Pelling J, Appleby J, Ledwich N, Dondo TB, Amin N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410159"},{"title01":"The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.","title02":"The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 December 22. doi: 10.1111\/bjh.70276. Online ahead of print","author":"Yeung DT, Grigg AP, Reynolds J, Branford S, Mazumdar D, Cunningham I, Shortt J, Rowlings P, Harrup R, Ross DM, Kipp D, Mills AK, Arthur CK, Schwarer A, Jackson K, Viiala N, Weinkove R, Yong ASM, Gazdar SG, White D, Shanmuganathan N, Hughes T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431370"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.","title02":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70288. Online ahead of print","author":"Balduzzi A, Valsecchi MG, Tran TH, Zuna J, Leoni V, Cario G, Fazio G, Gandemer V, Tasian SK, van der Sluis IM, Peccatori N, Parasole R, Monterisi S, Loh ML, Devidas M, Hunger SP, Kairalla JA, De Lorenzo P, Silverman LB, Biondi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448829"},{"title01":"T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.","title02":"T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70293. Online ahead of print","author":"Andersson ML, Lind O, Heimersson K, Berglof A, Del Peso Santos T, Pena-Perez L, Wang Q, Mulder TA, Zain R, Mansson R, Rosenquist R, Smith CIE, Osterborg A, Palma M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449785"},{"title01":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","title02":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025018059. Online ahead of print","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia.","title02":"10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025017753. Online ahead of print","author":"Dreyzin A, Yates B, Shalabi HN, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411486"},{"title01":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","title02":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017795. Online ahead of print","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia.","title02":"USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6404-6409. doi: 10.1182\/bloodadvances.2025017219","author":"Illarregi U, Gutierrez-Camino A, Lopez-Almaraz R, Arzuaga-Mendez J, Ramirez-Orellana M, Ashcraft E, Sinnett D, Astigarraga I, Martin-Guerrero I, Lopez-Lopez E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845231"},{"title01":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","title02":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018342. Online ahead of print","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan SV, Dhakal B, D'Souza A, Lin DI, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","title02":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6575-6589. doi: 10.1182\/bloodadvances.2024015762","author":"Liu X, Wu J, Li X, Pan R, Liu L, Huang T, Ma L, Chen G, Wang Q, Zhang N, Tong X, Tan Y, Jiang H, Liang Y, Shen M, Li R, Yin W, Zhang X, Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920990"},{"title01":"Acalabrutinib treatment for older (aged >\/=80 years) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.","title02":"Acalabrutinib treatment for older (aged >\/=80 years) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.","journal":"Blood","issue":"2025 December 25; 146(26):3153-3162. doi: 10.1182\/blood.2025028550","author":"Simon F, Ligtvoet R, Bohn JP, Nosslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ullrich K, Gartner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart M, Decker T, Chakupurakal G, Schottker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink AM, Furstenau M, Fischer K, Goede V, Hallek M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906922"},{"title01":"Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.","title02":"Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024026928. Online ahead of print","author":"Nishimura K, Isobe T, Shigehiro T, Nomura M, Zang W, Xiao M, Liao W, Koike Y, Nishimura A, Sato-Otsubo A, Yamazaki H, Ito H, Okada S, Matsumoto N, Saika W, Zhang Y, Aoyama Y, Hasegawa C, Yamasaki T, Kubota Y, Oki K, Kiyokawa N, Nagae G, Yoshida K, Nannya Y, Ueno H, Fukuda S, Tatsuno K, Tsutsumi S, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Eguchi M, Arakawa Y, Koh K, Deguchi T, Tomizawa D, Miyamura T, Ishii E, Mizutani S, Miyano S, Aburatani H, Ogawa S, Takaori-Kondo A, Yokoyama A, Abdel-Wahab O, Ernst P, Takita J, Ikawa T, Takagi M, Inoue D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460961"},{"title01":"LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt\/beta-catenin vulnerability in T-ALL.","title02":"LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt\/beta-catenin vulnerability in T-ALL.","journal":"Blood","issue":"2025 December 18; 146(25):3036-3049. doi: 10.1182\/blood.2025030161","author":"Delafoy M, Bonnet MF, Lengline E, Cieslak A, Touzart A, Balducci E, Simonin M, Lheritier V, Dourthe ME, Heid-Picard B, Latour S, Dombret H, Rousselot P, Baruchel A, Boissel N, Andrieu GP, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857670"},{"title01":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC.","title02":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC.","journal":"Br J Haematol","issue":"2025 December 14. doi: 10.1111\/bjh.70262. Online ahead of print","author":"Villaboni S, Stuart-Smith S, De Kreuk A, Rees DC, Brewin JN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41392388"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","title02":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70284. Online ahead of print","author":"Jin H, Guo Z, Zhu L, Huang F, Wu Y, Qiu H, Wang Y, Gong Y, He G, Fan L, Shi Z, Shen W, Qiao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41386566"},{"title01":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","title02":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70272. Online ahead of print","author":"Voso MT, de Botton S, Pfeilstocker M, Alvarez AF, Wang K, See WL, Guerrero MU, de Menezes DL, Petrlik E, Prebet T, Roboz GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387169"},{"title01":"Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.","title02":"Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.","journal":"Br J Haematol","issue":"2025 December 14. doi: 10.1111\/bjh.70285. Online ahead of print","author":"Bergonzi GM, Cozzo E, Tomelleri A, Piccolo C, Scorpio G, Gurnari C, Romano F, Matucci-Cerinic M, Dagna L, Bernardi M, Vago L, Ciceri F, Campochiaro C, Diral E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41392421"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017089. Online ahead of print","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","title02":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017005. Online ahead of print","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AY, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study.","title02":"Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study.","journal":"Leukemia","issue":"2025 December; 39(12):3052-3053. doi: 10.1038\/s41375-025-02807-z","author":"Xu F, Li Z, Fu H, Ma J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214138"},{"title01":"Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.","title02":"Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.","journal":"Blood advances","issue":"2025 December 9; 9(23):6189-6198. doi: 10.1182\/bloodadvances.2025017016","author":"Davidsen ID, Larsen MK, Loffler L, Skov V, Kjaer L, Knudsen TA, Sorensen AL, Christensen SF, Cordua S, Eickhardt-Dalboge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966426"},{"title01":"Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.","title02":"Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025018011. Online ahead of print","author":"Barbui T, Scandura JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370203"},{"title01":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","title02":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031454. Online ahead of print","author":"Lu M, Mia MB, Xia L, Mosoyan G, Hayat M, Schaniel C, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397284"},{"title01":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","title02":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2025 December 9. doi: 10.1056\/NEJMoa2515168. Online ahead of print","author":"Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Cervinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363800"},{"title01":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via upregulating the PKA\/Orai1\/ERK1\/2 pathway.","title02":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via upregulating the PKA\/Orai1\/ERK1\/2 pathway.","journal":"Haematologica","issue":"2025 December 1; 110(12):2997-3008. doi: 10.3324\/haematol.2024.287287","author":"Zhou M, Han H, Qi J, Zhang Z, Song X, Li X, Chu T, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534501"},{"title01":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.","title02":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.","journal":"Haematologica","issue":"2025 December 1; 110(12):3094-3098. doi: 10.3324\/haematol.2025.287408","author":"Moulis G, Chen F, Carli G, Ghanima W, Trautmann-Grill K, Stauch T, Schifferli A, Miah H, Rueter M, Ghiotto L, Tomasello R, Georgi A, McDonald V, Zaja F, Pettersen HH, Kuhne T, Lozano ML, Gonzalez-Lopez TJ, Provan D, Michel M, Cooper N, Rodeghiero F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568720"},{"title01":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes.","title02":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.288832. Online ahead of print","author":"Zhang N, Uzun G, Bakchoul T, Curtis BR, Newman PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376564"},{"title01":"Longitudinal plasma proteomics in romiplostim-treated patients with immune thrombocytopenia.","title02":"Longitudinal plasma proteomics in romiplostim-treated patients with immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 December 9. doi: 10.1111\/bjh.70279. Online ahead of print","author":"Nelson VS, Smit ER, de Haas M, Schipperus MR, van den Biggelaar M, Kapur R, Munoz Sandoval D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41362951"},{"title01":"Are there long-term effects of combination therapy for newly diagnosed adults with ITP?","title02":"Are there long-term effects of combination therapy for newly diagnosed adults with ITP?","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70255. Online ahead of print","author":"Peko GA, Bussel JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387255"},{"title01":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","title02":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025031449. Online ahead of print","author":"Leaf RK, Mones JV, Shenoy T, Warsame M, Beltrami-Moreira M, Panch S, Leavitt AD, Zon RL, Kendall EK, Shahamatdar S, Lim TL, Cui C, Jiang D, Kaunfer SA, Durai L, Hoge ST, Dias JA, Sha C, Holmes A, Easton N, Corley E, Zhao E, Li X, Spelman A, Amos CB, Soebbing DR, Shabih M, Jamison T, Liu B, Hussein G, Yadav SK, Elsaid MI, Owen DH, Mera A, Juras PK, Suresh A, Heskel MJ, Huang JJ, Glezerman I, Go RS, Reynolds K, Al-Samkari H, Kroll MH, Leaf DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359796"},{"title01":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","title02":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e956-e965. doi: 10.1016\/S2352-3026(25)00293-5","author":"Scordo M, Perales MA, Mauguen A, Lin A, Kunvarjee B, Paes Pena M, Mcavoy D, Nguyen LK, Hogan M, Chapman N, Bieler J, Cho C, Gyurkocza B, Harris AC, Spitzer B, O'Reilly RJ, Jakubowski AA, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Shaffer BC, Shah GL, Tamari R, Giralt SA, Boelens JJ, Curran KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338864"},{"title01":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","title02":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3639-3645. doi: 10.1200\/JCO-25-00809","author":"Mohty M, Socie G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kroger N, Stolzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092247"},{"title01":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","title02":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288736. Online ahead of print","author":"Zhao D, Nguyen LXT, Gong X, Chen F, Zhao X, Chen MH, Marcucci G, Zhang B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342184"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","title02":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300013. Online ahead of print","author":"Dhedin N, Bruno B, Paillard C, Gounfle E, Buchbinder N, Chardin MO, Gaba M, Arlet JB, Arnaud C, Jung C, Pondarre C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376570"},{"title01":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.","title02":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.","journal":"Haematologica","issue":"2025 December 1; 110(12):3164-3167. doi: 10.3324\/haematol.2025.288098","author":"Quigg TC, Kurt BA, Seaver LH, Holsworth AR, Duffner UA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874332"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","journal":"Haematologica","issue":"2025 December 1; 110(12):3150-3153. doi: 10.3324\/haematol.2025.288067","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","title02":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","journal":"Br J Haematol","issue":"2025 December 5. doi: 10.1111\/bjh.70269. Online ahead of print","author":"Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346275"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","title02":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017393. Online ahead of print","author":"Nishitani M, Graham RT, Wang T, DeVos JD, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","title02":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017838. Online ahead of print","author":"Murray JD, Einhaus TK, Radtke S, Bar KJ, Peterson CW, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324589"},{"title01":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","title02":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","journal":"Blood advances","issue":"2025 December 9; 9(23):6141-6157. doi: 10.1182\/bloodadvances.2025016915","author":"Hammoudi T, Nucera S, Troullioud Lucas AG, Ansari M, Balduzzi A, Bertaina A, Buechner J, Corbacioglu S, Dalle JH, Kalwak K, Lee D, Levine JE, Lindemans CA, Locatelli F, Meisel R, Nierkens S, Ottaviano G, Perez-Martinez A, Pichler H, Prockop SE, Pulsipher MA, Talano JM, Tewari S, Schultz KR, Shah NN, Verneris MR, Boelens JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902074"},{"title01":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","title02":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","journal":"Blood advances","issue":"2025 December 9; 9(23):5965-5975. doi: 10.1182\/bloodadvances.2024013727","author":"Djassemi N, Hanisch B, Motta C, Maghzian N, Vatsayan A, Durkee-Shock JR, Keller MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864193"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","title02":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","journal":"Blood","issue":"2025 December 11; 146(24):2914-2930. doi: 10.1182\/blood.2024026815","author":"Martinez TC, Jotte MRM, Khan S, Stoddart A, Blaylock H, Malik A, McNerney ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920873"},{"title01":"Platelet factor 4 regulates hematopoietic stem cell aging.","title02":"Platelet factor 4 regulates hematopoietic stem cell aging.","journal":"Blood","issue":"2025 December 4; 146(23):2765-2778. doi: 10.1182\/blood.2024027432","author":"Zhang S, Ayemoba CE, Di Staulo AM, Joves K, Patel CM, Leung EHW, Bueno MLP, Du X, Poncz M, Ong SG, Nerlov C, Maryanovich M, Chronis C, Pinho S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920871"},{"title01":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","title02":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","journal":"Blood","issue":"2025 December 4; 146(23):2779-2793. doi: 10.1182\/blood.2024028194","author":"Venkatesh H, Granados Centeno E, Luo Q, Arroyo M, Heltemes-Harris L, Knutson TP, Qiu Y, Haaning A, Webber BR, Bachanova V, Farrar MA, Tracy SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906918"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","title02":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031480. Online ahead of print","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","title02":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025032084. Online ahead of print","author":"Liu X, Zhang Z, Cui X, Guo R, Ding X, Ma L, Liu P, Yu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397285"},{"title01":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","title02":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","journal":"Lancet Oncol","issue":"2025 December; 26(12):1626-1637. doi: 10.1016\/S1470-2045(25)00605-9","author":"Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouche O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202834"},{"title01":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.","title02":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2025 December; 26(12):1563-1574. doi: 10.1016\/S1470-2045(25)00523-6","author":"Li H, Liu J, Ouyang Q, Wang S, Liu Y, Teng Y, Wang X, Cheng J, Tong Z, Sun T, Yan M, Zhou X, Li F, Nie J, Shao ZM, Ye C, Wang Y, Wu X, Li Z, Wu Y, Xiong H, Li H, Gan L, Niu Z, Zhang J, Zhang Q, Pan Y, Wu X, Zhang Y, Xie W, Xiao Y, Gao J, Zhao H, Yin Y, Qian Z, Sun S, Zhang H, Wang K, Lu J, Li Y, Wang X, Yang X, Wang Y, Wang Q, Song E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41308673"},{"title01":"Menstrual blood loss reduction to control anaemia (and more).","title02":"Menstrual blood loss reduction to control anaemia (and more).","journal":"Lancet Haematol","issue":"2025 December; 12(12):e929-e930. doi: 10.1016\/S2352-3026(25)00317-5","author":"van Zutphen KG, Askari S, Verhoef H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338859"},{"title01":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","title02":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","journal":"Lancet Haematol","issue":"2025 December 6. doi: 10.1016\/S2352-3026(25)00291-1. Online ahead of print","author":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41365312"},{"title01":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","title02":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3714-3727. doi: 10.1200\/JCO-25-00872","author":"Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouche O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187298"},{"title01":"Efficacy and safety of luspatercept in non-transfusion-dependent beta-thalassemia: long-term results from the BEYOND study.","title02":"Efficacy and safety of luspatercept in non-transfusion-dependent beta-thalassemia: long-term results from the BEYOND study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6108-6119. doi: 10.1182\/bloodadvances.2025016554","author":"Taher AT, Viprakasit V, Kattamis A, Perrotta S, Ricchi P, Porter JB, Coates TD, Forni GL, Musallam KM, Esposito O, Pilot R, Kuo WL, Lai Y, Reverte M, Wei R, Bueno LM, Cappellini MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875596"},{"title01":"Regional Brain Age is Decreased in Children with Sickle Cell Anemia.","title02":"Regional Brain Age is Decreased in Children with Sickle Cell Anemia.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017172. Online ahead of print","author":"Mirro AE, Power LC, Wang J, Germino-Watnick P, Roberts H, Cam Y, Guilliams K, Fellah S, Chen Y, An H, Lee JM, Ford AL, Fields ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324590"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation.","title02":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation.","journal":"Blood","issue":"2025 December 11; 146(24):2863-2869. doi: 10.1182\/blood.2025028370","author":"Falabregue M, Aurrand C, Cazaulon L, Boussetta N, Zumerle S, Djebrani-Oussedik N, Poupon J, Guilmeau S, Karim Z, Dupe E, Aucouturier A, Langella P, Bermudez-Humaran LG, Vaulont S, Peyssonnaux C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40925095"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2025 December 3. doi: 10.1038\/s41375-025-02814-0. Online ahead of print","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","title02":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","journal":"Leukemia","issue":"2025 December; 39(12):2907-2915. doi: 10.1038\/s41375-025-02767-4","author":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954213"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","title02":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","journal":"Leukemia","issue":"2025 December; 39(12):3026-3036. doi: 10.1038\/s41375-025-02756-7","author":"Mazzeo P, Penir SM, Shumilov E, Wolf S, Haupl B, Markus K, Shirneshan K, Rittscher K, Brzuszkiewicz E, Aydilek E, Treiber H, Oellerich T, Ganster C, Haase D, Koch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973765"},{"title01":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.","title02":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.","journal":"Leukemia","issue":"2025 December; 39(12):2872-2880. doi: 10.1038\/s41375-025-02775-4","author":"Sakuma M, Wang AK, Magaziner SJ, Keane SP, Meggendorfer M, Kern W, Haferlach C, Haferlach T, Beck DB, Walter W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41068485"},{"title01":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","title02":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3760-3768. doi: 10.1200\/JCO-25-01369","author":"Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, Green F, Zheng N, Wang Y, Liu J, Blanco JG, Dorff SE, Booth B, Choe M, Gehrke B, Bhatnagar V, Theoret M, Pazdur R, De Claro RA, Norsworthy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135032"},{"title01":"PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.","title02":"PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.","journal":"Haematologica","issue":"2025 December 1; 110(12):3125-3128. doi: 10.3324\/haematol.2025.287874","author":"Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605709"},{"title01":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","title02":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","journal":"Haematologica","issue":"2025 December 1; 110(12):3009-3021. doi: 10.3324\/haematol.2024.287091","author":"Feng J, Gou J, Wang Y, Wei W, Ma Y, Ren X, Zhao C, Cheng X, Lei L, Tan Z, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400458"},{"title01":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","title02":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6009-6018. doi: 10.1182\/bloodadvances.2025016966","author":"Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson L, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875887"},{"title01":"mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.","title02":"mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.","journal":"Blood advances","issue":"2025 December 9; 9(23):6175-6188. doi: 10.1182\/bloodadvances.2025016439","author":"Fulton-Ward T, Gudgeon N, Thirlwell I, Bishop EL, Marzullo B, Giles H, McIlroy G, Ferguson P, Kishore B, Rogers K, Alfasi N, Wong T, Aytain S, Tennant DA, Pratt G, Dimeloe S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938732"},{"title01":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.","title02":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.","journal":"Blood","issue":"2025 December 11; 146(24):2931-2944. doi: 10.1182\/blood.2024027496","author":"Navarro F, Lozano T, Fuentes-Garcia A, Sanchez-Moreno I, Larrayoz M, Justicia P, Perucha B, Martinez-Tabar M, Martinez-Turrillas R, Casares N, Martin-Otal C, Gorraiz M, Meermeier EW, Chesi M, Lake D, Bergsagel PL, Santamaria E, Calleja-Cervantes ME, San Martin-Uriz P, Jordana-Urriza L, Agirre X, Hervas-Stubbs S, Rodriguez-Madoz JR, Martinez-Climent JA, Prosper F, Lasarte JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971494"},{"title01":"Glu(tamine)ing together myeloma metabolism and CAR T efficacy.","title02":"Glu(tamine)ing together myeloma metabolism and CAR T efficacy.","journal":"Blood","issue":"2025 December 11; 146(24):2854-2855. doi: 10.1182\/blood.2025031096","author":"Wiita AP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379496"},{"title01":"Evolution of Multiple Myeloma from a Genomic Perspective.","title02":"Evolution of Multiple Myeloma from a Genomic Perspective.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2024026313. Online ahead of print","author":"Maura F, Samur MK, Munshi NC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359792"},{"title01":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.","title02":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.","journal":"Blood","issue":"2025 December 11; 146(24):2945-2962. doi: 10.1182\/blood.2025028441","author":"Bruno T, Cappelletto MC, Cortile C, Di Giovenale S, Amadio B, De Nicola F, Falcone I, Giuliani S, Palermo B, Catena V, Ciuffreda L, Cerruti F, Cascio P, Merola R, Masi S, De Pascale V, Annibali O, Ferraro S, Gumenyuk S, Pisani F, Marchesi F, Mengarelli A, Fanciulli M, Corleone G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920573"},{"title01":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.","title02":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.","journal":"Blood","issue":"2025 December 4. doi: 10.1182\/blood.2025031629. Online ahead of print","author":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M Dr, Theodorakakou F, Spiliopoulou V, Solia I, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346230"},{"title01":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.","title02":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.","journal":"Blood","issue":"2025 December 11; 146(24):2902-2913. doi: 10.1182\/blood.2025029360","author":"Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosinol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wasch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983036"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia.","title02":"Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia.","journal":"Leukemia","issue":"2025 December; 39(12):2978-2987. doi: 10.1038\/s41375-025-02720-5","author":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, Gough O, Schambach A, Sauer M, Heuser M, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034424"},{"title01":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure.","title02":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure.","journal":"Leukemia","issue":"2025 December; 39(12):3037-3041. doi: 10.1038\/s41375-025-02783-4","author":"Saul D, Lischer C, Bruns H, Ziegler N, Kannt A, Michel M, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41094011"},{"title01":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","title02":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300013. Online ahead of print","author":"Dhedin N, Bruno B, Paillard C, Gounfle E, Buchbinder N, Chardin MO, Gaba M, Arlet JB, Arnaud C, Jung C, Pondarre C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376570"},{"title01":"Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.","title02":"Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):2965-2973. doi: 10.3324\/haematol.2025.287504","author":"Xu ZL, Han TT, Zhu XL, Liu J, Lv M, Sun YQ, Mo XD, Cheng YF, Xu LP, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534493"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","title02":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","journal":"Br J Haematol","issue":"2025 December 5. doi: 10.1111\/bjh.70269. Online ahead of print","author":"Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346275"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","title02":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","journal":"Blood advances","issue":"2025 December 9; 9(23):6141-6157. doi: 10.1182\/bloodadvances.2025016915","author":"Hammoudi T, Nucera S, Troullioud Lucas AG, Ansari M, Balduzzi A, Bertaina A, Buechner J, Corbacioglu S, Dalle JH, Kalwak K, Lee D, Levine JE, Lindemans CA, Locatelli F, Meisel R, Nierkens S, Ottaviano G, Perez-Martinez A, Pichler H, Prockop SE, Pulsipher MA, Talano JM, Tewari S, Schultz KR, Shah NN, Verneris MR, Boelens JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902074"},{"title01":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","title02":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","journal":"Blood advances","issue":"2025 December 9; 9(23):5965-5975. doi: 10.1182\/bloodadvances.2024013727","author":"Djassemi N, Hanisch B, Motta C, Maghzian N, Vatsayan A, Durkee-Shock JR, Keller MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864193"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025018178. Online ahead of print","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque T, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss I, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","title02":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017393. Online ahead of print","author":"Nishitani M, Graham RT, Wang T, DeVos JD, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"How I Treat Advanced Phases of CML.","title02":"How I Treat Advanced Phases of CML.","journal":"Blood","issue":"2025 December 2. doi: 10.1182\/blood.2024026510. Online ahead of print","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","title02":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","journal":"N Engl J Med","issue":"2025 December 7. doi: 10.1056\/NEJMoa2509807. Online ahead of print","author":"Gori JL, Haddad E, Frangoul H, Kohn DB, Morris EC, Martin BN, Deary BA, Nickerson M, Scholz RL, Fernandez I, Leveille K, De Ravin SS, Kang EM, Pierzynski M, Estwick T, Littel P, Kuhns DB, Long Priel DA, Teira P, Turvey S, Arnold J, Evans MD, McManus M, Carpenter B, Waterman DP, Anzalone AV, Petrusich A, Osuna CE, O'Malley TT, Stewart-Ornstein J, Heath JM, Nehilla BJ, Asmal M, Malech HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358590"},{"title01":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","title02":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","journal":"Leukemia","issue":"2025 December; 39(12):2916-2925. doi: 10.1038\/s41375-025-02745-w","author":"Karakaslar EO, Argiro EM, Struckman NE, Shirali Hz R, Severens JF, Honders MW, Kloet SL, Veelken H, Reinders MJ, Griffioen M, van den Akker EB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954214"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.","title02":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.","journal":"Leukemia","issue":"2025 December; 39(12):2862-2865. doi: 10.1038\/s41375-025-02754-9","author":"Salit RB, Hexner EO, Gagelmann N, Kroger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083679"},{"title01":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2025 December; 39(12):2935-2945. doi: 10.1038\/s41375-025-02768-3","author":"Setiawan T, Muhammad JA, Marcellina N, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034423"},{"title01":"Medical tourism for cellular therapy: a clinical perspective.","title02":"Medical tourism for cellular therapy: a clinical perspective.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e978-e985. doi: 10.1016\/S2352-3026(25)00294-7","author":"Esther CHL, Fan EB, Hew YY, Poon LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338866"},{"title01":"Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report.","title02":"Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017662. Online ahead of print","author":"Alexander JL, Davila Saldana BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing J, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JM, Rayes A, Madden LM, Shereck EB, Miller HK, Forbes Satter LR, Martinez CA, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen AP, Chong H, Chopek A, Gillio AP, Joshi A, Rangarajan HG, Moore TB, Andolina JR, DeSantes K, Vander Lugt MT, Prockop SE, Shyr D, Sullivan KE, Parikh SH, Weinacht KG, Torgerson TR, Marsh RA, Dvorak CC, Chan AY, Haddad E, Heimall J, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346295"},{"title01":"Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","title02":"Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","journal":"Blood advances","issue":"2025 December 3. doi: 10.1182\/bloodadvances.2025018079. Online ahead of print","author":"Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Beguelin W, Casulo C, Cerhan JR, Green MR, Kahl BS, Kridel R, Link BK, Maurer MJ, Nadel B, Radtke A, Luttwak E, Salles GA, Sehn LH, Pasqualucci L, LaCasce AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337699"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.","title02":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2025 December 9; 9(23):5976-5987. doi: 10.1182\/bloodadvances.2024015282","author":"Iyer S, Mehta-Shah N, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Alpdogan O, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829107"},{"title01":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study.","title02":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study.","journal":"Blood advances","issue":"2025 December 9; 9(23):5954-5964. doi: 10.1182\/bloodadvances.2024014975","author":"Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845254"},{"title01":"Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP.","title02":"Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP.","journal":"Blood advances","issue":"2025 December 8. doi: 10.1182\/bloodadvances.2025016931. Online ahead of print","author":"Cetin O, Kos IA, Regitz E, Bewarder M, Rixecker TM, Tausch E, Schwarz EC, Jansky J, Lesan V, Schormann C, Neumann F, Loeffler M, Hallek MJ, Fischer K, Zophel S, Staiger AM, Ott G, Christofyllakis K, Bittenbring JT, Poeschel V, Kaddu-Mulindwa D, Staber PB, Ligtvoet R, Robrecht S, Ziepert M, Schmitz N, Hoth M, Kessel C, Stilgenbauer S, Altmann B, Thurner L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358738"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.","title02":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2758-2764. doi: 10.1182\/blood.2025028823","author":"Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka A, Ferreri AJM, Merli F, Zhao W, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fossa A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens K, Ielmini N, De Martino I, Walewski J, Trneny M, Cavalli F, Ricardi U, Johnson PWM, Davies A, Martelli M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40939190"},{"title01":"Sweet stuff is dangerous in DLBCL.","title02":"Sweet stuff is dangerous in DLBCL.","journal":"Blood","issue":"2025 December 4; 146(23):2739-2741. doi: 10.1182\/blood.2025031082","author":"Fend F, Quintanilla-Martinez L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343169"},{"title01":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","title02":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","journal":"N Engl J Med","issue":"2025 December 9. doi: 10.1056\/NEJMoa2514663. Online ahead of print","author":"Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363801"},{"title01":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","title02":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","journal":"N Engl J Med","issue":"2025 December 7. doi: 10.1056\/NEJMoa2514752. Online ahead of print","author":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358582"},{"title01":"Measurable residual disease assessment in multiple myeloma.","title02":"Measurable residual disease assessment in multiple myeloma.","journal":"Leukemia","issue":"2025 December 5. doi: 10.1038\/s41375-025-02830-0. Online ahead of print","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41350429"},{"title01":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.","title02":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.","journal":"Leukemia","issue":"2025 December; 39(12):2997-3003. doi: 10.1038\/s41375-025-02762-9","author":"Andersen LS, Navarro RB, Ekberg S, Rognvaldsson S, Levy MR, Sverrisdottir IS, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Thornorethardottir AR, Eythornorsson E, Jonsson A, Olafsson A, Durie BGM, Harding S, Landgren O, Love TJ, Kristinsson SY, Thorsteinsdottir S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40940581"},{"title01":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.","title02":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.","journal":"Leukemia","issue":"2025 December; 39(12):3004-3014. doi: 10.1038\/s41375-025-02766-5","author":"Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973768"},{"title01":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.","title02":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.","journal":"Leukemia","issue":"2025 December; 39(12):2866-2871. doi: 10.1038\/s41375-025-02776-3","author":"Zanwar S, Belge Bilgin G, Broski SM, Thorpe M, Bilgin C, Gonsalves W, Kapoor P, Kourelis T, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Leung N, Lin Y, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016943"},{"title01":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","title02":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","journal":"J Clin Oncol","issue":"2025 December 12; JCO2502305. doi: 10.1200\/JCO-25-02305. Online ahead of print","author":"Saldarriaga MM, Bellman P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385751"},{"title01":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","title02":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","journal":"J Clin Oncol","issue":"2025 December 11; JCO2500289. doi: 10.1200\/JCO-25-00289. Online ahead of print","author":"Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380103"},{"title01":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","title02":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","journal":"J Clin Oncol","issue":"2025 December 10; JCO2500924. doi: 10.1200\/JCO-25-00924. Online ahead of print","author":"Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370738"},{"title01":"A Fighter Bigger Than Myeloma.","title02":"A Fighter Bigger Than Myeloma.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3684-3685. doi: 10.1200\/JCO-25-00932","author":"Khan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41086373"},{"title01":"Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.","title02":"Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289245. Online ahead of print","author":"Besse A, Kraus M, Totu T, Buljan M, Janssen APA, Van der Stelt M, Matisikova K, Veprkova J, Sedlarikova L, Jurinakova T, Truger M, Haferlach C, Lopez MM, Kortum MK, Rasche L, Driessen C, Besse L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376558"},{"title01":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","title02":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288863. Online ahead of print","author":"Herzberg F, Korenkov M, Isaakidis K, Zang C, Wirth M, Muller S, Keller U, Demel UM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342169"},{"title01":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma.","title02":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3104-3108. doi: 10.3324\/haematol.2025.287563","author":"Feliciani G, Loi E, Amadori E, Antognoni E, Iamurri AP, Diano D, Bruno D, Cattabriga A, Caroli P, Marchesini M, Bezzi D, Cangini D, Matteucci F, Barone D, Nappi D, Musuraca G, Ceccolini M, Ronconi S, Azzali I, Martinelli G, Maffioli LS, Normanno N, Sarnelli A, Rossi A, Cerchione C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534490"},{"title01":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era.","title02":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era.","journal":"Haematologica","issue":"2025 December 1; 110(12):3053-3064. doi: 10.3324\/haematol.2025.287545","author":"Broughton M, Bhatta S, Sonali D, Bumma N, Khan AM, Devarakonda S, Umyarova E, Benson D, Rosko A, Cottini F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501390"},{"title01":"Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.","title02":"Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):3168-3170. doi: 10.3324\/haematol.2025.288359","author":"Rees MJ, Quach H, Jardine D, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820805"},{"title01":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma.","title02":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3133-3139. doi: 10.3324\/haematol.2025.288008","author":"Palacios JA, Bernal M, Vilchez JR, Garrido P, Jimenez P, Gutierrez-Bautista JF, Barrera-Aguilera MC, Ballesta L, Rodriguez T, Olivares-Duran MJ, Ruiz-Cabello F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534500"},{"title01":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.","title02":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3065-3077. doi: 10.3324\/haematol.2025.287985","author":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, Kwok M, Cicero KI, Hirayama AV, Basom R, Khouderchah C, Shadman M, Fong L, Cowan AJ, Gauthier J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534492"},{"title01":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","title02":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025018133. Online ahead of print","author":"Fang B, Zhu Z, Chang Y, He X, Li S, Li M, Yan S, Zhu D, Li Z, Mao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385406"},{"title01":"Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma.","title02":"Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017939. Online ahead of print","author":"Patel H, Hubbeling H, Yu KL, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385343"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018021. Online ahead of print","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380108"},{"title01":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","title02":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018454. Online ahead of print","author":"Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Perez-Montana A, Casanova M, Brena Atienza J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernandez R, Alvarez Rivas MA, Capote FJ, Garcia-Sanchez R, Perez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380099"},{"title01":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma.","title02":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017676. Online ahead of print","author":"Chong PS, Lim SJ, Tan TZ, Kong LR, De Mel S, Yong ALC, Gim Seng EY, Chng WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324599"},{"title01":"Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.","title02":"Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.","journal":"Blood advances","issue":"2025 December 9; 9(23):6001-6008. doi: 10.1182\/bloodadvances.2025016625","author":"Systchenko T, Nsiala L, Bobin A, Gardeney H, Motard C, Olivier G, Borde F, Corby A, Roul C, Fleck E, Denis G, Dieval C, Mottaz P, Boscagli A, Defossez G, Leleu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864187"},{"title01":"Medical tourism for cellular therapy: a clinical perspective.","title02":"Medical tourism for cellular therapy: a clinical perspective.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e978-e985. doi: 10.1016\/S2352-3026(25)00294-7","author":"Esther CHL, Fan EB, Hew YY, Poon LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338866"},{"title01":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","title02":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e956-e965. doi: 10.1016\/S2352-3026(25)00293-5","author":"Scordo M, Perales MA, Mauguen A, Lin A, Kunvarjee B, Paes Pena M, Mcavoy D, Nguyen LK, Hogan M, Chapman N, Bieler J, Cho C, Gyurkocza B, Harris AC, Spitzer B, O'Reilly RJ, Jakubowski AA, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Shaffer BC, Shah GL, Tamari R, Giralt SA, Boelens JJ, Curran KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338864"},{"title01":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","title02":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3639-3645. doi: 10.1200\/JCO-25-00809","author":"Mohty M, Socie G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kroger N, Stolzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092247"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","journal":"Haematologica","issue":"2025 December 1; 110(12):3150-3153. doi: 10.3324\/haematol.2025.288067","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"A new standard for relapsed or refractory follicular lymphoma.","title02":"A new standard for relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2025 December 5. doi: 10.1016\/S0140-6736(25)01965-8. Online ahead of print","author":"Harel R, Cohen JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360063"},{"title01":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","title02":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 2; JCO2500892. doi: 10.1200\/JCO-25-00892. Online ahead of print","author":"Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquieres H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janikova A, Mocikova H, Furst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329901"},{"title01":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","title02":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","journal":"J Clin Oncol","issue":"2025 December 10; JCO2502323. doi: 10.1200\/JCO-25-02323. Online ahead of print","author":"Pophali PA, Kenkre VP, Hayes CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370745"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502380. doi: 10.1200\/JCO-25-02380. Online ahead of print","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 7; JCO2502477. doi: 10.1200\/JCO-25-02477. Online ahead of print","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","title02":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","journal":"J Clin Oncol","issue":"2025 December; 43(34):3631-3635. doi: 10.1200\/JCO-25-01932","author":"Rossi D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056509"},{"title01":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3698-3705. doi: 10.1200\/JCO-25-00925","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991874"},{"title01":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","title02":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 12; JCO2501712. doi: 10.1200\/JCO-25-01712. Online ahead of print","author":"Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385760"},{"title01":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.","title02":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3652-3661. doi: 10.1200\/JCO-25-01534","author":"Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40802906"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","journal":"Haematologica","issue":"2025 December 1; 110(12):2895-2901. doi: 10.3324\/haematol.2025.288114","author":"Ghione P, Zinzani PL, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","title02":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","journal":"Haematologica","issue":"2025 December 1; 110(12):2913-2929. doi: 10.3324\/haematol.2024.286744","author":"Curran E, Luskin MR, Alachkar H, Aldoss I, Burke PW, Cassaday RD, Karol SE, Perissinotti AJ, Rank CU, Schmiegelow K, Webster J, Douer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40109190"},{"title01":"Erratum to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”.","title02":"Erratum to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”.","journal":"Haematologica","issue":"2025 December 1; 110(12):3180-3181. doi: 10.3324\/haematol.2025.288659","author":"Schmidt C, Scheubeck G, Jurinovic V, Sokler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hanel M, Liersch R, Durig J, Pott C, Hoster E, Unterhalt M, Hiddemann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321264"},{"title01":"Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma – a retrospective multicentre clinical study.","title02":"Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma – a retrospective multicentre clinical study.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287982. Online ahead of print","author":"Kama K, Treiber H, Kutilina A, Trefz S, Wollnitza S, Shumilov E, Finke J, Lenz G, Wulf G, Isbell LK, Aksoy A, Jensch A, Illerhaus G, Wendler J, Schorb E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376557"},{"title01":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.","title02":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.","journal":"Haematologica","issue":"2025 December 1; 110(12):3022-3031. doi: 10.3324\/haematol.2024.287162","author":"Schmidt C, Scheubeck G, Jurinovic V, Sokler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hanel M, Liersch R, Durig J, Pott C, Hoster E, Unterhalt M, Hiddemann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501414"},{"title01":"The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.","title02":"The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70277. Online ahead of print","author":"Picardi M, Vincenzi A, Pugliese N, Giordano C, Mascolo M, Vigliar E, Troncone G, Zeppa P, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332285"},{"title01":"A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.","title02":"A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.","journal":"Br J Haematol","issue":"2025 December 8. doi: 10.1111\/bjh.70273. Online ahead of print","author":"Zadro A, Arribas A, Colombo MV, Cannas E, Spriano F, Cascione L, Mensah AA, Simonetta F, Petta D, Candrian C, Arrigoni C, Bertoni F, Moretti M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41362022"},{"title01":"Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.","title02":"Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018527. Online ahead of print","author":"Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov AV, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun A, Ayyappan SR, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz J, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta AN, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar M, Anna JL, Stanisic A, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380101"},{"title01":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.","title02":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2025 December 9; 9(23):6063-6075. doi: 10.1182\/bloodadvances.2025016291","author":"van Besien H, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard J, Barker J, Martin P, Yamshon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40590871"},{"title01":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","title02":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025016646. Online ahead of print","author":"Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej RM, Bressel M, Di Iulio JL, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380113"},{"title01":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B cell lymphoma.","title02":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B cell lymphoma.","journal":"Blood advances","issue":"2025 December 9. doi: 10.1182\/bloodadvances.2025016858. Online ahead of print","author":"Yoon SE, Kang W, Cho J, Cho HJ, Chalita M, Oh HS, Hyun DW, Han S, Kim H, Sung H, Lee JY, Park B, Ryu KJ, Kim HY, Cho D, Kim WS, Kim SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364878"},{"title01":"Pharma steps back from Hodgkin lymphoma: now what?","title02":"Pharma steps back from Hodgkin lymphoma: now what?","journal":"Blood advances","issue":"2025 December 9; 9(23):6218-6219. doi: 10.1182\/bloodadvances.2025017650","author":"Lynch RC, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364449"},{"title01":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL.","title02":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL.","journal":"Blood advances","issue":"2025 December 9; 9(23):6130-6140. doi: 10.1182\/bloodadvances.2025016332","author":"Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902079"},{"title01":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","title02":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","journal":"Blood advances","issue":"2025 December 8. doi: 10.1182\/bloodadvances.2025016492. Online ahead of print","author":"Galtier J, Peanne R, Le Morvan V, Blondy T, Melane M, Bidon A, Chopin A, Prochazkova-Carlotti M, Poglio S, Merlio JP, Chevret E, Gros A, Pham-Ledard A, Beylot-Barry M, Bresson-Bepoldin L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358745"},{"title01":"NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma.","title02":"NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2025 December 9; 9(23):6092-6095. doi: 10.1182\/bloodadvances.2025016423","author":"Ahmed S, DiPersio J, Essell J, Diefenbach C, Perales MA, Castilla-Llorente C, Dahiya S, Liu Y, Xu H, Fanton C, Chaudhry S, Lee ZH, Marcondes AMQ, Tagliaferri MA, Zalevsky J, Miklos D, Turtle CJ, McGuirk J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779552"},{"title01":"Inclusion, characteristics and reporting of older patients in recent registration trials for DLBCL: A systematic review.","title02":"Inclusion, characteristics and reporting of older patients in recent registration trials for DLBCL: A systematic review.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025017530. Online ahead of print","author":"Neuendorff NR, Pugh K, Juthani R, Soudant C, Eochagain CM, Torka P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351516"},{"title01":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","title02":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017643. Online ahead of print","author":"Kong X, Xu-Monette ZY, Xu Z, Hsi E, Zhao X, Yan H, Nunns H, Au K, Visco C, Tzankov A, Dybkaer K, Yao S, Wu D, Wang C, Xu AM, Pan Z, Parsons BM, Chiu A, Tam W, Montes-Moreno S, Zhan F, Bernal-Mizrachi L, Zu Y, Zhang S, Moller MB, Chen W, Au Q, Merchant AA, Bhagat G, Li Y, Young KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346287"},{"title01":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","title02":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2794-2807. doi: 10.1182\/blood.2024027997","author":"Pal I, Illendula A, Joyner A, Manavalan JS, Deddens TM, Sabzevari A, Damera DP, Zuberi S, Marchi E, Fox TE, Dunlap-Brown ME, Jayappa KD, Khalife J, Craig JW, Loughran TP Jr, Feith DJ, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896830"},{"title01":"The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.","title02":"The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2808-2820. doi: 10.1182\/blood.2025029163","author":"Tatterton DJ, Newby ML, Allen JD, Sale B, Chiodin G, Duriez PJ, Butler J, McCann KJ, Scott DW, Morin RD, Dreval K, Davies AJ, Bryant DJ, Crispin M, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896832"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025018178. Online ahead of print","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque T, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss I, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","title02":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017005. Online ahead of print","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AY, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","title02":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025016618. Online ahead of print","author":"Mayerhofer C, Crompton E, Mayerhofer E, Kristiansen TA, Fukushima T, Keyes S, Sharda A, Li D, Da Silva C, Shrestha D, Kiem A, Feuchtinger T, Scadden DT, Miller PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351481"},{"title01":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","title02":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6009-6018. doi: 10.1182\/bloodadvances.2025016966","author":"Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson L, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875887"},{"title01":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.","title02":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.","journal":"Blood advances","issue":"2025 December 9; 9(23):6047-6058. doi: 10.1182\/bloodadvances.2025017011","author":"Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829117"},{"title01":"How can we chop CML with an ASXL1?","title02":"How can we chop CML with an ASXL1?","journal":"Blood","issue":"2025 December 4; 146(23):2741-2742. doi: 10.1182\/blood.2025031031","author":"Cortes J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343167"},{"title01":"Donor-derived CD7 CAR-T in T-ALL\/LBL: promise and pitfalls.","title02":"Donor-derived CD7 CAR-T in T-ALL\/LBL: promise and pitfalls.","journal":"Blood","issue":"2025 December 4; 146(23):2731-2732. doi: 10.1182\/blood.2025030672","author":"Aldoss I, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343165"},{"title01":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.","title02":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.","journal":"Blood","issue":"2025 December 4; 146(23):2821-2832. doi: 10.1182\/blood.2025030259","author":"Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, Maqsood M, Shahrin N, Saunders V, Kenyon RR, Lin M, Toubia J, McConnell J, Kaczorowski D, Ross DM, Yong ASM, Chee L, Shortt J, Viiala N, Braley J, Kok CH, Hughes TP, Branford S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896831"},{"title01":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","title02":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","journal":"Blood","issue":"2025 December 4; 146(23):2779-2793. doi: 10.1182\/blood.2024028194","author":"Venkatesh H, Granados Centeno E, Luo Q, Arroyo M, Heltemes-Harris L, Knutson TP, Qiu Y, Haaning A, Webber BR, Bachanova V, Farrar MA, Tracy SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906918"},{"title01":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","title02":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","journal":"Blood","issue":"2025 December 11; 146(24):2914-2930. doi: 10.1182\/blood.2024026815","author":"Martinez TC, Jotte MRM, Khan S, Stoddart A, Blaylock H, Malik A, McNerney ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920873"},{"title01":"Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.","title02":"Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.","journal":"Blood","issue":"2025 December 11; 146(24):2963-2978. doi: 10.1182\/blood.2025028988","author":"Derevyanko PK, Swart LE, Mata Casimiro LD, van Oort A, du Plessis M, van den Brink L, Ashtiani M, Zwaan CM, Krippner-Heidenreich A, Bonifer C, Schiffelers R, Vormoor J, Kellaway SG, Heidenreich O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991849"},{"title01":"How I Treat Advanced Phases of CML.","title02":"How I Treat Advanced Phases of CML.","journal":"Blood","issue":"2025 December 2. doi: 10.1182\/blood.2024026510. Online ahead of print","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.","title02":"Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025029210. Online ahead of print","author":"Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky D, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397287"},{"title01":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","title02":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","journal":"Leukemia","issue":"2025 December 9. doi: 10.1038\/s41375-025-02815-z. Online ahead of print","author":"Liu X, Shi Y, Zhang J, Shetty K, Chew K, Kucuk C, Gong Q, Esmeray E, Li H, Chen R, Pan S, Dabrowska K, Moore RE, Garcia-Mansfield K, Pirrotte P, Wang J, Li Y, Dong G, Lee L, McKeithan TW, Iqbal J, Chan WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366532"},{"title01":"Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.","title02":"Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.","journal":"Leukemia","issue":"2025 December; 39(12):3061. doi: 10.1038\/s41375-025-02811-3","author":"Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, Goto H, Endo T, Teshima T, Yang Y, Nakagawa M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214141"},{"title01":"Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.","title02":"Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.","journal":"Leukemia","issue":"2025 December; 39(12):2988-2996. doi: 10.1038\/s41375-025-02794-1","author":"Kurz KS, Zamo A, Drewes C, Madej E, Laurent C, Burroni B, Donzel M, Xerri L, Mescam L, Plank L, Gjerdrum LMR, Geyer J, Richter J, Oschlies I, Klapper W, Gramlich S, Doll J, Roth S, Maurus K, Staiger AM, Siebert R, Du MQ, Rosenwald A, Ott G, Horn H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204003"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 December 8. doi: 10.1016\/S2352-3026(25)00327-8. Online ahead of print","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","title02":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e935-e945. doi: 10.1016\/S2352-3026(25)00288-1","author":"Kater AP, Kersting S, Dubois JM, van der Holt B, da Cunha-Bang C, Te Raa D, Idink C, de Boer F, Droogendijk J, de Heer K, van der Burg L, Nijziel MR, Tick L, Levenga H, Silbermann M, Ludwig I, Beeker A, Bellido M, Dobber JA, Evers LM, van der Kevie-Kersemaekers AM, Mellink C, Meulendijks I, Cunha S, Abrahamse-Testroote M, Zwezerijnen G, Zijlstra J, Niemann CU, Levin MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338862"},{"title01":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","title02":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2025 December 7. doi: 10.1016\/S0140-6736(25)02436-5. Online ahead of print","author":"Magnano L, Rivero A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371239"},{"title01":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","title02":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","journal":"Lancet","issue":"2025 December 7. doi: 10.1016\/S0140-6736(25)02360-8. Online ahead of print","author":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371238"},{"title01":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","title02":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","journal":"Lancet","issue":"2025 December 5. doi: 10.1016\/S0140-6736(25)01778-7. Online ahead of print","author":"Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360064"},{"title01":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","title02":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","journal":"Haematologica","issue":"2025 December 1; 110(12):3078-3082. doi: 10.3324\/haematol.2024.286626","author":"Alvey EN, Yap KL, Rathbun P, Fitzpatrick C, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40013396"},{"title01":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","title02":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):2974-2985. doi: 10.3324\/haematol.2024.287180","author":"Sasi BK, Tarantelli C, Martindale S, Civanelli E, Cannas E, Sartori G, Arribas AJ, Fernandes SM, Shupe SJ, Machado JH, Tyekucheva S, Ren Y, Lahn M, Van der Veen L, Di Conza G, Bertoni F, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534489"},{"title01":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.","title02":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):3145-3149. doi: 10.3324\/haematol.2025.288057","author":"Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605713"},{"title01":"BTKi + humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","title02":"BTKi + humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","journal":"Haematologica","issue":"2025 December 1; 110(12):2890-2892. doi: 10.3324\/haematol.2025.288196","author":"Dogliotti I, Federico M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605702"},{"title01":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients.","title02":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients.","journal":"Haematologica","issue":"2025 December 1; 110(12):3154-3158. doi: 10.3324\/haematol.2025.288145","author":"Atallah-Yunes SA, Rees MJ, Habermann TM, Wang Y, Munoz J, Iqbal M, Villasboas JC, McPhail ED, Witzig TE, Ansell SM, Nowakowski GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534511"},{"title01":"Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.","title02":"Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.","journal":"Br J Haematol","issue":"2025 December 8. doi: 10.1111\/bjh.70268. Online ahead of print","author":"Ortega-Francisco S, Prudente de Aquino MT, La Rosa C, Chiuppesi F, Gutierrez MA, Miller J, Li J, Mack-Onyeike J, Zhou Y, Zhou Q, Kaltcheva T, Patterson A, Dempsey S, Thomas S, Tiemann K, Yang D, Rida W, Wussow F, McKee K, Taplitz R, Raiden E, Siddiqi T, Rosen S, Diamond DJ, Danilov A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360730"},{"title01":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","title02":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70284. Online ahead of print","author":"Jin H, Guo Z, Zhu L, Huang F, Wu Y, Qiu H, Wang Y, Gong Y, He G, Fan L, Shi Z, Shen W, Qiao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41386566"},{"title01":"Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.","title02":"Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.","journal":"Br J Haematol","issue":"2025 December 4. doi: 10.1111\/bjh.70275. Online ahead of print","author":"Perusini MA, Patino AF, Andrews C, Assouline SE, Brandwein JM, Chow S, Popradi G, Sanford D, Savoie L, Saini L, Nadia B, Khalaf D, Schuh AC, Yee K, Gupta V, Maze D, Chan SM, Schimmer AD, Sabry W, Sibai H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344892"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","title02":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70272. Online ahead of print","author":"Voso MT, de Botton S, Pfeilstocker M, Alvarez AF, Wang K, See WL, Guerrero MU, de Menezes DL, Petrlik E, Prebet T, Roboz GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387169"},{"title01":"Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling.","title02":"Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling.","journal":"Blood advances","issue":"2025 December 9. doi: 10.1182\/bloodadvances.2025016400. Online ahead of print","author":"Soto CA, Lesch ML, Becker JL, Sharipol A, Khan A, Schafer XL, Li Z, Streeter AR, Becker MW, Munger JC, Frisch BJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364872"},{"title01":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","title02":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","journal":"Blood advances","issue":"2025 December 3. doi: 10.1182\/bloodadvances.2024015408. Online ahead of print","author":"Lefeivre T, Grosu TI, Tudose C, Jones L, Leon TE, Wynne K, Oliviero G, Smith O Professor, Trinquand A, Mansour MR, Ryan CJ, Bond J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337688"},{"title01":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","title02":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025017243. Online ahead of print","author":"Kuehn HS, Gil Silva AA, Klangkalya N, Esteve-Sole A, Goel S, Niemela JE, Stoddard JL, Chong H, Williams KW, Ip W, Framil Seoane M, Loganathan SK, Anantharachagan A, Garcia-Soidan A, Shaffren SB, Bindernagel C, Mendez P, Miller RZ, Abolhassani H, Hoytema van Konijnenburg DP, Geerlinks AV, Cabanillas D, Zonneveld-Huijssoon E, Rutgers A, Tangye SG, Ma CS, Grey A, O'Young P, Aldave Becerra JC, Lyons JJ, White A, Claiborne M, Doroudchi A, Modena BD, Milner JD, Solanich X, Farela Neves J, Platt C, Hammarstrom L, Routes J, Verbsky J, Butte M, Lesmana H, Griffiths WJ, Kumararatne DS, Hauck F, Allende LM, Rodriguez-Gallego C, Elfeky R, Rubin TS, Boztug K, Fleisher TA, Rosenzweig SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380100"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017089. Online ahead of print","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.","title02":"FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025018168. Online ahead of print","author":"Rohrbacher L, Nixdorf D, Stadler H, Brauchle B, Markl F, Gottschlich A, Hoffmann GV, Philipp N, Hanel G, Kirmaier ME, Marcinek A, Kazerani M, Richter D, Magno G, Goldstein RL, Theurich S, Straub T, Kobold S, Arvedson T, Bucklein VL, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324594"},{"title01":"The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.","title02":"The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.","journal":"Blood advances","issue":"2025 December 9; 9(23):6158-6174. doi: 10.1182\/bloodadvances.2024015427","author":"Arman K, Ross J, Piskor EM, Lazzari L, Calderon V, Reulet G, Vera M, St-Hilaire E, Wurtele H, Wilhelm BT, Moroy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921006"},{"title01":"Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.","title02":"Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.","journal":"Blood advances","issue":"2025 December 9; 9(23):6042-6046. doi: 10.1182\/bloodadvances.2025017109","author":"Goergen E, Robrecht S, Ligtvoet R, Fischer K, Eichhorst B, Langerbeins P, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921002"},{"title01":"Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.","title02":"Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6076-6089. doi: 10.1182\/bloodadvances.2025017345","author":"Cabrera-Serrano AJ, Sanchez-Maldonado JM, Rodriguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A, Cornejo-Calvo E, Garcia-Martin P, Ter Horst R, Benavente Y, Jerez A, Landi S, Espinet B, Maffei R, Lopez-Nevot MA, Ramos-Campoy S, Gonzalez-Olmedo C, Chen-Liang TH, Moreno V, Jannus F, Marcos-Gragera R, Carretero-Fernandez M, Sampaio-Marques B, Gamez I, Garcia-Alvarez M, Camp NJ, Dierssen-Sotos T, Kamaso J, Perez EM, Norman AD, Luppi M, Li Y, Alcoceba M, Campa D, de San Jose S, Marasca R, Ludovico P, Clay-Gilmour A, Canzian F, Ibanez M, Netea MG, McKay J, Casabonne D, Berndt SI, Slager SL, Sainz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902075"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.","title02":"Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.","journal":"Blood","issue":"2025 December 11; 146(24):3003. doi: 10.1182\/blood.2025031015","author":"Souto Filho JTD, Paulo AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379492"},{"title01":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","title02":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031480. Online ahead of print","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.","title02":"Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025029875. Online ahead of print","author":"Zhang L, Kang H, Valerio M, Hoang DH, Pathak KV, Garcia-Mansfield K, Lu X, Guo W, Fu YH, He X, Chen YC, Chen Z, Ghoda LY, Buettner R, Li Z, Blackmon A, Li L, Zhang B, Pirrotte P, Marcucci G, Kuo YH, Nguyen LXT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397241"},{"title01":"Defusing AML: targeting t(8;21) forces myeloid maturation.","title02":"Defusing AML: targeting t(8;21) forces myeloid maturation.","journal":"Blood","issue":"2025 December 11; 146(24):2857-2859. doi: 10.1182\/blood.2025031252","author":"Obeng EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379499"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","title02":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2794-2807. doi: 10.1182\/blood.2024027997","author":"Pal I, Illendula A, Joyner A, Manavalan JS, Deddens TM, Sabzevari A, Damera DP, Zuberi S, Marchi E, Fox TE, Dunlap-Brown ME, Jayappa KD, Khalife J, Craig JW, Loughran TP Jr, Feith DJ, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896830"},{"title01":"Hijacked helpers: Tr1 cells fuel immune escape in B-ALL.","title02":"Hijacked helpers: Tr1 cells fuel immune escape in B-ALL.","journal":"Blood","issue":"2025 December 4; 146(23):2736-2737. doi: 10.1182\/blood.2025030985","author":"Seiffert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343168"},{"title01":"Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.","title02":"Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287918. Online ahead of print","author":"Hogeling SM, Sternadt D, La Rose N, Geugien M, Pereira-Martins D, Van den Heuvel FAJ, Kuchnio A, Pietsch CE, Philippar U, Huls G, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376547"},{"title01":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","title02":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289085. Online ahead of print","author":"Cheng F, Li W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376545"},{"title01":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","title02":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.289104. Online ahead of print","author":"Lagana A, Fanciullo D, Kasmi D, Germano CA, Nardacci MG, Scalzulli E, Carmosino I, Bisegna ML, Minotti C, Nostro F, Milani ML, Buffolino S, Limongi MZ, Ielo C, Diverio D, Martelli M, Breccia M, De Propris MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342176"},{"title01":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","title02":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288928. Online ahead of print","author":"Sandhu M, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342189"},{"title01":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","title02":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300191. Online ahead of print","author":"Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376578"},{"title01":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","title02":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288872. Online ahead of print","author":"Kallstrom J, Niinimaki R, Fredlund J, Vogt H, Korhonen LS, Castor A, Schmiegelow K, Thastrup M, Ek T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342181"},{"title01":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3200 patients.","title02":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3200 patients.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300076. Online ahead of print","author":"Molica M, Giannarelli D, De Fazio L, Rossi M, Perrone S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376581"},{"title01":"Olverembatinib in chronic myeloid leukemia: is less actually better?","title02":"Olverembatinib in chronic myeloid leukemia: is less actually better?","journal":"Haematologica","issue":"2025 December 1; 110(12):2884-2886. doi: 10.3324\/haematol.2025.288065","author":"Perusini MA, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534512"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","journal":"Haematologica","issue":"2025 December 1; 110(12):2895-2901. doi: 10.3324\/haematol.2025.288114","author":"Ghione P, Zinzani PL, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Leukemia stem cells in acute myeloid leukemia – mimicking the “space and time continuum”?","title02":"Leukemia stem cells in acute myeloid leukemia – mimicking the “space and time continuum”?","journal":"Haematologica","issue":"2025 December 1; 110(12):2877-2880. doi: 10.3324\/haematol.2025.288003","author":"Plesa A, Roumier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671495"},{"title01":"Relapsed acute lymphoblastic leukemia: back to the drawing board.","title02":"Relapsed acute lymphoblastic leukemia: back to the drawing board.","journal":"Haematologica","issue":"2025 December 1; 110(12):2875-2876. doi: 10.3324\/haematol.2025.288191","author":"Jacoby E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605705"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"Sugar-free transforming growth factor beta1 increases the fitness of myelodysplastic neoplasm\/acute myeloid leukemia cells.","title02":"Sugar-free transforming growth factor beta1 increases the fitness of myelodysplastic neoplasm\/acute myeloid leukemia cells.","journal":"Haematologica","issue":"2025 December 1; 110(12):2887-2889. doi: 10.3324\/haematol.2025.288156","author":"Solary E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568718"},{"title01":"Comment on “Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report”.","title02":"Comment on “Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report”.","journal":"Haematologica","issue":"2025 December 1; 110(12):3178-3179. doi: 10.3324\/haematol.2025.288110","author":"Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371896"},{"title01":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell\/myeloid mixed phenotype acute leukemia.","title02":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell\/myeloid mixed phenotype acute leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):3129-3132. doi: 10.3324\/haematol.2025.287932","author":"Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568715"},{"title01":"Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention.","title02":"Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention.","journal":"Haematologica","issue":"2025 December 1; 110(12):2881-2883. doi: 10.3324\/haematol.2025.288227","author":"Bankar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820796"},{"title01":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.","title02":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.","journal":"Haematologica","issue":"2025 December 1; 110(12):2942-2953. doi: 10.3324\/haematol.2024.287090","author":"Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griskevicius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Lowenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304060"},{"title01":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.","title02":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):2986-2996. doi: 10.3324\/haematol.2024.287116","author":"Zhang X, Yang Y, Liu B, Du X, Wang X, Zhu H, Yu L, Li Z, Zhao S, Yang L, Ma Y, Meng L, Zhang Y, Li G, Yang L, Wang B, Ran X, Huang J, Gao N, Wen Q, Wen Y, Zhao Y, Zhu Y, Han Y, Liu Z, Du X, Weng J, Gale RP, Zhou L, Zhang Y, Jiang Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304058"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","title02":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):2974-2985. doi: 10.3324\/haematol.2024.287180","author":"Sasi BK, Tarantelli C, Martindale S, Civanelli E, Cannas E, Sartori G, Arribas AJ, Fernandes SM, Shupe SJ, Machado JH, Tyekucheva S, Ren Y, Lahn M, Van der Veen L, Di Conza G, Bertoni F, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534489"},{"title01":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a is resistant to ATRA but sensitive to arsenic-based therapy.","title02":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a is resistant to ATRA but sensitive to arsenic-based therapy.","journal":"Haematologica","issue":"2025 December 1; 110(12):3083-3087. doi: 10.3324\/haematol.2025.287318","author":"Wu S, Yu Y, Lin X, Zhou X, Zhou Y, Luo P, Shen H, He J, Liu L, Liu X, Zhang DL, Liu Y, Xiao H, Zhou F, Liu H, Zhang Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501402"},{"title01":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia.","title02":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):2954-2964. doi: 10.3324\/haematol.2024.287119","author":"Gong B, Yang M, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501400"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Benchmarking the paediatric T-cell ALL subtype classifier, TALLSorts.","title02":"Benchmarking the paediatric T-cell ALL subtype classifier, TALLSorts.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70263. Online ahead of print","author":"Gulbey O, James T, Cranston RE, Furmanczyk D, Schwab C, Lawson A, Kearns P, Vora A, Roels J, Van Vlierberghe P, Harrison CJ, Ross MT, Enshaei A, van Delft FW, Moorman AV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387177"},{"title01":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.","title02":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.","journal":"Leukemia","issue":"2025 December; 39(12):3042-3046. doi: 10.1038\/s41375-025-02779-0","author":"Goodman SJ, Butcher DT, Guger SL, Diehl E, Brzezinski J, Spiegler B, Nieman BJ, Kallurkar P, Boulet Craig A, Krajinovic M, Laniel J, Laverdiere C, Sinnett D, Lippe S, Turinsky A, Shago M, Strug LJ, Ito S, Hitzler JK, Schachar R, Weksberg R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107616"},{"title01":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.","title02":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December; 39(12):3059. doi: 10.1038\/s41375-025-02788-z","author":"Vu TT, Stolzel F, Wang KW, Rollig C, Tursky ML, Molloy TJ, Ma DD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107617"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 December; 39(12):3060. doi: 10.1038\/s41375-025-02793-2","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184635"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 December 2. doi: 10.1038\/s41375-025-02824-y. Online ahead of print","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41331358"},{"title01":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","title02":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e935-e945. doi: 10.1016\/S2352-3026(25)00288-1","author":"Kater AP, Kersting S, Dubois JM, van der Holt B, da Cunha-Bang C, Te Raa D, Idink C, de Boer F, Droogendijk J, de Heer K, van der Burg L, Nijziel MR, Tick L, Levenga H, Silbermann M, Ludwig I, Beeker A, Bellido M, Dobber JA, Evers LM, van der Kevie-Kersemaekers AM, Mellink C, Meulendijks I, Cunha S, Abrahamse-Testroote M, Zwezerijnen G, Zijlstra J, Niemann CU, Levin MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338862"},{"title01":"Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.","title02":"Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e946-e955. doi: 10.1016\/S2352-3026(25)00284-4","author":"Cao HY, Zhang H, Zhang Y, Hu XH, Yang L, Yang YL, Zhang YM, Wu B, Huang ZQ, Huang R, Wang RJ, Wan CL, Wu DP, Dai HP, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338863"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 December 8. doi: 10.1016\/S2352-3026(25)00327-8. Online ahead of print","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Acute myeloid leukaemia at the extremes.","title02":"Acute myeloid leukaemia at the extremes.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e927. doi: 10.1016\/S2352-3026(25)00326-6","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338856"},{"title01":"Leprosy and leukaemia: an unexpected interaction.","title02":"Leprosy and leukaemia: an unexpected interaction.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e986. doi: 10.1016\/S2352-3026(25)00261-3","author":"Zhou N, Peng P, Xu G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338867"},{"title01":"B-cell targeted therapies in acute lymphocytic leukaemia.","title02":"B-cell targeted therapies in acute lymphocytic leukaemia.","journal":"Lancet","issue":"2025 December 13; 406(10521):2751-2752. doi: 10.1016\/S0140-6736(25)02220-2","author":"Lunia A, Misbah SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41390204"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 7; JCO2502477. doi: 10.1200\/JCO-25-02477. Online ahead of print","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","title02":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502691. doi: 10.1200\/JCO-25-02691. Online ahead of print","author":"Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363770"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502380. doi: 10.1200\/JCO-25-02380. Online ahead of print","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"J Clin Oncol","issue":"2025 December 1; JCO2502762. doi: 10.1200\/JCO-25-02762. Online ahead of print","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41325561"},{"title01":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","title02":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3739-3749. doi: 10.1200\/JCO-25-01357","author":"Gottschalk H, Moricke A, Conter V, Schrappe M, Stary J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213101"},{"title01":"Is there a best frontline therapy in chronic myeloid leukemia?","title02":"Is there a best frontline therapy in chronic myeloid leukemia?","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287813. Online ahead of print","author":"Jain AG, Dalgetty M, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376561"},{"title01":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.","title02":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287766. Online ahead of print","author":"Flynn KE, Atallah E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376566"},{"title01":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","title02":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","journal":"Haematologica","issue":"2025 December 1; 110(12):2913-2929. doi: 10.3324\/haematol.2024.286744","author":"Curran E, Luskin MR, Alachkar H, Aldoss I, Burke PW, Cassaday RD, Karol SE, Perissinotti AJ, Rank CU, Schmiegelow K, Webster J, Douer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40109190"},{"title01":"Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.","title02":"Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.287756. Online ahead of print","author":"Rea D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342177"},{"title01":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","title02":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289116. Online ahead of print","author":"Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D, Palumbo GA, Di Raimondo F, Romano A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376555"},{"title01":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","title02":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","journal":"Haematologica","issue":"2025 December 1; 110(12):3078-3082. doi: 10.3324\/haematol.2024.286626","author":"Alvey EN, Yap KL, Rathbun P, Fitzpatrick C, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40013396"},{"title01":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","title02":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","journal":"Haematologica","issue":"2025 December 1; 110(12):3009-3021. doi: 10.3324\/haematol.2024.287091","author":"Feng J, Gou J, Wang Y, Wei W, Ma Y, Ren X, Zhao C, Cheng X, Lei L, Tan Z, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400458"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2279. doi: 10.1056\/NEJMc2515262","author":"Fleischman RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337729"},{"title01":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","title02":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 6. doi: 10.1056\/NEJMoa2515458. Online ahead of print","author":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindstrom V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Bottcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfo L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358601"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2279-2280. doi: 10.1056\/NEJMc2515262","author":"Wang Y, Zhu Z, Liang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337730"},{"title01":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.","title02":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.","journal":"Leukemia","issue":"2025 December; 39(12):2895-2906. doi: 10.1038\/s41375-025-02752-x","author":"Miraki-Moud F, Ariza-McNaughton L, KoKo T, Othman J, Stronge R, de Bono J, Russell N, Thomas I, Gilkes A, Burnett A, Santiago LR, Cafferty F, Taussig L, Thornhill A, O'Connor S, Bonnet D, Taussig DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935826"},{"title01":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies.","title02":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies.","journal":"Leukemia","issue":"2025 December; 39(12):3054-3055. doi: 10.1038\/s41375-025-02772-7","author":"Rodriguez L, Delhommeau F, Soussi T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016942"},{"title01":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","title02":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","journal":"Leukemia","issue":"2025 December; 39(12):2907-2915. doi: 10.1038\/s41375-025-02767-4","author":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954213"},{"title01":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","title02":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","journal":"Leukemia","issue":"2025 December; 39(12):2916-2925. doi: 10.1038\/s41375-025-02745-w","author":"Karakaslar EO, Argiro EM, Struckman NE, Shirali Hz R, Severens JF, Honders MW, Kloet SL, Veelken H, Reinders MJ, Griffioen M, van den Akker EB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954214"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.","title02":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.","journal":"Leukemia","issue":"2025 December; 39(12):2968-2977. doi: 10.1038\/s41375-025-02769-2","author":"Purhonen M, Tatun M, Luukkainen K, Hung K, Sundquist H, Tafjord O, Soderlund S, Adnan-Awad S, Dohlen A, Heikkinen J, Koskenvesa P, Siitonen S, Mustjoki S, Shanmuganathan N, Bryce C, Danielsson S, Hjorth-Hansen H, Olsson-Stromberg U, Kumagai T, Kimura S, Ross DM, Bruck O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958033"},{"title01":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).","title02":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).","journal":"Leukemia","issue":"2025 December; 39(12):2926-2934. doi: 10.1038\/s41375-025-02644-0","author":"Cusan M, Larkin K, Nicolet D, Jurinovic V, Mrozek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, Gorlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973764"},{"title01":"Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia.","title02":"Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia.","journal":"Leukemia","issue":"2025 December; 39(12):2978-2987. doi: 10.1038\/s41375-025-02720-5","author":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, Gough O, Schambach A, Sauer M, Heuser M, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034424"},{"title01":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.","title02":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.","journal":"Leukemia","issue":"2025 December; 39(12):2946-2956. doi: 10.1038\/s41375-025-02774-5","author":"Voss RK, Pastor Loyola VB, Cardenas MF, Kumar P, Maciaszek JL, Namwanje M, Ma J, Neary JL, Jin M, Umeda M, Wilkinson MR, Payne-Turner D, Eldomery MK, Ma J, Gu J, Dalton J, Melton S, Liu YC, Foy S, Rusch M, Wheeler DA, Zhang J, Nichols KE, Karol SE, Inaba H, Ribeiro R, Rubnitz JE, Klco JM, Wang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057686"},{"title01":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","title02":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","journal":"Leukemia","issue":"2025 December; 39(12):2858-2861. doi: 10.1038\/s41375-025-02784-3","author":"Rodriguez-Arboli E, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083680"},{"title01":"DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.","title02":"DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.","journal":"Leukemia","issue":"2025 December; 39(12):2835-2847. doi: 10.1038\/s41375-025-02758-5","author":"Bakewell J, Moorman AV, Ryan SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40940582"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2025 December 3. doi: 10.1038\/s41375-025-02814-0. Online ahead of print","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","title02":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","journal":"Leukemia","issue":"2025 December 8. doi: 10.1038\/s41375-025-02804-2. Online ahead of print","author":"Mikkelsen T, Helenius M, Ampatzidou M, Attarbaschi A, Andres-Jensen L, Borkhardt A, Conde Cuevas N, Escherich G, Hagleitner MM, Halsey C, Josephs-Spaulding J, Lundgren L, Pehn S, Polychronopoulou S, Stoltze U, Toksvang LN, Wahlberg A, Junk SV, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361660"},{"title01":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","title02":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 12. doi: 10.1038\/s41375-025-02817-x. Online ahead of print","author":"Struckman NE, Koutsoumpli G, de Jong RCM, van der Lee DI, Remst DFG, Smith SI, Honders MW, Hagedoorn RS, de Ru AH, Matsuda M, Ishikawa F, Tak T, Valk PJM, Heemskerk MHM, van Veelen PA, Falkenburg JHF, Griffioen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41388195"},{"title01":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","title02":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 10. doi: 10.1038\/s41375-025-02827-9. Online ahead of print","author":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372600"},{"title01":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","title02":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 10. doi: 10.1038\/s41375-025-02825-x. Online ahead of print","author":"Haaksma LH, Palmieri R, Reuvekamp T, Tettero JM, Ngai LL, Bachas C, Kelder A, Scholten WJ, Gradowska P, Arena V, Joao Simione A, Maurillo L, Venditti A, Lowenberg B, Ossenkoppele GJ, de Leeuw DC, Ikoma-Colturato MRV, Buccisano F, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372597"},{"title01":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","title02":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","journal":"Leukemia","issue":"2025 December 9. doi: 10.1038\/s41375-025-02818-w. Online ahead of print","author":"Dehgane L, Mallet E, Brasseur C, Krzisch D, Zeitouni W, Hitier C, Ayoub M, Dubois K, Perez Carretero C, Roos-Weil D, Choquet S, Maloum K, Bravetti C, Armand M, Garnier D, Hernandez-Rivas JM, Susin SA, Nguyen-Khac F, Chapiro E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366531"},{"title01":"40 years of LEUKEMIA.","title02":"40 years of LEUKEMIA.","journal":"Leukemia","issue":"2025 December 8. doi: 10.1038\/s41375-025-02840-y. Online ahead of print","author":"Hochhaus A, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361661"},{"title01":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","title02":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","journal":"Lancet Oncol","issue":"2025 December 1. doi: 10.1016\/S1470-2045(25)00526-1. Online ahead of print","author":"Cheville AL, Herrin J, Pachman DR, Grzegorczyk V, Kroenke K, Ridgeway JL, Minteer SA, Austin JD, Griffin JM, Chlan L, Tofthagen C, Mitchell SA, Smith A, Ruddy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344348"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2280. doi: 10.1056\/NEJMc2515262","author":"Munir T, Cairns DA, Hillmen P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337731"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","title02":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","journal":"Leukemia","issue":"2025 December; 39(12):3026-3036. doi: 10.1038\/s41375-025-02756-7","author":"Mazzeo P, Penir SM, Shumilov E, Wolf S, Haupl B, Markus K, Shirneshan K, Rittscher K, Brzuszkiewicz E, Aydilek E, Treiber H, Oellerich T, Ganster C, Haase D, Koch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973765"},{"title01":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.","title02":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.","journal":"Leukemia","issue":"2025 December; 39(12):2957-2967. doi: 10.1038\/s41375-025-02755-8","author":"Visentin A, Gaffo E, Furstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfo L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973766"},{"title01":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2025 December; 39(12):2935-2945. doi: 10.1038\/s41375-025-02768-3","author":"Setiawan T, Muhammad JA, Marcellina N, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034423"},{"title01":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.","title02":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 December; 39(12):2881-2894. doi: 10.1038\/s41375-025-02739-8","author":"Kanari M, Jimenez Garcia I, Steffen FD, Krattiger LA, Bataclan C, Liu W, Simona BR, Deplancke B, Naveiras O, Ehrbar M, Bornhauser B, Bourquin JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931046"}]